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ABSTRACT
The final glycosylation pattern of recombinant proteins might be determined by the choice
of the host cell, cell culture conditions and the purification. Each step influences glycosylation
and improved glycosylation of the product may thus be obtained by changing relevant
parameters of the respective step. In the present study the glycosylation of two
pharmaceutically relevant glycoproteins was studied with respect to host cell, culture
conditions and purification. The limiting step in the process was identified. The development
of a technique was initiated for the high-throughput screening of cells showing favourable
glycosylation characteristics. 
Erythropoietin (EPO) and immunoglobuline G
1
 (IgG
1
) were produced using different
cell-types and CHO clones. According to high-pH anion exchange chromatography
(HPAEC) the IgG
1
 produced by different CHO clones generally carried complex-type
biantennary N-glycans with a clone-dependent degree of terminal galactosylation. Core
fucosylation was essentially complete. According to HPAEC, HEK-293 cells produced a
qualitatively identical pattern, albeit with a higher level of galactosylation and possibly a small
amount of afucosyl-N-glycans or N-glycans carrying GlcNAc
i
. N-glycans derived from IgG
1
produced in SP2/0 cells were extended additionally with terminal α-galactose and terminal
NeuAc. N-glycans from EPO produced by different CHO clones consisted generally of bi-,
tri-, and tetraantennary N-glycans with a variable degree of terminal sialylation. Core
fucosylation was essentially complete. The results indicated clearly a cell-line and cell-clone
dependent glycosylation.
Both glycoproteins were produced by CHO cells under different culture conditions. For a
variety of parameters the glycosylation remained unchanged. For IgG
1
 and EPO the
temperature was identified as one parameter influencing the oligosaccharide structures. Using
EPO as model glycoprotein intracellular nucleotide-sugar availability and its effects on
glycosylation were tested. Due to low intracellular concentrations of nucleotide-sugars these
could not be measured directly but precursor feeding experiments, whereby levels of
intracellular UDP-N-acetylhexosamine and CMP-N-acetylmannosamine could be increased,
suggested that the changes in glycosylation at different temperatures can not be explained by
changed intracelullar nucleotide-sugar availability only. 
The glycosylation of IgG remained constant during the purification process. For EPO it
was shown that sialylation may be improved by employing anion-exchange chromatography
and hydroxyapatite chromatography. A major drawback of this approach were the low
recoveries of EPO.
In summary the results indicated that adequate glycosylation of recombinant proteins is
best addressed at the choice of the host cell. The development of a screening technique was
started allowing the screening of cells producing the protein with a favourable glycosylation
pattern. Single cells may be immobilised in alginate beads. On the surface of these beads
specific antibodies directed against the product are located. Captured product may be
analyzed using carbohydrate-specific lectins and screening may be automated using a FACS.
Because of time limitations this work could not be finished. Using secretory component as
model glycoprotein it was shown however that the principle of the detection has potential for
further development..
ZUSAMMENFASSUNG
Die Glykosilierung rekombinanter Proteine kann von einer Vielzahl an Parametern
beeinflusst werden. Die Wahl der Zelllinie, der Kulturbedingungen und der
Aufarbeitungsmethoden entscheiden über die Glykosilierung des Produktes und eine gezielte
Veränderung einer oder mehrer Parameter kann daher potentiell zur Optimisierung des
Glykosilierungsmusters genutzt werden. In der vorliegenden Arbeit wurde die Glykosilierung
zweier pharmazeutisch relevanter Glykoproteine studiert die von verschiedenen Zelllinien,
unter verschiedenen Produktionsbedingungen und Aufarbeitungsmethoden produziert
wurden. 
Erythropoietin (EPO) und Immunoglobulin G1 (IgG1) wurden in verschiedenen
Zelltypen und CHO Klonen produziert. Analyse der N-Glykane by High-pH anion exchange
chromatography (HPAEC) ergab dass IgG produziert von CHO Zellen generell komplexe
biantennäre N-Glykane trug. Das Niveau der terminalen Galaktosylierung war dabei von dem
verwendeten Klon abhängig. HPAEC Analyse von N-Glykanen aus HEK-293 Zellen zeigte
qualitativ eine identische Glykosilierung wenn auch die Präsenz geringer Mengen
unfukosylierter Strukturen oder von N-Glykanen mit β1-4 N-acetylglucosaminstrukturen für
diesen Zelltyp nicht auszuschliessen war. N-Glykane von HEK Zellen zeigten generell eine
höhere terminale Galaktosylierung als CHO Zellen. N-Glykane von IgG die in SP2/0 Zellen
produziert wurden trugen zusätzlich terminale α-galactose und Sialinsäuren. Die Sialylierung
von N-Glykanen produziert von verschiedenen CHO Klonen und isoliert von EPO zeigte
ebenfalls deutliche klonale Unterschiede.
Beide Glykoproteine wurden unter verschidenen Produktionsbedingungen von CHO
Zellen hergestellt. Die Kultivierungstemperatur wurde als ein Parameter identifiziert der
Einfluss auf die Glykosilierung beider Proteine zeigte. Für die EPO-Herstellung wurde
getestet ob eine verminderte Kultivierungstemperatur einen Einfluss auf die Menge von
intrazellulären Nukleotidzuckern ausübt. Niedrige intrazelluläre Konzentrationen
verhinderten jedoch eine direkte Messung der Nukleotidzucker. Anhand zusätzlicher
Experimente bei denen die intrazelluläre Konzentration der Nukleotidzucker durch Zugabe
der Ausgangssubstanzen hervorgerufen wurde zeigten jedoch dass die durch einen
Temperaturunterschied hervorgerufenen Veräderungen der Glykosilierung nicht mit den
Änderungen in intrazellulären Nukleotidzuckerkonzentrationen alleine erklärt werden kann. 
Für EPO wurde gezeigt dass die Sialylierung eines Proteins mit Hilfe von
Anionenaustauschchromatografie und Hydroxyapatitchromatografie erheblich verbessert
werden kann. Der Nachteil dieser Methode lag an den niedrigen Ausbeuten die oft mit einer
spezifischen Aufreinigung einergehen. 
Zusammenfassend zeigte sich also dass die Glykosilierung am besten schon bei der Wahl
der Produktionszelllinie optimisiert wird. Es wurde versucht eine Screeningmethode zu
entwicklen, die auf der Immobilisierung einzelner Zellen in einer Alginatmatrix beruht. Auf
der Alginatoberfläche befindet sich ein spezifischer Antikörper der dass von der Zelle
produzierte Protein bindet. Das gebundene Protein kann dann mit Hilfe von Lektinen auf die
Glykosilierung getestet werden. Die Arbeit an diesem Screeningsystem konnte aus
Zeitgründen nicht beendet werden. Es wurde jedoch anhand des Modellglykoporteins
Secretory Component gezeigt dass der Detektionsmechanismus funktioniert. Nach einer
Phase der Optimierung könnte die Methode dann automtisiert werden um eine grosse
Anzahl von Zellen auf Ihre Glykosilierungseigenschaften zu testen und den am besten
geeigneten Produktionsklon ausfindig zu machen. 
ABBREVIATIONS AND SYMBOLS
abbreviations in alphabetical order
ADCC antibody-dependent cellular cytotoxicity
AEX anion exchange chromatography
anti-RhD anti-Rhesus D-antibody
BHK baby hamster kidney
CDR complementary determining region
C
H
constant region heavy chain
CHO chinese hamster ovary
C
L
constant region light chain
CMP cytidine monophosphate
Con A concanavalin A
DNA deoxyribonuleic acid
DO dissolved oxygen
ELISA enzyme-linked immuno sorbent assay
EPO erythropoietin
ER endoplasmatic reticulum
ES/MS electrospray mass spectrometry
F
ab
antibody binding fragment of immunoglobulin
FACE fluorophore assisted carbohydrate electrophoresis
FACS fluorescent automated cell sorting
F
c
effector fragment of immunoglobulin
FCS foetal calf serum
Fuc fucose
FSH follicle stimulating hormone
FITC fluorescin isothiocyanate
FT fucosyltransferase
GA golgi apparatus
Gal galactose
GalNAc N-acetylgalactosamine
GDP guanidine diphosphate
Glc glucose
GlcN glucosamine
GlcNAc N-acetylglucosamine
GlcNAc
i
intersecting (or bisecting) N-acetylglucosamine
Gln glutamine
GnT N-acetylglucosaminyltransferase
GPI glucosamine-6-P-isomerase
GPS glucosamine-6-P-synthase
HAC hydroxy apatite chromatography
HEK human embryonic kidney
HexNAc N-acetylhexosamine
HPAEC high-pH anion-exchange chromatography
HPLC high performance liquid chromatography
hSC human secretory component
IEF isoelectric focusing
IgA, IgG immunoglobuline A, G
IEX ion exchange chromatography
IFN interferon
LacNAc N-acetyllactosamine
LC-ES/MS liquid chromatography electrospray mass spectrometry
MALD-MS matrix-assisted laser-desorption mass spectrometry
Man mannose
ManN mannosamine
ManNAc N-acetylmannosamine
MES 2-morpholinoethane sulfonic acid
MOPS 3-morpholinopropane sulfonic acid
Na-but sodium butyrate
NC nitrocellulose
NeuAc N-acetylneuraminic acid
NeuGc N-glycolylneuraminic acid
NMR nulear magnetic resonance
PAD pulsed amperometric detection
PVDF poly vinyliden fluoride
RP-HPLC reversed phase high performance liquid chromatography
SEC size exclusion chromatography
SC secretory component
SCRW secretion capture and report web
SDS sodium dodecyle sulfate
ST sialyltrasnferase
STR stirred tank reactor
TGN trans golgi network
rhuEPO recombinant human erythropoietin
UDP uridine diphopsphate
UV ultraviolet
V
H
variable region heavy chain
V
L
variable regioin light chain
Abbreviations for carbohydrate structures are not listed here because of the complicated
structures related to the abbreviations. For these abbreviations please refer to the
corresponding tables 3-1, 3-3 and 3-4 in chapter 3.
symbols (the most frequently units are given)
c concentration [mg/l]
µ specific growth rate [h-1]
pH
e
extracellular pH [-]
pH
i
intracellular pH [-]
n number of samples [-]
q specific production rate [pg/cell h]
s standard deviation [-]
t time [d], [h], [min]
T temperature [°C]
X viable cell concentration [cells/ml]
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5CHAPTER 1    INTRODUCTION
Pharmaceutical proteins often do not consist of a polypeptide chain only. During their
biosynthesis they usually undergo a series of co- and posttranslational modifications.
Structures like phosphor groups or carbohydrates, are covalently attached to the polypeptide
backbone. Contrary to the synthesis of the protein moiety these posttranslational
modifications are not directed by a template. Environmental factors may change enzymatic
activity of glycosyltransferases, gene expression and the availability of precursor structures. As
a consequence glycoproteins normally are heterogeneous with regard to the glycosylation.
This observation has an important impact on the biotechnological production of
glycoproteins. The product obtained might differ from its human counterpart and the
obtained product heterogeneity is, for obvious reasons, not desired in the production of
biopharmaceuticals. Glycan structures not present in humans are potentially antigenic and
different glycoforms may show differences in biological behaviour. Thus a better knowledge
of the decisive factors during process development which influence the glycosylation and, by
this, the quality of the product is of great value for the biopharmaceutical industry aiming at
the production of a homogeneous, biologically active and well-defined product.
Glycoproteins produced by animal cells serve as reagents in research or for medical
purposes. Early glycoproteins used for medical purposes were usually purified from human
blood, like the anti-Rhesus D-antibody (anti-RhD) or urine, like erythropoietin (EPO).
Nowadays recombinant products are given the preference because they are generally
considered safer with regard to the transmission of contagious diseases and because they
ensure a constant supply. Because the presence of glycans and the proper glycan structures
may (but must not) be important for glycoprotein function attention has to be paid to the
adequate glycosylation of pharmaceutical proteins. Although human-like glycosylation seems
an obvious goal, production of recombinant pharmaceuticals aims usually at the production
of the most active glycoform(s), providing these do not elicit immunogenic responses in
patients. The most active glycoform may differ from human-type glycosylation.
Figure 1-1 shows schematically the typical stages of a process development for the
production of recombinant proteins. After isolation of the DNA the first steps are the choice
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and the transfection of the host cell. A sufficiently large cell bank has to be created. Then
cultures at a small scale are carried out serving mainly three purposes: the production of some
material for assay development, the development of the downstream processing and the
improvement of the culture conditions. After some scale-up experiments normally a limited
number of batches will be produced for animal studies and clinical trials. Relevant stages
concerning the glycosylation during process development are the choice of the host cell and
the clone, the culture conditions and the downstream processing. 
The figure includes the chapters where those steps important for recombinant protein
glycosylation are being addressed. Chapter 3 shows the results on the structure analysis for
N-glycans derived from EPO and anti-RhD. Final conclusions of the work will be drawn in
chapter 8. Chapter 1 gives an introduction in general aspects of glycosylation like common
structural features of mammalian glycoprotein glycans and their biosynthesis. At the end the
glycoproteins used in this study will be briefly presented. A more detailed and specific
introduction is given at the beginning of each chapter.
1.     Structures of glycoprotein glycans
Glycoprotein glycans can be attached to a protein in three different ways: via the ε-NH
2
group of asparagine residues, via the OH-groups of usually serine or threonine or through an
ethanolamine phosphodiester linkage. The work presented here focuses on the first group,
the so-called N-glycans. 
Eukaryotic cells have a conserved mechanism for N-glycan biosynthesis. All N-glycans
produced by a eukaryotic cell normally will consist of a pentasaccharide- or trimannosyl-core
Figure 1-1. General process development flow chart for the production of recombinant proteins. Shaded the
steps which exert an influence on the glycosylation of the final product, in italics the corresponding chapters
where the subject is addressed in the present thesis. 
choice and stable transfection of a host cell
selection of stable transfectants
isolation of cDNA
creation of cell banks
bench/ medium scale production
production runs
downstream processing
improvement of culture conditions
developement downstream processing
assay development/ glycosylation analysis
scale-up experiments
clinical trialsanimal studiesformulation
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structure (Man
3
GlcNAc
2
) which may be extended by a variety of monosaccharide residues or
oligosaccharide side chains. Monomers involved in mammalian oligosaccharide synthesis are
fucose (Fuc), mannose (Man), galactose (Gal), N-acetyglucosamine (GlcNAc),
N-acetylgalactosamine (GalNAc) and the sialic acids N-acetylneuraminic acid (NeuAc) and
N-glycolylneuraminic acid (NeuGc). Glucose is involved in glycan processing and appears on
intermediary structures but not on processed carbohydrate chains (see paragraph 2.2.,
page 10).
Figure 1-2 shows the potential monosaccharide residues attached to the pentasaccharide
core structure of mammalian N-glycans. The residues include α1-3 or α1-6 linked fucose or
intersecting (bisecting) GlcNAc
i
. The core structure may be extended by side chains attached
to the α1-3 or α1-6 linked mannose residue as shown in figure 1-3.
In oligomannose-type N-glycans the pentasaccharide core structure is extended by Man
residues. Hybrid-type N-glycans carry exclusively mannose residues on the α1-6Man
Figure 1-2. The pentasaccharide core structure
of mammalian N-glycans in italics. Potential
monosaccharide residues of the core structure
are written in bold. GlcNAcβ1-4 in bold will be
referred to as intersecting or bisecting GlcNAc
i
.
Figure 1-3. Basic structure of the three major types of N-linked oligosaccharides. Elongation of the chains as
described below, the core structure might be substituted as shown in figure 1-2. Mammalian N-glycans of phar-
maceutical interest are often of the complex-type.
GlcNAcβ1-4 Manβ1-4GlcNAcβ1-4GlcNAc
Manα1-6
Manα1-3
Fucα1-6
Fucα1-3
Manβ1-4GlcNAcβ1-4GlcNAc
Manα1-6
Manα1-3
Manα1-2Manα1-6
Manα1-2Manα1-3
Manα1-2Manα1-2
Manβ1-4GlcNAcβ1-4GlcNAc
Manα1-6
Manα1-3
Manβ1-4GlcNAcβ1-4GlcNAc
Manα1-6
Manα1-3
Galβ1-4GlcNAcβ1-2
Galβ1-4GlcNAcβ1-2
Manα1-2Manα1-6
Manα1-2Manα1-3
Galβ1-4GlcNAcβ1-2
oligomannose type N-glycan
complex type N-glycan
hybrid type N-glycan
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antennae while the α1-3Man is substituted with GlcNAc and Gal residues. Common
structures in mammalian cells are complex type N-glycans carrying alternating GlcNAc and
Gal residues on both arms. These antennae may be further elongated with
N-acetyllactosamine repeats, a Galβ1-4GlcNAc element. At the α1-3 and α1-6Man further
branching of the structures may occur giving rise to structures carrying up to five so-called
antennae, see figure 1-4.
Additional diversity in N-glycan heterogeneity includes sulfation of monosaccharides and
the variations in the terminal sugar molecule. N-glycans may be terminated by neutral
monosaccharide structures or by sialic acids. Sialic acids in mammalian cells usually are either
NeuAc or NeuGc acid attached via α2-3 or α2-6 linkages. 
2.     Biosynthesis
N-glycan biosynthesis initiates in the endoplasmatic reticulum (ER) with the transfer of a
pre-synthesized oligosaccharide structure to the polypeptide backbone of the protein. The
oligosaccharide structure is trimmed and eventually the protein is transported to the golgi
apparatus (GA) where further trimming reactions take place. Subsequently monosaccharides
are added from activated precursor structures to the growing oligosaccharide chains. The
precursor structures are transported into the GA by specific antiporters with the equivalent
nucleoside monophosphate from the cytosol into the lumen of the GA, reviewed in
(Hirschberg et al., 1998). The final glycosylation consequently may be determined by the
accessibility of the glycosylation site, regulation of glycosyltransferase genes, the synthesis and
transport of nucleotide sugars into the golgi, compartmentalisation of the glycosyltransferases
and competition between the enzymes. The synthesis and transport of the precursor
structures are discussed first, then the actual N-glycan biosynthesis will be described.
Figure 1-4. Complex type N-glycans might be extended with up to five branches. Each branch is added by a
specific N-acetylgucosaminyltransferase (GnT), see paragraph on biosynthesis. GnT III catalyses addition of
the intersecting GlcNAc
i
 and is not shown here. Adapted from (Bergwerff, 1994).
Manβ1-4GlcNAcβ1-4GlcNAc
Manα1-6
Manα1-3
GlcNAcβ1-6
GlcNAcβ1-2
GlcNAcβ1-4
GlcNAcβ1-2
GlcNAcβ1-4
GnT V
GnT II
GnT VI
GnT I
GnT IV
penta- tetra- tri- tri’- di- antennary N-glycans
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2.1.   Biosynthesis of nucleotide-sugars
As mentioned earlier N-glycans consist normally of a limited set of monosaccharide
components. Roughly these may be divided into pentoses, hexoses, N-acetylhexosamines and
sialic acids. The only pentose present in mammalian N-glycans, fucose, is transported as
GDP-activated fucose (GDP-Fuc) into the lumen of the GA, hexoses as UDP-Galactose
(UDP-Gal), N-acetylhexosamines as UDP-N-acetylglucosamine (UDP-GlcNAc) or UDP-N-
acetylgalactosamine (UDP-GalNAc), sialic acids as CMP-acetylneuraminic acid or CMP-N-
glycolylneuraminic acid (CMP-NANA and CMP-NGNA) (Abeijon et al., 1997).
The biosynthesis of nucleotide sugars is schematically presented in figure 1-5. Glucose
(Glc) enters the biosynthetic pathway of nucleotide sugar synthesis via glucose-6-phosphate
Figure 1-5. Biosynthetic pathway of nucleotide-sugar precursor structures and transport of nucleotide-sugars
into the golgi lumen. Enzymes are as follows: (1) glucose-6-phosphatase, (2) glucose-P-isomerase, (3) glu-
cosamine-6-P-isomerase (GPI) for ammonium or glucosamine-6-P-synthase (GPS) if gln is the ammonium do-
nor, (4) glucosamine-6-P N-acetyltransferase, (5) N-acetylglucosmaine-6-P mutase, (6) UDP-N-acetyl-
glucosamine pyrophosphorylase, (7) UDP-N-acetylglucosamine-2-epimerase/N-acetylmannosamine kinase, (8)
N-acetylmannosamine kinase, (9) N-acetylneuraminate 9-phosphate synthase, (10) N-acetylneuraminate
9-phosphatase, (11) CMP-N-acetylneuraminate synthase, (12) phospho-glucomutase, (13) UTP-glucose-1P-uri-
dylyltransferase, (14) UDP-G-4-epimerase, (15) glucosamine kinase, (16) UDP-N- acetylglucosamine kinase.
Glc
G lc-6-P        G lc-1-P        UDP-Glc         UDP-Gal
Fru-6-P
G lcN-6-P
G lcNAc-6-P
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CMP-NANA 
UDP-GlcNAc         UDP-GalNAc
NeuAc
ManNAc
ManNAc-6-P            NeuAc-9-P
G lc
M anN
Gln
NH 4+
G ln 
NH4+
H2O,Glu Golgi-apparatus
Cytosol
M edium
-
-
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(Glc-6-P). From Glc-6-P either the UDPHex pool is replenished via Glc-1-P, or Glc-6-P is
converted into fructose-6-P (Fru-6-P). This conversion is the first step in the formation of
UDP-N-acetylhexosamines (UDP-HexNAcs). Ammonium may be directly incorporated into
glucosamines (Valley et al., 1999) and enters metabolism via the glucosamine-6-P-isomerase
(GPI) enzyme under the formation of GlcN-6-P (Cayli et al., 1999). GlcN-6-P may be
alternatively formed by glucosamine-6-P-synthase (GPS) activity transferring the ammonium
from glutamine under formation of glutamate (Teplyakov et al., 2001). As the next step
GlcN-6-P is converted by a mutase into GlcN-1-P and subsequently by phosphorylase
activity into UDP-GlcNAc. UDP-GlcNAc may be transferred directly into the GA or after
transformation into UDP-GalNAc. 
A part of the UDP-HexNAc serves as a substrate for UDP-N-acetylglucosamine-2-
epimerase/N-acetylmannosamine kinase converting UDP-GlcNAc into N-acetyl-
mannosamine (ManNAc). The synthesis of ManNAc is the first step of the formation of
CMP-sialic acids. Then ManNAc is converted first to NeuAc and from there to
CMP-activated N-acetylneuraminic acid (CMP-NANA) which subsequently is transported to
the GA-lumen by a specific CMP-sialic acid antiporter. CMP-NANA inhibits its own
production at higher cytosolic concentrations and its transport into the GA-lumen may be
inhibited by high UDP-GlcNAc concentrations (Pels Rijcken et al., 1995). 
2.2.   N-glycan biosynthesis
Attachment of N-glycans in mammalian cells starts invariably on the luminal side of the
endoplasmatic reticulum (ER) with the transfer of an Glc
3
-Man
9
-GlcNAc
2
-diphosphate-
dolichol precursor to the ε-NH
2
 of asparagine. Not every Asn residue is subject to this
modification. To be recognized by the oligosaccharyltransferase the Asn must be part of a
tripeptide sequence Asn-Xxx-Ser/Thr where Xxx is any amino acid but proline. Figure 1-6
represents schematically glycan biosynthesis as nowadays assumed, reviewed by (Kornfeld
and Kornfeld, 1985). It should be noted that the subcellular arrangement of
glycosyltransferases is not yet fully elucidated (Colley, 1997).
Still in the ER the glycan structure is trimmed to a Man
8
-GlcNAc
2
-structure. ER-Golgi
intermediate compartments translocate the protein to the cis compartment of the GA. In the
cis compartment more mannose residues are split off by mannosidase I activity yielding a
Man
5
GlcNAc
2
-structure. While lysosomal glycoproteins are extended with P-GlcNAc other
glycoproteins are transported to the medial compartment for further processing. After
N-acetylglucosaminyltransferase I (GlcNAc-transferase I, GnT I) transferred a GlcNAc
residue to the Manα1-3 branch mannosidase II cleaves the remaining mannose residues
which are not part of the pentasaccharide core structure. GnT II catalyses the attachment of
another GlcNAc to the now liberated α1-6 branch of the oligosaccharide. GlcNAc
i
 is
transferred by GnT III to the core structure of the N-glycan. GnT III uses several structures
of the medial compartment as substrate and probably prevents further action of GnT II, IV
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and V, but not GnT VI (Brockhausen et al., 1988), reviewed by (Dennis et al., 1999), see also
figure 1-4. As a next step the fucosylation reaction is likely to be carried out. The activity of
fucosyltransferase was reported to be prevented by presence of GlcNAc
i
 (Schachter et al.,
1983; Priatel et al., 1997), although some papers reported the presence of N-glycans carrying
Figure 1-6. Biosynthesis of a complex-type core-fucosylated biantennary, fully sialylated N-glycan. The follow-
ing enzymes are involved in N-glycan biosynthesis: (1) glucosidase I, (2) glucosidase II, (3) α-1,2 mannosidase
of the ER, (4) N-acetylglucosaminylphosphotransferase, (5) UDP-N-acetyl-glucosamine-lysosomal-en-
zyme-N-acetyl-glucosamine-phosphotransferase, (6) N-acetyl-glucosamine-1-phosphodiester-N-acetyl-glu-
cosaminidase, (7) mannosidase I, (8) GlcNAc-transferase I, (9) mannosidase II, (10) GlcNAc-transferase II, (11)
fucosyltransferase, (12) galactosyltransferase, (13) sialyltransferase. GnT III may add GlcNAc
i
 before the steps
8, 9 or 10, or after GnT IV or GnT V activity. GnT IV and GnT V activity (see figure 1-4) occurs in the medial
compartment. Adapted and modified from (Kornfeld and Kornfeld, 1985; Kobata, 1992; Michal, 1992; Dennis
et al., 1999).
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both monosaccharide residues (Fujii et al., 1990). The medial compartment is also the
location for further branching reactions catalyzed by GnTs. 
Then the N-glycans are transported to the trans compartment of the GA where elongation
of the branches by Gal, GlcNAc and sialic acids takes place. After having been processed in
the trans compartment the glycoproteins are transported to the trans golgi network (TGN).
From the TGN vesicles emerge that carry the assembled glycoprotein to its target.
3.     Why glycoprotein glycans are important
Protein-linked oligosaccharides are highly variable, hydrophilic, bulky structures and are
usually situated on the outer protein surface. A single tetraantennary glycan may mask 25 nm
2
of a protein surface (Montreuil, 1984), highly glycosylated proteins might be almost entirely
covered by carbohydrates. It is thus not surprising that the oligosaccharide fraction possesses
a big influence on protein characteristics. Protein characteristics affected by the carbohydrate
portion are protein folding, intracellular trafficking, biological activity, protein solubility,
modulation of antigenic determinants, circulatory life-time, protein heterogeneity and
protease protection, reviewed by (Varki, 1993) and (Stanley, 1992). 
Protein folding. Because glycan and protein synthesis are, at least partly, simultaneous events
they influence each other. The protein structure by rendering glycosylation sites more or less
accessible to glycosyltransferases and carbohydrates by affecting the folding of the protein. A
prominent example of glycosylation influencing the protein conformation is immunoglobulin
where the conformation of the hinge region is stabilized by carbohydrate-protein interactions
(Walker et al., 1989; Dwek et al., 1995; Wormald et al., 1997). Loss of the interaction may
result in decreased biological activity of antibodies (Lund et al., 1995). Deletion of a
N-glycosylation site resulted also in loss of activity and a generally less stable
lecitin-cholesterol acetyltransferase, probably due to a different protein conformation close to
the active site (Kosman and Jonas, 2001). Nuclear Magnetic Resonance (NMR) studies
showed that the carbohydrates of CD2 stabilized an unfavorable protein conformation (Wyss
et al., 1995). It is generally acknowledged that protein conformation determines the type of
N-glycosylation of a distinct glycosylation site, either by steric hindrance or through
protein-oligosaccharide or oligosaccharide-oligosaccharide interactions, reviewed by
(Cumming, 1991). This may explain why particular glycosylation sites of one glycoprotein
usually carry conserved types and/or other structural features of N-glycans, independent of
the cell-type or the culture conditions used for production. 
Intracellular trafficking. Glycoprotein carbohydrates may have signal functions for the
transport of glycoproteins to their destination. Phosphorylation of the N-glycans of
lysosomal glycoproteins acts as signal for the transport of these proteins to the lysosomes (see
step 5 and 6 in figure 1-6), reviewed by (Varki, 1993). After the GlcNAc residue is cleaved
these enzymes are transported to the lysosomes. 
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Biological activity. Among the different protein features affected by glycosylation the
biological activity deserves special attention. There are two basic mechanisms to be
distinguished. One is the decrease in biological activity such as determined by antibody
dependent cellular cytotoxicity (ADCC) assays, not related to blood clearance, the other is
rapid removal of asialoglycoproteins from circulation which is often the reason for decreased
in vivo activity (discussed below). The consequences for the value of a pharmaceutical protein
are however similar. ADCC assays measure the lysis of antibody-coated cells by natural killer
cells or macrophages. CAMPATH-1H (Wellcome Group), an anti-cancer and anti rheumatoid
arthritis (RA) antibody performed better in lymphocyte ADCC assay when the N-glycan at
the conserved glycosylation site (see paragraph 4.1., page 14) carried GlcNAc
i
, (Lifely et al.,
1995). 
Circulatory life-time. Some sialylated glycoproteins which showed biological activity in in vitro
and in in vivo studies lost the in vivo activity after desialylation whilst preserving their in vitro
activity. The phenomenon is generally explained by the recognition of terminal galactose
residues by hepathic receptors of the liver and the fast removal of these protein from blood
circulation (Takeuchi et al., 1990). Recombinant follicle-stimulating hormone (FSH) produced
by a wild-type CHO cell and in mutant cells defective in sialic acid transport showed identical
in vitro bioactivity (receptor binding) but the asialo FSH lacked in vivo activity. Low circulatory
life-time due to the absence of terminal sialylation was also discussed as a reason why EPO
produced in tobacco cells showed in vitro but no in vivo biological activity (Matsumoto et al.,
1995). Desialylated FSH generated by glycosylation mutants also retained in vitro biological
activity but lost its in vivo activity almost completely (Galway et al., 1990).
Protein solubility. Glycosylation generally renders proteins less hydrophobic, especially if the
carbohydrates are terminated by charged structures like sialic acids. Unglycosylated
erythropoietin (EPO) produced by E. coli tends to aggregate at elevated temperatures or after
prolonged incubation (Narhi et al., 2001). Similar observations were made for FSH (Galway
et al., 1990). 
Antigenic determinants. Immunogenic epitopes are either the type of an oligosaccharide
residue or the linkage type by which the residue is attached (residue meaning carbohydrate
and non-carbohydrate fractions). Besides representing the immunogenic epitope,
carbohydrate structures may cover potentially immunogenic carbohydrate or protein
structures (masking). Terminal α-galactose residues (galα1-3gal) are a major obstacle in
successful xenotransplantation (Joziasse and Oriol, 1999). The enzyme responsible for the
synthesis, Galβ1-4GlcNAc α-1-3galactosyltransferase, is present in all mammalians except
humans, apes and old world monkeys where it has been deleted through a frameshift
mutation (Larsen et al., 1990). α1-3 linked fucose at the reducing terminus of a carbohydrate
chain is present on human glycoproteins only in the brain. Contact to external tissue is
prevented by the blood-brain barrier. Although present in a specific human organ the
structure may elicit strong immune response by the human body. The reactive determinant of
IgE from sera of honey bee venom allergic patients often is composed of α1-3 fucose
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attached to the asparagine-linked GlcNAc (Tretter et al., 1993). Antibodies directed against
the NeuGc were first detected in the 1920s in patients receiving injections of products
derived from animal sera (Hanganutziu-Deicher antibodies/HD- antibodies). Chicken
(which, like humans, do not produce N-glycans containing NeuGc) studies and in vitro studies
using HD-antibodies suggest that significant amounts of terminal NeuGc may elicit an
immunogenic reaction in humans (Schauer, 1988; Noguchi et al., 1995). Hypermannose
oligosaccharides, as sometimes produced by yeast, reviewed by (Herscovics and Orlean, 1993)
and polylactosamine structures (Feizi, 1987) may also act as immunogenic determinants of
glycoproteins.
Protein heterogeneity. Macro- and microheterogeneity of glycoproteins has already been
addressed. The number of structure variants created by variation in the oligosaccharide chains
can be enormous because of the variability in monomer composition, linkage types,
substitution with non-carbohydrate residues. 36 glycoforms of IgG were identified only for
glycan variations on the conserved glycosylation site at Asn-297 (Rademacher et al., 1986).
Given that glycoproteins may posses more than one glycosylation site the number of
potential structures can be considerably higher. 
Protease protection. Because glycoprotein surfaces are partially covered by carbohydrates it
was suggested that glycans may also function as a protection against proteolytic digestion.
Most cases mentioned in the literature so far link O-glycosylation to protease resistance.
Proteolytic digestion of apoliprotein (a) was increased after cleavage of the O-linked
oligosaccharides (Garner et al., 2001).
Cell-cell adhesion. A prominent example is the direction of leukocytes to injured tissue.
Triggered by chemical signalling from close-by injuries, P-selectins appear on the surface of
epithelial cells of blood vessels. P-selectins are a group of carbohydrate-binding lectins to
which passing leukocytes are attracted, slowed down and thus directed to the injured site in
the body (Alper, 2001). 
4.     The model glycoproteins
In this paragraph protein structure, N-glycosylation, function and the pharmaceutical
interest of the model glycoproteins Immunoglobulin 1 (IgG
1
), erythropoietin (EPO) and
secretory component (SC) are discussed in more detail.
4.1.   IgG
1
 and the haemolytic disease of the newborn
Mammalian cells oppose infections by two particular defense mechanisms. While the
innate immune system reacts non-specifically against infectious agents the response of the
adaptive immune system is highly specific. In the adaptive immune system B-lymphocytes,
Introduction
15
having recognized an immunogenic molecule, will initiate production of antibodies directed
against the antigen. Several classes of antibodies are involved in the defense by the innate
immune system. IgG is the most frequent antibody found in human serum. Resistance of the
infection towards an antigen normally improves by repeated infection. 
Haemolytic disease of the newborn occurs when rhesus D negative (RhD
-
) mothers give
birth to Rhesus positive (RhD
+
) children. The fetal blood is likely to mix with blood of the
mother either because of small haemorrages during pregnancy or during delivery. The
immune system of the mother will recognize the RhD antigen and produce anti-Rh
D-antibodies. Contrary to AB0 immunogenicity RhD needs immunization and there is no
danger for the first born. During a subsequent pregnancy the immunized mother already
carries antibodies directed against the new fetus. If the mother’s antibodies enter the system
of the child and attack the RhD
+
 erythrocytes, the liver or brain of the child may be seriously
or even lethally damaged. 
In the current therapy RhD
-
 mothers giving birth to a RhD
+
 child are treated with two
doses of anti-Rh D-antibodies during pregnancy. Prophylactic injection of antibodies will
prevent in most cases immunization of the mother and poses no danger for future
pregnancies because they are rapidly removed from the blood. Although 85% of Europeans
are Rh
+
 the problem occurs frequently. In Switzerland alone 12000 mothers are treated
annually with anti-RhD. Currently the antibody is purified from the blood of healthy RhD
-
men, inoculated with RhD
+
 erythrocytes, however the number of male volunteers is
decreasing while ethical considerations mean that this production method will be soon
legislated against. Besides human derived products are considered a risk because of the
potential transmission of infectous diseases.
The predominant antibodies involved in the anti-RhD immune response are IgG
1
 and
IgG
3
. In vitro activity assays suggested that both mediate heamolysis by different F
c 
receptors
(Kumpel, 1997). It is not yet clear if the presence of both isotypes is necessary for successful
removal of RhD
+
 red blood cells in vivo. The present study focuses exclusively on the
glycosylation of IgG
1
. Figure 1-7 shows schematically the structure of IgG
1
. The protein
consists of two identical heavy chains and two identical light chains. Antigens are recognized
and bound by the antigen binding region F
ab
, the F
c
 part mediates effector functions. The
entire protein has an approximate molecular weight of 150 kDA. Both types of chain consist
of variable parts (V
L
 and V
H
) and constant regions (C
L
 and C
H
). The constant region C
H
2
comprises the conserved N-glycosylation site at Asn 297. The sugar moiety at this
glycosylation site accounts for 2-3% of the molecular weight of the protein. 
Structures of IgG N-glycans attached to Asn-297 have been thoroughly investigated by
HPAEC and 
1
H-NMR (Rothman, 1989; Bergwerff, 1994). When produced in mammalian
cells, glycan structures are usually of the biantennary, complex type with potential
core-fucosylation, the presence of GlcNAc
i
, terminal sialylation and the occasional
occurrence of the galα1-3gal epitope. Site-occupancy is usually complete. A common
N-glycan derived from human serum is shown in figure 1-8.
116
The level of galactosylation on the conserved glycosylation site has been frequently
discussed as a factor influencing the antibodies behavior in biological activity assays
(Rothman et al., 1989). In vivo the level of terminal galactosylation decreases with age (Parekh
et al., 1988), during pregnancy or during malignancies like rheumatoid arthritis (Tsuchiya et
al., 1989). Antibodies lacking the outer arm galactosylation probably have greater flexibility of
the hinge region which is normally stabilized by oligosaccharide-protein interactions (Dwek et
al., 1995). Pathogenicity of low-galactosyl N-glycans on IgG has also been discussed
(Rademacher, 1994). Particularly for the anti-RhD it has been found that a higher
galactosylation level improved the antibodies performance in ADCC assays (Hadley et al.,
1995). Further it was reported that GlcNAc
i
 has a positive effect on ADCC activity of the
anti RhD antibody (Kumpel et al., 1994). 
Figure 1-7. Schematic structure of Immunoglobulin G
1
. The variable regions are located at the amino-ter-
minal, antigen binding part (F
ab
-fragment) of the molecule. IgG is built of two identical protein subunits,
each composed of a heavy chain (MW 50000) and a light chain (MW 25000). The subunits are variable with
respect to the N-glycan attached to the conserved glycosylation site at Asn-297. Additional glycosylation
sites may occur in the complementary determining regions (CDR) of the F
ab
 fragment. The oligosaccharide
chains at Asn-297 are directed inwards and stabilise the protein conformation. 
Figure 1-8. Largest carbohydrate structure found on human serum antibodies according to (Kobata, 1990).
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4.2.   Erythropoietin
Recombinant human erythropoietin (rhuEPO) was one of the first recombinant proteins
on the market. It received approval by the FDA in 1986 for the treatment of patients suffering
from chronic renal failure, side effects of chemotherapy and transfusion-dependent diseases.
In healthy adult individuals EPO is produced in the kidney. It circulates in the blood and is
eventually transported to the bone marrow. There it acts as a growth factor by binding to
erythroid progenitor cells and stimulating the proliferation and differentiation of erythroid
progenitor cells into erythrocytes. The function of EPO is schematically shown in figure 1-9.  
EPO is composed of 166 amino acids, has a molecular mass of 18.4 kDA and contains two
disulfide bonds Cys7-Cys161 and Cys29-Cys33 (Lai et al., 1986). The three-dimensional
structure is not yet known. N-glycosylation occurs at Asn 24, 38 and 83 and O-glycosylation
at Ser 126 (Lai et al., 1986). Normally the N-glycosylation consists of bi-, tri-, and
tetraantennary, fucosylated, highly sialylated complex type N-glycans with zero to three
N-acetyllactosamine repeats (LacNAc- repeats). The structures are schematically represented
in figure 1-10. Carbohydrates account for approximately 40% of the molecular weight of
EPO. The degree of sialylation and antennarity depends on the glycosylation site. Sialylation
and antennarity were reported to be higher at Asn 38 and 83 if compared to Asn 24
(Kawasaki et al., 2000). Both, recombinant and human urinary EPO contain a high amount of
sialylated N-glycans (usually >80%) (Takeuchi et al., 1988; Watson et al., 1994). 
Sialylation is not necessary for recognition of EPO by erythroid progenitor cells (Dordal et
al., 1985). Apparently asialo EPO binds faster to its receptor than the native glycoform (Imai
et al., 1990). EPO with biantennary sialylated N-glycans as major carbohydrate structure
showed higher in vitro but lower in vivo biological activity when compared to EPO with mainly
tetraantennary sialylated structures (Takeuchi et al., 1989). Continuing the studies (Takeuchi et
al., 1990) and (Higuchi et al., 1992) found that desialylation increased in vitro activity of EPO
Figure 1-9. Schematic representation of the regulation of red blood cell formation by erythropoietin. EPO is
formed in the kidney and stimulates the production and maturation of red blood cells in the bone marrow.
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three-fold and activity could be further increased by removing the Gal and GlcNAc-residues.
In contrast the removal of the O-glycan had no effect on the in vitro biological activity, even
though the O-glycosylation site is located close to the active site of the protein (Higuchi et al.,
1992). Removal of the core-structure resulted in loss of the in vitro activity. 
In vivo activity of EPO is highly dependent on sialylation of the protein. This fact is
normally explained by rapid clearance of asialo-erythropoietin from circulation by hepatic
Gal- receptors (Chang and Chang, 1988). (Fukuda et al., 1989) showed that asialo
erythropoietin is cleared more than ten times faster from the blood of rats than the sialylated
counterpart. It was also reported that Gal receptor-mediated removal was increased for
structures with a high number of LacNAc-repeats. The low biological activity of insufficiently
glycosylated erythropoietin was confirmed by a variety of authors (Dordal et al., 1985; Inoue
et al., 1994; Storring et al., 1998; Burg et al., 1999). The production of recombinant EPO thus
clearly aims at a product carrying high antennary, highly sialylated N-glycans.
4.3.   Secretory Component
In order to understand the role of secretory component its function has to be regarded in
a broader context. Dimeric Immunoglobulin A is the main antibody in human secretions such
as saliva, colostrum, digestive tract, lungs, tears and breast milk. These mucosal surfaces are
the main contact areas between the human immune system and the environment and serve as
a first barrier against infections by microorganisms. Most of these surfaces also have some
innate immune defense in addition to the humoral defense by IgA. If the antigens pass the
first protective border and enter the organism they may elicit an immunogenic response,
including the synthesis of IgA. Secretory IgA (sIgA) consists of two monomeric
immunoglobulin molecules connected by the so-called J-chain and attached to secretory
Figure 1-10. Typical N-glycan structures from EPO are bi-, tri- or tetraantennary, potentially carry up to three
N-acetyllactosamine repeats and are terminated to a high degree with sialic acids. The graph illustrates structural
heterogeneity of the carbohydrate structures. The core structure may consist of 2-4 branches. In some cases the
branches are elongated with 1 or 2 LacNAc repeats. Addition of the LacNAc repeats may occur at any branch.
Any of the branches may be terminated with sialic acid residues. Residues in not directly connected to a branch
may occur on any branch of the structure or may be absent. 
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component. The monomeric components of IgA are similar to the structures of IgG
displayed in figure 1-7.
As shown in figure 1-11 SC captures the arriving dimeric IgA in the blood and transports it
in vesicles across the epithelium into the mucosal secretions where it remains attached to the
IgA and protects the antibody from degradation and hydrolysis in an often (due to the innate
immune system) unfriendly environment, apparently by protecting the hinge region of the
immunoglobulin (Crottet and Corthesy, 1998). Deglycosylated SC was found to be more
prone to tryptic digestion (Hughes et al., 1999). SC is produced by epithelial cells.
Recombinant SC may be used to improve mucosal defense by stabilizing IgA of varying
specificities and has been produced by a variety of cells (Rindisbacher et al., 1995; Crottet et
al., 1999).
Secretory component is built of five subunits and contains seven putative N-glycosylation
sites at Asn 65, 72, 117, 168, 403, 451 and 481. Its apparent molecular weight including the
N-glycans is approximately 70 kDa (Munster et al., 1972). SC purified from human milk
carries biantennary structures with fucosylated branches (Mizoguchi et al., 1982). N-glycan of
human SC were of partially fucosylated biantennary complex type, terminated by either
galactose or NeuAc (Hughes et al., 1999). Monosaccharide analysis revealed a high level of
fucosylation of N-linked oligosaccharides (Munster et al., 1972). A remarkable feature of the
Figure 1-11. Schematic representation of the function of SC.IgA is produced by plasma cells in the mucosa or
bone marrow cells. Two IgA’s are linked via a so-called J-chain and then bind to secretory component which is
located at the surface of endothelial cells. Via vesicles the dimer is transported to the outer side of the epethilial
cells and secreted onto mucosal surfaces. SC remains attached to IgA and protects the molecule against prote-
olytic attack.
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N-glycans was the relatively high level of fucosylation at terminal galactose residues.
Fucosylation occurred only on branches which were not terminated with sialic acids. Some
structures are exemplarily displayed in figure 1-12. The glycosylation of recombinant SC has
so far not been published.
Figure 1-12. Typical N-glycan structures from human SC are of the biantennary complex type. Structures may
be terminated by sialic acids or alternatively carry α1-3linked fucose at the terminal galactose residue. Branches
of one molecule may be different but never carry both the α1-3 fuc and the NeuAc (Hughes et al., 1999). 
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CHAPTER 2      MATERIALS AND METHODS
1.     Chemicals and reagents
Standard chemicals and reagents used frequently are summarized below or described
where appropriate. Listing in alphabetical order.
A-L. 2-β-Mercaptoethanol was obtained from Fluka (cat.-no 63689), acetic acid was also
from Fluka (Buchs, Switzerland, cat.-no 45730). Acetonitrile was purchased from Romil
(cat.-no. 190), bovine serum albumine from Fluka (cat.-no. 05488) and Coomassie Brilliant
Blue R 250, from Fluka (cat.-no. 27815). Disodium hydrogen diphosphate was procured from
Fluka (cat.-no. 71645). Dimethyl sulfoxide (DMSO) was obtained from Sigma (cat.-no.
D-2650). Dithiothreitol (DTT) was from Pierce (cat.-no. 20290) foetal calf serum from Gibco
life sciences (cat.-no 10084-168), ethanol p.a. from Fluka (cat.-no. 02860). 1-Ethyl-3(3-
dimethylaminopropyl)carbodiimide-HCl (EDC) was purchased from Pierce (cat.-no. 229801),
ethylenediaminetetraacetic acid (EDTA) from Fluka (cat.-no. 3679). Also purchased from
Fluka was glycerole (cat.-no. 49769), anhydrous and glycine, (cat.-no. 50049). Guanidine
hydrochloride was obtained from Fluka (cat.-no. 56939). Hydrochloride was obtained from
Aldrich (cat.-no. 31894-9).
M-Z. Magnesium chloride was purchased from Fluka, cat.-no 63064. Methanol
(MeOH205) was obtained from Romil (cat.-no. 67-56-1). Polyoxyethylenesorbitan
monolaureate (Tween 20) was obtained from Sigma (cat.-no. P-1379). Sodium acetate
(NaOAc) anhydrous was from Fluka (cat.-no. 71180), sodium azide was purchased from
Fluka (cat.-no. 71290). Sodium chloride was supplied by Fluka (cat.-no 71380) as well as
sodium dihydrogen phosphate dihydrate, Fluka (cat.-no 71502) and Sodiumdodecylsulfate
(SDS) Fluka (cat.-no. 71725). Sodium hydroxide (except for Dionex eluent preparation) was
purchased from Fluka (cat.-no 71692). Triethanolamine (Tris) was from Fluka (cat.-no. 90280)
and triethanolamine-hydrochloride (Tris-HCl) from Acros (cat.-no. 170055000) or Fluka
(cat.-no 93347). Trifluoroacetic acid, purum (TFA) was also from Fluka (cat.-no. 91700). 
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2.     Cell Culture
2.1.   Small scale culture for EPO production
A vial from the working bank was defrozen at 37°C in a water bath and resuspended in 20
ml pre-warmed MAM-PF2 medium supplemented with 2 mM glutamine (Sigma, cat.-no.
G-8540). Cultivation was carried out at 37°C in T-flasks in an atmosphere of 5%CO
2
. Cells
not growing normally - up to 5x10
5
 - 8x10
5
 cells/ml at a viability of 95% within 3 days after
thawing the vial from the working bank - were discarded and the inoculum was started again.
Cell spin cultures were carried out in 500 ml spinner flasks obtained from Integra (cat.-no.
182026, Integra, Fernwald, Germany) containing 200 ml medium. The inoculum for cell spin
cultures at 34°C was also grown at 37°C. Spinner flasks of one experiment were always
started from an identical inoculum. Inoculum concentration was, if not indicated otherwise,
3x10
5
 cells/ml. For the feeding experiments with nucleotide precursor structures the medium
was supplemented either with 10 mM mannosamine, added as D-mannosamine
hydrochloride (Sigma cat.-no. A-8176) and 2 mM cytidine (Acros cat.-no. 111810100) to
increase intracellular CMP-NANA concentrations or with 10 mM glucosamine, added as
D-glucosamine hydrochloride (Sigma, cat.-no. G1514) and 2 mM uridine (Acros, cat.-no.
140770250) to increase UDP-N-acetylglucosamine levels. Cells for the feeding experiments
were grown at 37°C, unless otherwise stated.
2.1.1.  Cultivation in stirred tank reactors at different scale
For experiments at larger scale a 2 l Labfors bioreactor (Infors, Bottmingen, Switzerland)
was started from the cell spin cultures carried out as described in paragraph 2.1. Experiments
in bioreactors were either carried out at the 2-l scale or the culture from the 2-l reactor served
as inoculum for cultures in the 20 l Techfors (Infors, Bottmingen, Switzerland) reactor with
12 l working volume. If not specified differently cultures were carried out in MAM-PF2
medium (Bioconcept, Allschwil, Switzerland) at 37°C, pH 7.2. Repeated batch experiments
were carried out in the Techfors reactor. The pH was maintained at 7.2 by automatic addition
of a 0.3 M NaOH solution, air saturation of 40% was achieved by sparging the reactor with
air. The culture medium was further supplemented with 1% (v/v) of a 10% (w/v) solution of
Pluronic F-68 (Sigma, cat.-no. P-1300) in UHP-water and 0.1% (v/v) of a 30% aqueous
solution of Antifoam A (Sigma, cat.-no. A-5758). 80% of the cell culture supernatant was
harvested sterile during the exponential growth phase at a cell concentration of 1.5 -2x10
6
cells/ml and replaced by the same volume of fresh medium. To assess the effect of
monosaccharide supplementation on glycosylation repeated batch cultures were carried out in
the presence of 1 g/l mannose (Fluka, cat.-no. 63582) and 1 g/l galactose (Fluka, cat.-no.
48263). Because the cells were running out of nutrients the cell culture medium of the second
repeated batch experiment was supplied with 200 ml of a sterile filtered solution of: 75.7 g
glucose, 4.4 g glutamine, 4.8 g asparagine, 2.1 g serine, 7.5 g mannose and galactose each.
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Addition was carried out after day 4 for the culture at 34°C and after day 3 for the culture at
37°C. 
2.1.2.  Measurement of cell concentration and cell viability
For the production of EPO and SC a sample from the culture was diluted with trypan blue
(Sigma, cat.-no. T-8154). The dilution was dependent on the cell density. At least 50 cells were
counted using a Neubauer hemocytometer (Neubauer, Merck, cat.-no. 6522000). Cell viability
was assessed by trypan blue staining (Trypan blue solution, Sigma, cat.-no. T8154).
2.1.3.  Cultivation of CHO cells for clonal comparison of glycosylation
Cells were grown in MAM-PF2 medium at 37°C, 5% CO
2
 in T-flasks. After two transfers
cells from a 25 ml T-flask were centrifuged and resuspended in 50 ml fresh medium. After 24
h the supernatant was centrifuged for 3 min at 500 g and 10 ml aliquots were shock-frozen
and stored at -80°C. Samples were concentrated in Centricon ultrafiltration devices prior to
glycosylation analysis.
2.2.   Cultivation of CHO, SP2/0 and HEK cells for IgG production
For antibody production by SP2/0 cells a vial from the working bank was defrozen in a
water bath at 37°C and resuspended in 10 ml pre-warmed DMEM F12 medium (Gibco,
cat.-no. 32500-019) containing 2% Foetal Calf Serum (FCS, Gibco cat.-no. 10084-168),
dialyzed and IgG-free, 1% Nutridoma SP (Boehringer Mannheim Cat.-No. 1011367) and 500
nM methotraxate (MTX from Sigma cat.-no. M-8407). IgG was separated from FCS using
protein A streamline purification as described in chapter 3.1. prior to use. Inoculation of the
12 l reactor was effected at 2x10
5
 cells/ml. The reactor was maintained at 37°C, pH 7.2 and
DO was maintained at 40% air saturation.
HEK-293 cells were grown at 37°C in DMEM F12 medium containing 5% IgG-free FCS
for maintenance and 2% of IgG-free FCS during production. Ca
2+
-transfection was carried
out at pH 7.4, pH was decreased to pH 7.1 for production. 
All CHO clones were derived from the parent cell line CHO DG44 (dhfr
-
/dhfr
-
) (de Jesus
et al., 1999). Adherently growing cell lines CHO MDJ1 and CHO MDJ8m were grown in
roller bottles. CHO AMW and CHO MDJ8s were grown serum-free in stirred tank reactors
of 1 l working volume (Applikon, Schiedham, Holland), at 20% dissolved oxygen. Cultures
were carried out in Biowhittaker medium ProCHO CDM (Biowhittaker Walkersville, MD)
supplemented with 4 mM glutamine. If not specified otherwise cultures were performed at
pH 7.2 and 37°C and at 2x10
5
 cells/ml inoculum concentrations.
Cultures of the adherently growing cell lines CHO MDJ1 and CHO MDJ8m were carried
out in DMEM F12 medium containing 2% IgG-free FCS for routine maintenance and for
growth phase. The cells were inoculated in the roller bottles at 2x10
5
 cells/ml and cultivated
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for 3 days. After the cultivation period the medium was removed, the cells were washed with
phosphate buffered saline (PBS) pH 7.5 and new fresh serum-free DMEM F12 medium was
added. After a production period of 4 days the supernatant was harvested and processed as
described in paragraph 3. Cell concentration and cell viability were measured as described in
paragraph 2.1.2.
2.3.   Cultivation of CHO SSF3 for production of secretory component
CHO SSF3 were obtained from Novartis (Basle, Switzerland). Cells were grown in
batch-cultures in serum- and protein-free CHOMaster HP-5 medium (Dr. F. Messi, Cell
Culture Technologies, Zürich, Switzerland). Cultures for the production were carried out
either in 2l STRs (Biolafitte, St. Germain-en-Laye, France) or in spinner flasks using the same
conditions as already described for the production of EPO in paragraph 2.1. Cell
concentration and viability were assessed as mentioned in paragraph 2.1.2.
2.4.   Calculations
Growth rate was calculated from:
with X= viable cell concentration [cells/ml], t= time [h], µ= specific growth rate [h-1]. 
The specific production rate was calculated according to:
with c=concentration [mg/l], q= specific production rate [mg/h/cell], X= viable cell
concentration [cells/ml].
3.     Downstream Processing
3.1 Purification of IgG1
Protein A affinity chromatography. A three step purification was carried out for the production
scale from 10 l to 50 l. The first capture step involved affinity chromatography using
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recombinant protein A (Streamline recombinant protein A, Amersham Pharmacia Biotech,
No. 17-1281-02) on a fluidized bed “Streamline”–system (Amersham-Pharmacia Biotech,
Uppsala, Sweden). The cell culture supernatant was applied to the column by upward flow
directly from the reactor, washed with 50 mM phosphate buffer pH 7.5 containing 1 M NaCl
and subsequently eluted in the inverse direction with 0.1 M citrate buffer, pH 3.0. Citric acid
monohydrate was obtained from (Fluka cat.-no. 27487). The eluting IgG was immediately
neutralized to pH 6.0 using 500 mM sodium phosphate buffer, pH 6.5
Cation exchange chromatography. The second step involved cation exchange chromatography
on a SP Sepharose FF (Pharmacia, cat.-no. 17-0729-01) column (XK 16/10, Amersham
Pharmacia Biotech, Uppsala, Sweden). The column was equilibrated in 50 mM sodium
phosphate pH 7 (buffer A). Sample was loaded at 5ml/min and, after loading, the column
was washed again with buffer A until a stable baseline was obtained. Subsequently the column
was washed with 50 mM NaOAc, pH 4.0 containing 200 ml NaCl to dissociate remaining
recombinant protein A, followed by a second washing step with buffer A until the pH of the
effluent remained stable. Elution was carried out using a NaCl gradient: 0-8 min from
0%-10% buffer B (50 mM sodium phosphate, pH 7.5, 1 M NaCl), 8-24 min to 50% B and to
100% B at 31 min. 
Size exclusion chromatography. The final purification step involved size exclusion
chromatography (SEC) on a HiPrep Sephacryl S-200 HR column (Sepahcryl S-200 from
Pharmacia, cat.-no. 17-0871-01), equilibrated with 50 mM HAc, 150 mM NaCl, 0,05% NaN
3
at pH 5.0 (separation buffer) at a flow rate of 0.8 ml/min. After equilibration the sample was
applied and eluting IgG-containing fractions collected based on UV
280nm
 absorbance. 
Small scale affinity purification. IgG was batch-purified by addition of recombinant protein A
Streamline-material to centrifuged, cell-free supernatant of the cultures. Incubation was
carried out overnight at 4° C on a horizontal lab shaker at 200 rpm (Infors, Switzerland). The
Streamline recombinant protein A was collected after sedimentation, loaded into a column
and subsequently washed with 10 column volumes of phosphate buffered saline (PBS) at pH
7.5. Elution was carried out as described for the fluidized bed column with 0.1 M citrate
buffer, pH 3.0. The recombinant protein A material was collected and stored at 4°C in 20%
ethanol for regeneration. Immediately after elution the pH of the antibody-containing eluate
was adjusted to pH 6.0 by the addition of 0.5 M Na-phosphate, pH 6.5. The samples were
sterile filtered using 0.2 µm filters (Sartorius, cat.-no. 16534), 0.02% (w/v) NaN
3
 were added
and stored at +4°C. The batch purification was carried out for all 1 l-cultures discussed in
chapter 5 and chosen for comparative reason because it comes relatively close to the
purification of the large-scale cultures. A typical elution profile for the batch purification is
shown in figure 2-1.
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3.2 Purification of erythropoietin 
Sample concentration. The harvest was clarified by centrifugation for 5 min at 3000 rpm, the
supernatant decanted into another centrifugal device and centrifuged again for 5 min at
13000 rpm. The supernatant was then passed through a 3.0 micron Zeta plus microfiltration
cartridge followed by a 0.2 micron cartridge Zeta plus, both obtained from Cuno. Small
molecular weight compounds where then removed by ultrafiltration using a Centrasette
casette omega 10 kDa from Pall Filtron (Pall, Basle, Switzerland). 
Anion exchange chromatography. The capture step involved ion exchange chromatography on a
XK 50 column or a Sepharose HighPrep Q XL 16/ 10 column and an ÄKTA system from
Amersham Pharmacia Biotech (Uppsala, Sweden). 20 mM phosphate buffer pH 7.5 was used
as eluent A. Eluent B had the same composition as eluent A with the addition of 2 M NaCl.
Before application to the column the conductivity of the cell culture supernatant was adjusted
with eluent A to 5 mS. At a flow rate of 5 ml/min eluent A was kept at 100% for five column
volumes (CVs), then the sample was applied to the column which was subsequently washed
with another 5 CVs of eluent A. The EPO was eluted by a step gradient to 300 mM eluent B
for 5 CVs and the column washed with 100% eluent B for another 5 CVs. Re-equilibration to
the starting conditions was obtained by washing the column with 5 CVs eluent A. Fractions
of 5 ml were collected using a fraction collector Frac 900 (Amersham Pharmacia Biotech,
Uppsala, Sweden). 
Hydroxyapatite chromatography. EPO was purified further on a hydroxyapatite column (HA
ultrogel, Biosepra, P/N 247751). The column was equilibrated in 20 mM Tris/HCl, 5 mM
CaCl
2
, 0.75 M NaCl and 19% isopropanol at pH 6.9 (sample buffer) before the loading of the
sample. After sample application the column was first washed with 1 CV of sample buffer
and then with 10 mM Tris/HCl, 5 mM CaCl
2
, pH 6.9. Elution was carried out with a linear
gradient from 0-500 mM potassium phosphate in 10 mM Tris/HCl, pH 6.9.
In one experiment the eluting fraction from the hydroxyapatite column was passed again
over an anion exchange column (HiTrap Q Sepharose HP) on the ÄKTA system. The HiTrap
column was equilibrated in 10 mM Tris/HCl, pH 6.9, the sample was loaded and then washed
Figure 2-1. Two batch purification of IgG using re-
combinant protein A. IgG eluted as a single clearly de-
fined peak.
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with 10 CV of 30 mM NaOAc containing 1 mM glycine (Fluka, cat.-no. 50049), pH 4.5,
followed by a re-equilibration with 15 CV of 50 mM Tris/HCl, pH 7.5. Elution was then
carried out with a gradient to 30% of 50 mM Tris/HCL, 1 M NaCl, pH 7.5 in 20 CV.
Fractions were collected for analysis by IEF.
All purification steps were carried out using the ÄKTA explorer 100 system (Amersham
Pharmacia Biotech, Uppsala, Sweden) equipped with a fraction collector Frac 900. Detection
was effected at 280 nm.
3.3.   Purification of Secretory Component
Sample concentration. Cell culture supernatant was centrifuged for 5 min at 1000 g and
subsequently concentrated using an Amicon ultrafiltration cell model 3 (Millipore, Lausanne,
Switzerland). The ultrafiltration cell was equipped with a 10 kD ultrafiltration membrane
YM-10 (Millipore, cat.-no. 13722) and kept under a constant nitrogen pressure of 3 bar. 100
ml of culture supernatant were concentrated to a volume of approximately 4 ml and then
transferred into the binding buffer for Con A affinity chromatography (see below).
Concanavalin A affinity chromatography. For concanavalin A (ConA) affinity chromatography
11 ml of ConA immobilised on Sepharose 4B (Fluka, Switzerland, No 27700) was filled into a
column (1.2 internal diameter i.d.). Prior to sample application the column was washed with 5
mM NaOAc at pH 5.2 containing 0.1 M NaCl, 1 mM CaCl
2
, MnCl
2
, (Manganese chloride
tetrahydrate, Fluka, cat.-no. 63536), MgCl
2
 (Magnesium chloride hexahydrate, Fluka cat.-no.
63065) and 0.02% (w/v) NaN
3
 (binding buffer). The concentrated supernatant was then
applied at a flow rate of 6 ml/min using an Alitea peristaltic pump, model XV (Alitea,
Sweden). For elution 0.3 M methyl-α-D-mannoside (Fluka, cat.-no. 67770) was added to the
binding buffer (elution buffer) and detection was carried out at 215 nm (Verbert, 1995). The
column was extensively washed with binding buffer, pH 3.0 after each run. For storage 0.02%
sodium azide were added to the binding buffer.
Size exclusion chromatography. Desalting of the sample was achieved by passage through a
Bio-Gel P2 (BioRad, cat.-no. 150-4114) column. The column was first equilibrated with PBS
pH 7.4, and 3.5 ml of the sample subsequently applied to the column at a flow rate of 40
ml/h. The void volume containing the protein was collected and filter sterilized using 0.2 m
filters (Sartorius, cat.-no. 16534). The sterile protein solution was stored at +4°C in the
presence of 0.02% (w/v) NaN
3
.
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4.     Analysis
4.1.   Sample concentration
Deglycosylation, IEF-analysis and proteolytic digestion required buffer exchange and/or
sample concentration prior to the experiment. Buffer exchange for proteolytic digestion was
achieved by dialysis against the corresponding buffer using Pierce Slide-A-Lyzer cartridges 10
kDa MWCO (Pierce, cat.-no. 66425). Erythropoietin was concentrated with Centricon YM
ultrafilration devices, 10 kD MWCO (Millipore, cat.-no. 4206) or Microcon
microconcentrators, 10kD MWCO (Millipore, cat.-no. 42407), depending on the volume of
the sample. The same devices were used for the buffer exchange of EPO and SC samples. For
IgG Centricon YM ultrafiltration devices, 30 kD MWCO (Millipore, cat.-no. 4209) were
employed. Centrifuges used were either an Eppendorf (Vaudaux Eppendorf, Basel,
Switzerland) centrifuge 5417R at 13000 rpm or a Hermle Z320K (Hermle, Wehringen,
Germany) at 6000 rpm (4000g). 
4.2.   SDS-Page with Coomassie blue staining
SDS-Page was carried out according to the protocol given by (Lämmli, 1970) on 12.5%
(v/v) acrylamide slab gels made from acrylamide bis 37.5:1 (w/w), 2.6%, BioRad (cat.-no.
161-0158), ammonium persulfate (APS), Fluka (cat.-no. 09913), Dithiotreitol (DTT) obtained
from Pierce, (cat.-no. 20290), N'N'N'N'-Tetramethylethylenediamine (TEMED) from BioRad
(cat.-no. 161-0801). Separation was performed at 200V using the power supply units 3000 Xi
or EPS 600 from BioRad. Coomassie blue staining was achieved by incubating the gel for 30
min in dying solution water:methanol:ACN 5:4:1 (v/v) containing 0.1% (w/v) Coomassie
blue. Gels were destained with an aqueous solution containing 40% methanol and 7% acetic
acid. SDS-Page broad range standard from BioRad (cat.-no. 161-0317) was used as molecular
weight standard.
4.3.   Proteolytic digestion of proteins and electrospray mass spectrometry
For reduction and alkylation the protein was dissolved in 6 M guanidine/HCl and 0.5 mM
EDTA in 0.1 M Tris/HCl, pH 8.5. A 50-fold molecular excess of DTT over total disulfide
was added under nitrogen to reduce disulfide bonds and the solution was shaken for two
hours at 150 rpm in an Eppendorf shaker at 37°C. After addition of a two-fold molar excess
of iodoacetic acid (Fluka, cat.-no. 57840) over DTT under nitrogen the sample was incubated
in the dark at ambient temperature for one hour. An excess of DTT with respect to iodoacetic
acid was added to stop the reaction. The solution was then dialysed overnight in the dark
against 2 M guanidine/HCl in 0.1 M Tris/HCl at pH 8.5 using a Slide-A-Lyzer Cartridge with
a molecular weight cutoff of 30 kDa. 
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The reduced and alkylated protein was diluted 1:2 (v/v) with 0.1 M Tris/HCl buffer, pH
8.5. Subsequently sequencing grade trypsin, TPCK treated (Promega cat.-no. V-5011)
dissolved in 50 mM acetic acid was added at a ratio of protease: protein 1:100 (w/w) and the
sample incubated for 16h at 37°C. Incubation was continued for 7h after a second addition of
trypsin resulting in a 1:50 (w/w) ratio of protein over protease. A peptide map was made after
16h and 23h to confirm that digestion was essentially complete. Peptide mapping was carried
out on a Kontron HPLC system comprising a diode array detector DAD 440 (Kontron,
Basle, Switzerland), a Shimadzu autosampler, Shimadzu SIL-9A (Shimadzu, Basle,
Switzerland), and a Kontron Iris 32s pump on a reversed phase Sulpecosil LC-18 column
(cat.-no. 59209, Sulpecosil, Buchs, Switzerland). Effluent was monitored at 215nm and
280nm. Eluent A contained 0.1% TFA in UHP-water, eluent B consisted of 0.085% TFA in
water:ACN 1:5 (v/v). Proteolytic digests were eluted with a gradient remaining constant for 5
min at 5% eluent A and 95% eluent B, followed by a linear gradient to 50% A and 50% B for
85min and to 5% A and 95% B from 90-110 min. 
Liquid chromatography/electrospray mass spectrometry (LC/ES-MS) IgG was carried out
on a Finnigan LCQ ion trap mass spectrometer in the positive ion mode. On-line RP-HPLC
was performed using the same gradient as specified for off-line HPLC. Effluent was
monitored at 215 nm. Oligosaccharide containing peptides were identified by characteristic
carbohydrate fragment ions at m/z= 204 and m/z= 366.
For identification of the carbohydrate structures the biosynthetic pathway and the mass of
the pentasaccharide core structure were taken into consideration. Carbohydrate masses were
obtained by substracting the known peptide mass, calculated from the peptide sequence, from
the overall mass of the glycopeptide as measured by MS. Table 2-1 gives the masses for
potential monosaccharide residues. In case of biantennary complex-type N-glycans as present
on IgG the experimentally obtained masses usually lead to unique structure proposals.
4.4.   N-glycan release from glycoproteins in solution
The IgG buffer was exchanged to 50 mM phosphate buffer, pH 7.5 with a Millipore
Centricon ultrafiltration device (30 kDa MWCO). SDS was added to give a 1:2 (w/v) ratio.
Reductive conditions were obtained by adding TCEP, ((tris[2-carboxyethyl]phosphin)-
hydrochloride (Pierce, cat.-no 20940) up to a final concentration of 3 mM. The antibody then
was denatured for 5 min at 95°C. Subsequently 10% Nonidet P-40 (NP-40, Fluka, cat.-no.
74385) were added to obtain a ratio of SDS/ NP-40 1:2 (w/v). N-glycanase F digestion of the
Table 2-1.  Monosaccharide mass increments.The theoretical oligosaccharide masses were calculated from the
monosaccharide masses shown below.
monosaccharide fucose hexose GlcNAc NeuAc
mass increment [Da] 146.1 162.1 203.2 291.3
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N-glycans was performed by addition of 1U N-glycanase F (cat.-no. E-5006) per 1 mg
antibody and incubation overnight at room temperature on a lab shaker. After incubation
protein was precipitated by addition of MeOH to a final concentration of 80%, followed by
centrifugation at 13000 rpm in an Eppendorf centrifuge. The precipitate was redissolved
twice in 80% aqueous MeOH and centrifuged to recover all N-glycans from the precipitate.
The pellet was discarded and the supernatant evaporated under vacuum in a Speed Vac
(Savant, SpeedVac Plus UVS 400A and SC 110A rotor). The remaining pellet was
resuspended in 300 µl 2% aqueous ACN containing 0.07% TFA and passed over a Sep Pak
Light C18 Cartridge (Waters, cat.-no. WAT023501) which had been prewashed with 50%
aqueous ACN, 0.07% TFA. Elution was carried out with 15% ACN containing 0.07% TFA.
The solvents were removed under vacuum using a Speed Vac and the sample resuspended in
100 µl Milli-Q water and stored at -20°C. Prior to analysis samples were desalted by pipetting
a droplet of the sample on a VSWP membrane (Millipore, cat.-no. VSWP 02500) floating on
UHP-water for 15 min.
4.5.   N-glycan release from blotted proteins
This method needs less sample and more samples can be handled simultaneously. It
corresponds with some modifications to the method given in (Weitzhandler et al., 1993). 100
µg of protein were denatured in sample buffer for 5 min at 95°C and then applied to a 12.5%
SDS-Page gel. After SDS-Page the samples were electroblotted at 200 mA for 70 Vh to a 0.1
µm PVDF membrane (Millipore, cat.-no. ISEQ15150). The membrane was stained with
Coomassie blue for 10 min and subsequently destained with an aqueous solution of 40%
MeOH and 10% acetic acid. After the membrane was dried at 4 °C the band corresponding
to EPO was excised and transferred into a capped Eppendorf tube. The membrane was
carefully wetted with 10 µl MeOH followed by addition of 200 µl 10 mM phosphate buffer
containing 0.1% TritonX-100, reduced, (Sigma, cat.-no. X-100 RS). The incubation was
started by addition of 5 mU N-glycanase F. Incubation was carried out for 48 h on an
Eppendorf shaker at 37°C.
4.6.   HPAEC analysis of carbohydrates
Briefly summarized OH-groups of enzymatically or chemically released N-glycans are
ionized at a pH of approximately pH 12, obtained by NaOH addition to the eluents.
Depending on the substitutions present on the different monosaccharide residues the
unsubstituted OH-groups show slightly varied pKa values. The small differences in these pKa
values are then used to separate at high pH the different glycan structures on a quarternary
ammonium ion exchange column. Separation is further influenced by the size, anomerity,
linkage type and composition of the structures. 
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N-glycan analysis was carried out on a Dionex DX 500 system equipped with a P 40
gradient pump, an ED 40 electrochemical detector and an AS 3500 autosampler (Dionex
Switzerland AG, Solothurn). Eluent A was Milli-Q-water, eluent B 0.5 M NaOH solution,
prepared from a 50% NaOH solution, (TJ Baker, Deventer Holland, cat.-no. 7067), eluent C
1 M NaOAc. The NaOAc solution was filtered through a 0.2 µm filter (Schleicher and Schüll,
Dassel, Germany, cat.-no. 4011314) before use. Eluents were degassed before use and kept
under constant helium-pressure.
Gradient 0 was initially used for the analysis of N-glycans from IgG
1
. If gradient 0 is not
explicitly indicated gradient 1, which simply had a steeper NaOAc-gradient but was otherwise
identical, was used for the analysis. The NaOH concentration was kept constant at 30%
NaOH. From 0-5 min gradient 0 remained unchanged at 68.5% A and 1.5% C. A linear
gradient over 29 min to 62% A and 8% eluent B was followed by another linear gradient for
30 min to 45% eluent A and 25% eluent C. During a third linear gradient the percentage of
eluent A was decreased to 20% A and 50% B within 60 min. Then the column was washed
for 5 min at 0% A and 70% B before it was re-equilibrated at the initial settings.
Gradient 1, which was used for analysis of IgG1-derived N-glycans remained constant at
30% eluent B over the whole gradient. The other eluents changed as follows: 68.5% eluent A
and 1.5% eluent C for 5.5 min, followed by a linear gradient of 29 min to 62% eluent A and
8% eluent C. Within the next 30 min the gradient changed linearly to 45% eluent A and 25%
eluent C and then in 10 min to 20% eluent A and 50% eluent B. Subsequently the column was
washed with 70% eluent C followed by a return to the starting conditions for 15 min. 
Gradient 2 was employed for the separation of the native structures from rhuEPO. Eluent
B was kept constant at 20% throughout the gradient. Starting concentrations were 78%
eluent A and 2% eluent B. The linear gradient to 60% A and 20% B was started immediately
at t= 0.5 min until t= 60 min. The column was then washed for 15 min at 80% eluent C and
re-equilibrated for another 15 min at the starting concentrations.
Gradient 3 was used for the elution of the desialylated N-glycans from rhuEPO. The
concentrations of 80% eluent A, 20% eluent B and 0% eluent C remained constant for the
first 2.5 min. Then eluent C concentration was increased to 5% and eluent A decreased to
75% within 55 min using a linear gradient. Washing of the column was performed at 30%
eluent A and 50% eluent C for 15 min before returning to the starting conditions which were
maintained for 15 min. The concentration of eluent B remained constant at 20% during the
gradient.
Pulsed Amperometric Detection (PAD). PAD-settings of the ED 40 detector were
identical for all gradients. From 0 s to 0.4 s at +0.05 V, from 0.41 to 0.60 at 0.75 V and from
0.61 to 1.00 at –0.15 V.
An error calculation was carried out on HPAEC N-glycan analysis for the CHO MDJ8s
and CHO AMW cultures. Mean values were calculated according to:
The standard deviation s was calculated according to:
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With n being the number of samples, x the value of the sample, x the mean value of all
measurements and s being the standard deviation.
Identification of carbohydrate structures required additional techniques such as
exoglycosidase treatment, reviewed in (Prime et al., 1996) or spiking with oligosaccharide
standards. HPAEC does not provide absolute quantities as a result because the sensitivity of
the pulsed amperometric detection (PAD) detector varies depending on the structural
features of the compound oxidised on its surface. The term used will be semi-quantitative to
indicate that a given structure may be quantitatively compared to the same structure of
another sample but different structures can not be quantitatively compared or only be
compared with a larger error. Detection limits depend on the sample preparation, especially
the injection buffer, and are normally in the lower picomole range (Dionex, 1997). Cleavage
of the N-glycans by N-glycanase F was controlled by SDS-Page. HPAEC is one of the most
frequently used methods in glycosylation analysis (McGuire et al., 1996; Kunkel et al., 1998),
reviewed in (Lee, 1990; Townsend and Hardy, 1991).
4.7.   Identification of oligosaccharide structures
Oligosaccharide structures were identified using HPAEC either in combination with
exoglycosidases or co-injection with purchased standards. All oligosaccharide standards were
obtained from ECBio (Porto Salvo, Portugal). N-acetylneuraminic acid was obtained from
Aldrich (cat.-no. 85565-0). 
N-glycans from EPO were identified by spiking with standards either in their native or in
their desialylated form. Elution times are listed below. Please note that elution times might be
slightly different in the chromatograms shown later because the column was exchanged
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during the thesis which resulted in slight changes in the retention time. For the structures
please refer table 3-4 and 3-5 in chapter 3. Using gradient 2 elution times were as follows:
bi-0R 14.73 min, tri-0R A 15.72 min, tri-0R B 16.28 min, tetra-0R 16.6 min, bi-1NeuAc-0R
24.48 min, bi-2NeuAc-0R 34.48 min, tri-3NeuAc-0R 46.12 min, tetra-4NeuAc-0R 54.85 min,
tetra-4NeuAc-1R 51.92 min and tetra-4NeuAc-2R 50.28 min. Neutral N-glycans were eluted
using gradient 3 and had the following retention times: bi-0R 31.2 min, tri-0R A 35.95 min,
tri-0R B 37.53 min, tetra-0R 40.05 min, tetra-1R 44.93 min, tetra-2R 49.40 min.
Further structure identification was carried out by digestion with exoglycosidases. All
exoglycosidases were purchased from Glyco Inc. Exoglycosidase digestion was carried out as
described in the instructions provided by the manufacturer except that a phosphate buffer
was given the preference over the recommended buffer since many digestion buffers interfere
with the HPAEC analysis. If necessary buffer pH was adjusted using 1 M HCl and 1M
NaOH. Sample pH was controlled with pH-paper. A sample was always analysed against a
control treated in exactly the same way as the sample but not containing the enzyme.
Sialidase digestion. Free N-glycans from EPO and IgG were digested overnight at 37°C on a
lab shaker with sialidase from either V. cholerae (Glyko, Cat.-No. X-5020) or A.ureafaciens
(Glyko, Cat.-No. 80040) in 50 mM phosphate buffer, pH 5.5. Digestions with sialidase from
V. cholerae was carried out at 1 U/ml enzyme concentration, digestions with sialidase from A.
ureafaciens at 0.5 U/ml enzyme concentration. Contrary to digestions with V.cholerae digestions
with sialidase from A.ureafaciens showed a clear peak for NeuAc using gradient 3. Despite a
clearly defined peak for NeuAc the amount of sialic acid per mol erythropoietin could not be
determined from this analysis since the precise amount of blotted protein was unknown.
α-Galactosidase digestion. α-galactosidase from green coffee bean cleaves specifically
Galα1-3,4,6Gal/Glc linkages (Glyko, Cat.-No. X-5007). It was used to prove absence/
presence of galα1-3gal structures. Incubation was carried out overnight on an Eppendorf
shaker at 300 rpm, 37°C in 50 mM phosphate buffer pH 6.5 at 5 U/ml enzyme per ml
incubation buffer. 
β-Galactosidase digestion. Released N-glycans from the protein were degalactosylated by
addition of β-galactosidase from Bovine testes (Glyko, Cat.-No. X5013) which specifically
cleaves Galβ1-4GlcNAc/GalNAc linkages. Incubation was carried out overnight on an
Eppendorf shaker at 37°C and 300 rpm. Degalactosylation was carried out at an enzyme
concentration of 80 mU/ml.
α-Fucosidase. Defucosylation was performed overnight on an Eppendorf shaker at 37°C
and 300 rpm in presence of 0.5 U/ml α-fucosidase from bovine kidney (Glyko, Cat.-No.
X-5006) in 50 mM phosphate buffer at pH 6.0. The enzyme is specific for Fucα1-6(>2,3,4)R
linkages and was used to study core fucosylation.
β-N-acetylhexosaminidase. The enzyme from Jack bean was purchased from (Glyko, cat.-no.
X-5003) and cleaves GlcNAc/GalNAcβ1-2,3,4,6R linkages. Incubations were carried out at
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enzyme concentrations of 10 U/ml overnight on a lab shaker at 300 rpm and 37°C in
phosphate buffer pH 6.0.
Endo-β-galactosidase. The enzyme from Bacteroides fragilis purchased from (Glyko, cat.-no
E-5001) cleaves the β1-4 linkage in N-acetyllactosamine sequences. N-glycans were digested
by incubation with 100 mU/ml enzyme overnight at 37°C on a lab shaker at 300 rpm in 50
mM phosphate buffer, pH 5.8 containing 250 mg bovine serum albumin and 1 mM NaCl. 
4.8.   Quantification of Carbohydrate Structures by HPAEC
Because the sensitivity of the pulsed amperometric detector (PAD) of the HPAEC system
depends on the oxidised structure no absolute quantification can be carried out by HPAEC.
Since sensitivity remains always constant towards distinct structures the amount can be
quantified and the resulting fractions can be compared to each other (semi-quantitative
analysis). Quantification was carried out using the PeakNet software, version 5.1. After each
the baseline was adjusted manually and the area under the peaks was integrated. For the native
structures of EPO the entire area under one group of peaks representing an identical number
of sialic acid residues was jointly integrated. 
4.9.   Isoelectric Focusing
IEF requires small sample amounts and can be easily carried out on unpurified proteins in
culture supernatants providing that a specific detection method, like immunostaining, is used.
A low amount of sialic acid residues leads to an increased pI of the sample and thus in a shift
of the bands to a more basic region of the gel (Morimoto et al., 1996). IEF was carried out at
least in part on crude supernatants after concentration of the samples and a buffer exchange.
The different sialylation isoforms of erythropoietin can be separated by IEF in the pH
range of 3.5 to 6.5. For the method described here the Pharmacia PHAST system was used
(Pharmacia, Uppsala, Sweden). 250 µg of protein in 3 µl were diluted with an equal volume of
IEF sample buffer containing 0.54 g urea, 600 µl UHP-water, 5 µl Pharmalyte pH 4-6.5
(Pharmacia, cat.-no 17-0452-01) and 50 µl of bromphenol blue (0.05% solution in water),
purchased from Fluka, (cat.-no. 18030). The samples were applied to gels (Pharmacia Phast
Gel dry IEF, Pharmacia 17-0677-01) with a 6/4 sample applicator (Pharmacia,
cat.-no18-0012-29), the gels were rehydrated in 0.4 g urea, 50 µl Pharmalyte pH 2.5-5
(Pharmacia, cat.-no 17-0451-01) and 16.6 µl Pharmalyte pH 4-6.5 for 90 min prior to the
actual run. Separation of the differently charged forms of EPO was achieved by a
pH-gradient ranging from pH 3.5 to 6.5. For separation temperature was kept constant at
15°C, current at 2.5 mA and at 3.5 W. 2000 V were applied for 75 Vh followed by 200 V for
30 Vh. The different glycoforms of EPO were separated with 2000 V for 300 Vh. The
proteins were then blotted on a poly vinylidene fluoride membrane PVDF-membrane, 0.45
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µm pore size, Immobilon P Millipore (cat.-no IPHV 00010) at 20 V, 25mA, 1 W and 15°C for
30 min using Pharmacia PHAST transfer filter paper (Pharmacia cat.-no. 18-1003-18). After
electroblotting the membranes were blocked by addition of a 1% (w/v) solution of BSA in
Tris buffered saline (TBS), pH 7.4 for 1 h at room temperature, then incubated with rabbit
anti-human EPO (Serotec, cat.-no. AHP410Z) at a dilution of 1:1500 for 1 h at room
temperature followed by incubation with goat anti-rabbit alkaline phosphatase labeled
obtained from Jackson Immuno Research laboratories (cat.-no. 111-055-045) at a dilution of
1:15000 for another hour. Between each step and after the last incubation step the membrane
was washed twice with TBS-T followed by two washings with TBS. Staining was carried out
with 200 µl NBT/ BCIP stock solution obtained form Roche (cat.-no. 1681451) suspended in
10 ml substrate buffer (12.1 g Tris buffer, pH 9.5 containing 5.84 g NaCl, 10.17 g MgCl
2
 in 1
l UHP-water) until seven bands of the European Pharmacopeia EPO standard were visible.
The staining was stopped by rinsing the membranes with UHP-water.
Because the carbohydrates remain on the protein for this analysis, IEF gives an
information on the sialylation of the combined glycans still attached to the protein, including
O-glycosylation. This information differs from the information provided by HPAEC which
detects released N-glycans. The method has been already successfully used for sialylation
analysis of EPO (Storring et al., 1998). For data evaluation the samples on a blot were
compared directly in relation to the European Pharmacopeia standard. Intensity of the bands
was measured using the Pharmacia Image Master software, version 1.1. The blots were
scanned and the intensity of all bands on the blot were measured using first the standard
detection settings. Depending on the quality of the blot and the detection settings were
adjusted manually for optimal band recognition. The values used for the graphic depiction are
based on the average signal intensity of the respective bands. For plotting the value of the
most intensive band was set at 100% and all other values adapted correspondingly.
4.10.  Nucleotide-sugar analysis by HPAEC
Nucleotide-sugar analysis was carried out as described by (Tomiya et al., 2001). 3x10
6
 cells
were taken per sample, centrifuged at 100g at 0°C for 3 min. The cell pellet was resuspended
in 10 ml ice-cold PBS and the cells were centrifuged again using the aforementioned settings.
After washing, cells were suspended in 300 µl ice-cold ethanol and sonicated for 1 min with 5
sec pulses at maximum intensity using a Sonicator type 853819 obtained from B. Braun
(Melsungen, Germany) equipped with a Scientific Vibra Cell from Bioblock (Fisher Bioblock
Scientific, Illkirch, France). Subsequently solvent was evaporated from frozen samples under
vacuum using a SpeedVac (Savant SpeedVac plus UVS400A equipped with a SC110A rotor).
After complete evaporation of the solvent the nucleotides were dissolved in 100 µl phosphate
buffer pH 9.2. Samples were either shock-frozen in liquid nitrogen and stored at -80°C or
directly injected. For the analysis the Dionex system described earlier was equipped with a
Dionex A 20 UV-detector and a CarboPac PA-100 column (Dionex AG, Sunnyvale, CA).
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Detection of the sugar nucleotides was effected at 262 nm. Identification of the nucleotide
sugars was carried out by co-injection with standards (UDP-Gal and UDP-Glc 1.64 nmol
each, UDP-GalNAc and UDP-GlcNAc 1.54 nmol each, CMP-NANA 1.81 nmol). The
elution of the standards is shown in figure 2-2. Signal broadening between 10 and 25 min was
caused by a constant elution gradient and led to poor resolution of UDP-HexNAc- and
UDP-Hex-structures. Standards were purchased from: UDP-glucose, (Calbiochem cat.-no.
670120), UDP-N-acetylglucosamine (UDP-GlcNAc, Calbiochem, cat.-no. 670107), Cytidine
(Acros, cat.-no. 111810100), cytidine-5-mono- phosphate (CMP, Sigma cat.-no. C-1006),
uridine (Acros, cat.-no. 140770250) and uridine- 5-diphosphate (UDP, Sigma cat.-no.
U-4125). 
The eluents used for HPAEC analysis were 10 mM sodium hydroxide (A) and 1.25 M
NaOAc in 10 mM sodium hydroxide (B). Buffer B was filtered using 0.2 µm filter (Schleicher
und Schüll, Dassel, Germany, cat.-no. 4011314) before use. Eluents were degassed with
helium and kept under constant helium pressure. The gradient started with 20% (v/v) eluent
B rising to 55% B after 10 min. The gradient then remained constant for 15 min at 55% B
followed by a linear increase to 80% B after 35 min and 100% B after 40 min where it
remained stable for 10 min. After each run the column was allowed to stabilize at the initial
conditions for 20 min. Detection was effected using a Dionex AD-20 at 262 nm, a Carbopac
PA-100 column and the same Dionex system as used for the carbohydrate analysis.
4.11.   Quantification of IgG by ELISA
ELISA plates were incubated overnight at 4°C with 50 µl goat anti-human IgG (Sigma
cat.-no. I-3382) in carbonate/bicarbonate buffer at pH 9.6 at a final antibody concentration
of 3 µg/ml. After incubation overnight the coating solution was removed and the wells
washed three times with PBS/Tween followed by blocking with 200 µl of PBS containing
Figure 2-2. HPAEC-UV chromatograms of nucleotide-sugar standards. Chromatograms show separation of
the standards. Identification was carried out in separate runs for each standard. 
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0.1% (v/v) Tween 20 and 5% Foetal Calf Serum (FCS) for 30 min at 37°C and then washed
three times with PBS/Tween. Prior to sample application the samples were diluted in
PBS/Tween/FCS and the standard, human IgG, reagent grade (Sigma cat.-no. I-4506)
reconstituted and frozen in aliquots in PBS/Tween/FCS at 5 g/ml were diluted 10 times in
the same buffer. Of the standard a dilution range from 15-500 ng/ml was used, two wells with
PBS/Tween served as blanks. 50 µl of standard and samples were pipetted into the wells and
incubated for 1 h at 37°C. After incubation the wells were washed 5 times with PBS/ Tween.
50 µl of anti-human IgG, γ-chain specific (Sigma, cat.-no. A-3188) at a working dilution of
1/2500 in PBS/Tween/FCS were added to each well and the plate was incubated for 1 h at
37°C. After incubation the wells were washed 5 times with PBS/Tween. The plates were then
incubated in the dark with p-Nitrophenil phosphate (Sigma, FAST pNPP substrate tablets,
cat.-no. N-1891), according to the instructions provided by the manufacturer for 30 min at
room temperature. Before reading the absorbance at 405 nm the reaction was stopped by
addition of 50 µl NaOH per well.
4.12.  Quantification of IgG and SC by UV
The samples were measured against the 0.1 M citrate buffer, pH 3.0 of the protein at
280nm. For the relation of the absorption to IgG- and SC-concentration the theoretic
absorption coefficient of 1.41/mg protein (IgG) and 1.1/mg protein (SC) were used.
Quantification was carried out on an Uvikon 930 spectrophotometer from Kontron (Zürich,
Switzerland) against the corresponding buffer.
4.13.  Quantification of EPO
EPO was quantified by RP-HPLC. Before injection samples were centrifuged at 2200 g in
a Sigma 113 centrifuge for 10 min and subsequently passed over a EC 125/4 Nucleosil 300-5
C4 MPN column (cat.-no. 720045.40, Macherey-Nagel, Oensingen, CH) installed on a HP
1100 ChemStation (Agilent Technologies). 
Figure 2-3. Calibration curve for EPO quantification
by RP-HPLC at 215 nm.
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Eluent A was 0.1% (v/v) TFA in UHP- water, eluent B consisted of 0.085% (v/v) TFA
and 80% (v/v) ACN in UHP-water. The gradient remained initially constant for 5 min at 47%
eluent B followed by a linear increase of eluent B to 67% B from 5-25 min, continued to 95%
B within 5 min. Afterwards the column was allowed to re-equilibrate for 10 min at 47% eluent
B. The flow rate was kept constant at 1 ml/min, detection was effected at 215 nm. For the
quantification 2.5 µg of the EPO standard (European Pharmacopeia) was injected with each
run.
5.     Secretion Capture and Report Web
5.1.   Chemicals and reagents in alphabetical order
Alginic acid sodium salt was obtained from Sigma (cat.-no. A-0682, lot 9005-38-3).
Monoclonal IgG, anti-human-secretory component was purchased from Sigma (cat.-no.
I-663). Biotin was purchased from Acros (cat.-no. 230090010). 5-(and-6)- carbofluorescein
succinimidyl ester was obtained from Molecular Probes (Eugene, OR). EZ-Link Biotin-LC-
Hydrazide was obtained from Pierce (cat.-no. 21340), fluorescein-iso-thiocyanate (FITC) was
obtained from Fluka (cat.-no. 46950), fluorescein-Concanavalin A from Vector Laboratories
(CA, USA, cat.-no. FL-1001), hydroxylamine hydrochloride was from Fluka (cat.-no. 55460).
2-morpholinoethane sulfonic acid monohydrate (MES) was obtained from Sigma (cat.-no
69890). 3-Morpholinopropane sulfonic acid monohydrate (MOPS) was purchased from
Sigma (cat.-no. M-3138). Sodium alginate (PMVG) was purchased from (Pronova
Biopolymer, Drammen, Norway, batch.-no 411-256-05), sodium meta periodate from Acros
(cat.-no 7790-28-5). Streptavidin, affinity purified was purchased from Pierce (cat.-no. 21122),
fluorescein-labeled streptavidin was obtained from Pierce (cat.-no 21224). Fluorescently
labelled Ricinus Communis Agglutin I (RCA I) lectin was obtained from Vector Laboratories
(cat.-no. FL-1081).
5.2.   Buffers
MES buffer. MES buffer was prepared by dissolving 0.1 M MES in 900 ml UHP-water. pH
was adjusted to pH 5.5 using either 1 M HCl or 1 M NaOH, the volume was then adjusted to
1l. 
MOPS/CaCl
2
 buffer for bead formation. 10 mM MOPS and 110 mM CaCl
2
 were dissolved in
900 ml UHP-water. The pH was adjusted to pH 7 using HCl and NaOH before correcting
the volume to 1 l.
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MOPS/CaCl
2
 buffer for bead storage. As described above except that the solution contained
10 mM CaCl
2
. For long-term storage exceeding a few days 0.02% NaN
3
 were added to the
buffer. 
Na-bicarbonate. 0.1 M Na-bicarbonate buffer pH 9.0 was used for the fluorescent labeling
reactions. 0.1 M sodium bicarbonate were dissolved in 900 µl UHP-water. pH was adjusted
using 1 M HCl or 1 M NaOH. Then the volume was adjusted to 1 l.
5.3.   Desialylation of Secretory Component
2 mg of SC were incubated with 1U/ml sialidase from A. ureafaciens overnight on a
Eppendorf shaker at 37°C in 50 mM phosphate buffer pH 5.5. After desialylation 0.5 mg of
the sample were used for the control of desialylation by HPAEC according to the protocol
given in paragraph 4.4. after N-deglycosylation by N-glycanase F. 
5.4.   Sample concentration and buffer exchange
If not indicated otherwise samples were concentrated and the buffer exchanged using
Centricon or Microcon ultrafiltration devices, depending on the volume of the sample.
Centrifuges used were either an Eppendorf centrifuge 5417R at 13000 rpm or a Hermle
Z320K at 6000 rpm (4000g).
5.5.   Biotinylation of alginate
2% alginate (w/v) was slowly added to a well-stirred solution of 0.1 M MES, pH 5.5.
Stirring was continued until the solution was clear. EZ-link was added in a molar ratio of 1:20
with respect to the COOH groups present on the protein resulting in a maximal occupation
of 5% of the OH-groups. EDC in 0.1 M MES buffer pH 5.5 was added up to a final
concentration of 1 mM and the sample was stirred overnight at room temperature before the
solution was dialyzed against 10 mM MOPS and 0.92% (w/v) NaCl, pH 7.0 for two days.
Because of the volume increase during dialysis the solution usually was diluted to 1.5-1.7%
alginate (w/v). The modified alginate was filtered sterile and kept at 4°C. For long-term
storage 0.02% NaN
3
 were added to the solution. 
5.6.   FITC labelling
Prior to labelling the buffer of the respective protein was exchanged to 0.1 M
Na-bicarbonate buffer, pH 9.0 using Centricon or Microcon ulrafiltration devices. Samples
were concentrated to a protein concentration of at least 2 mg/ml. 5 mg of the dye were
dissolved in DMSO and the dye solution was slowly added to the well stirred protein solution.
244
After an incubation for one hour on a lab shaker at room temperature in the dark the reaction
was stopped by addition of 1:10 (v/v) of a 1.5 M hydroxylamine solution, pH 8.5. The sample
was dialysed against PBS, pH 7.5 using Pierce Slide-A-Lyzer cartridges, 10 kDa MWCO, at
4°C in the dark on a magnetic stirrer. After dialysis 0.02% NaN
3
 were added and the protein
solution was stored at 4°C in the dark.
5.7.   Biotinylation of the capture antibody
The antibody at was oxidised by addition of 1 ml of cold sodium periodate solution to 1 ml
of cold IgG solution at 2 mg/ml IgG in 0.1 M sodium acetate buffer at pH 5.5 (coupling
buffer). Oxidation was stopped after 30 min at 0°C in the dark by addition of glycerol at 15
mM final concentration. The stopping reaction was allowed to proceed for 5 min at 0°C in
the dark. Following a desalting step in a Slide-A-Lyzer cartridge overnight at 4°C against the
coupling buffer the biotinylation reaction was started by addition of a 50 mM biotin hydrazide
solution in DMSO to a 1:10 (v/v) ratio. The biotinylation reaction was carried out for 2 hours
with agitation at room temperature. Then the sample was dialyzed with a Slide-A-Lyzer
cartridge, 10 kDa MWCO, against coupling buffer at 4°C to remove unreacted biotin. The
sample was stored at 4°C. 0.02% NaN
3
 were added if the solution was stored for more than a
few days. 
5.8.   Incubation of the beads for preliminary experiments without cells
Each step of the bead modification was controlled using fluorescently labeled molecules.
Fluorescence of the sample was measured on a Zeiss Axiovert 100 M confocal microscope
(Zeiss, Oberkochen, Germany) using the LSM 510 software against a negative control.
Excitation was achieved at 488 nm using an argon-ion laser, emission was detected at 520 nm.
The negative control was always incubated with the same amount of fluorescent molecule but
was lacking the last step in bead modification, i.e. the control sample for the attachment of
the capture antibody did not carry streptavidin. 
5.8.1.  Bead formation
Beads were formed manually by dripping biotinylated alginate into the MOPS/CaCl
2
buffer using a syringe type Microlance 3 (Becton and Dickinson, cat.-no. 2005-09) syringe.
Beads were allowed to polymerize for 30 min in the bead formation buffer at room
temperature on a horizontal lab shaker at 100 rpm before being transferred to the
MOPS/CaCl
2
 storage buffer. The beads had an approximate diameter of 1-2 mm and were
stored at 4°C, for long term storage 0.02% NaN
3
 were added.
Materials and Methods
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5.8.2.  Incubation with streptavidin
10 ml of beads in MOPS/CaCl
2
 storage buffer were incubated with 7.5 nmol of
streptavidin for 30 min at 37°C on a lab shaker. After incubation the beads were washed three
times with MOPS/CaCl
2
 storage buffer to remove unbound streptavidin. For the control
experiment fluorescein-labeled streptavidin was used, ratios between labeling molecule and
alginate were identical to the ratios used for the incubation with non-labeled streptavidin. 
5.8.3.  Incubation with fluorescently labelled proteins
Capture antibody, SC and lectin from Concanavalin A. 10 +1 beads in 0.5 ml storage buffer were
incubated for 30 min at 37°C in an Eppendorf tube on a lab shaker. If not indicated otherwise
the amount of the fluorescein-labeled protein added for 10 beads was 200 pmol. A negative
control (see above) was incubated in parallel. After the incubation the beads were washed at
least 4 times with MOPS/CaCl
2
 storage buffer. 
RCA I lectin. For the quantification of the fluorescence on the bead surface a higher
number of beads was used as sample to ensure statistical relevance of the results. About 0.5
ml volume of beads were incubated in a 2 ml Eppendorf tube according to the protocol given
above using 1 nmol of fluorescently labeled lectin from RCA I. 
5.9.   Quantification of fluorescence on the bead surface
Confocal microscopy is not useful in determining the fluorescence on the surface of the
beads. For the taking images a fluorescent microscope Axiovert 100 (Zeiss, Oberkochen,
Germany) and a the Zeiss Axiom software were used. Excitation/Emission were effected at
488 nm and measured at 520 nm. Quantification was carried out using a LabView based
program (programed by Dr. Philip Girard). Fluorescence of a defined bead surface was
measured and the mean value of the surfaces of the sample and the control beads were
compared.
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CHAPTER 3      IDENTIFICATION OF N-GLYCAN 
STRUCTURES
summary
Comparative studies on glycosylation of recombinant proteins under different production
conditions normally do not require exhaustive identification of structural oligosaccharide details.
Often only a certain aspect of the glycosylation is of interest because of its pharmaceutical
value, the relative abundance or because it shows significant changes depending on the culture
conditions. Still, some basic knowledge of the main structures is mandatory for the
interpretation of the results. The carbohydrate analysis in this study aimed at the identification
of the most variable and the most abundant glycan structures of a given protein. Analytical
methods were chosen with regard to their reliability for batch to batch analysis and their
capability to separate the structures of interest. High pH anion exchange chromatography
analysis in combination with exoglycosidase digestion or co-injection with standards turned out
to be in most cases sufficient to identify and monitor these structures. In some cases additional
analysis by Liquid chromatography-electrospray mass spectrometry and isoelectric focusing
were performed to confirm the results. N-glycosylation of the IgG was generally of the
biantennary complex type with an essentially completely fucosylated core structure. Some
N-glycans carried terminal sialic acid residues or the galα1-3gal epitope. Major N-glycan
structures studied on EPO were of the tri- and tetraantennary complex type with zero to two
N-acetyllactosamine repeats, partial terminal sialylation and essentially complete core
fucosylation. Due to the complexity of N-glycans from EPO not all structures could be identified.
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A large number of techniques is nowadays available for oligosaccharide analysis.
Glycosylation studies may be carried out by 
1
H Nuclear Magnetic Resonance (
1
H-NMR)
(Nimtz et al., 1993; Bergwerff et al., 1995), High Performance Liquid Chromatography
(HPLC) with fluorescently labelled carbohydrates (Anumula and Dhume, 1998), Electrospray
Mass Spectrometry (ES-MS) (Hughes et al., 1999), Matrix Assisted Laser Desorption
Ionisation (MALD) MS (Manna et al., 2001), Fast Atom Bombardment Mass Spectrometry
(Sasaki et al., 1988), High pH Anion Exchange Chromatography (HPAEC) (McGuire et al.,
1996; Schlenke et al., 1999), Fluorophore Assisted Carbohydrate Electrophoresis (FACE)
(Masada et al., 1996; Kunkel et al., 1998), Gas-Chromatography (GC) on methylated
carbohydrates (Routier et al., 1997), Isoelectric Focusing (IEF) (Elkon, 1984) and Lectin
Affinity Chromatography (Tandai et al., 1991). The most complete characterisation of glycans
by a single method may be achieved by 
1
H-NMR analysis. However, 
1
H-NMR requires
relatively large amounts of highly pure sample and results are, due to the complex nature of
oligosaccharides, often difficult to interpret. Techniques more frequently used are either
HPLC/HPAEC or mass spectrometric methods. 
1
H-NMR, HPLC- methods, FACE and some mass spectrometric methods require release
of the carbohydrates from the protein backbone prior to analysis. Common methods are
enzymatic cleavage of eukaryotic N-glycans using recombinant N-glycanase F or chemical
release of carbohydrates by hydrazinolysis. N-glycans might be released from proteins in
solution (Verbert, 1995) or from proteins immobilised on a poly vinylidene fluoride (PVDF)
membrane (Papac et al., 1998).
Any of the methods mentioned above supplies distinct but incomplete information on the
glycosylation. A full characterisation of protein glycosylation requires the use of several
analytical techniques providing complementary data. Ideally the methods chosen serve
equally to counter check the results obtained by the other method(s). The complete analysis
of protein-linked oligosaccharides comprises the identification of the glycosylation sites, site
occupancy (macroheterogeneity) and site specific glycan microheterogeneity including type
and number of monosaccharide residues, linkage types, branch-specific glycosylation,
identification of non-carbohydrate substituents like sulfate, phosphate, alkyl- or acyl-groups
and is a tedious and time-consuming task. Semi-automated systems, like FACE are becoming
more popular and sophisticated but provide only limited information on structural details.
Complete identification of the carbohydrate structures might not always be the goal of a
study. Sometimes only a certain feature of the glycosylation is of interest. In this case the kind
of information required guides the choice of the analytical method(s) employed. Structure
analysis may further be simplified if the biosynthetic pathway and common features of
glycoprotein glycans, like the pentasaccharide core structure of eukaryotic N-glycans, are
taken into account. 
In this work structure analysis focused on the identification of the most abundant
structures and those carbohydrate structures which showed the major changes due to
alterations in the production process. A complete characterisation of the oligosaccharides was
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not intended. Preference was given to methods allowing reliable, semi-quantitative batch-to-
batch comparison. Ideally these methods required little or no sample clean-up since
purification steps, e.g. ion exchange chromatography, might be selective and the analytical
result might not reflect the actual glycosylation of the product in the reactor. On the other
hand glycosylation analysis on crude or little purified culture supernatants carries the risk of
including contaminants into the analysis. Adequate controls had to be chosen showing that
the glycans analysed originated exclusively from the glycoprotein of interest. 
In this chapter the results of the structure analysis of IgG and EPO will be presented and
the analytical approach for the batch-to-batch analysis will be discussed. As mentioned
beforehand a complete characterization of N-glycans is time-consuming. Thus model
glycoproteins were chosen which comprised already well-investigated oligosaccharide
structures. The samples discussed in this chapter were chosen arbitrarily as to represent the
complete set of N-glycan structures observed in this thesis. SC was not used as a glycoprotein
for cell cultures but for the development of a screening method which demanded much less
structure analysis. The results of the glycosylation analysis of SC are shown in chapter 7.
1.     N-glycan analysis
In this study glycan analysis was limited to N-linked oligosaccharides, the only exception
being IEF on EPO. IEF does not discriminate between different glycosidic linkage types and
gives combined information on O- and N-glycans. IgG
1
 did not carry O-glycans as
determined by SDS-Page. EPO usually contains a partially glycosylated O-glycosylation site at
Ser 126 (Sasaki et al., 1988). Within N-glycosylation the variable structural features of the
oligosaccharides turned out to be the level of galactosylation and sialylation for the antibody
and level of sialylation, branching and number of N-acetyllactosamine repeats for the EPO. 
Figure 3-1 displays schematically the general approach for the N-glycan analysis. Sample
preparation included separation of the glycoprotein from other proteins which was achieved
either by chromatographic or electrophoretic methods. HPAEC on enzymatically released
N-glycans and IEF on crude cell culture supernatants were used for batch to batch
comparison of the different production runs. Identification of HPAEC signals was achieved
either by exoglycosidase digestion or by co-injection with purchased standards. For the IgG
the results obtained by HPAEC were confirmed by LC/ES-MS.
It should be noticed that the interpretation of the analytical results considered the
pentasaccharide core structure an integral part of each N-glycan structure. Structures
contradictory to the N-glycan biosynthetic pathway were excluded, thereby limiting the
number of potential structures. In the choice of the model glycoproteins preference was given
to glycoproteins which were already well investigated additionally simplifying structure
identification.
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2.     The glycosylation of the anti-rhesus D-antibody
The carbohydrate analysis of antibody-derived glycans presented in this chapter was
carried out on samples from different cell types and produced under different culture
conditions, discussed in chapter 4 and 5. Samples were produced in stirred tank reactors and
purified by protein A affinity chromatography. Deglycosylation was achieved by N-glycanase
F digestion.
Generally, all antibodies carried complex type, essentially entirely core-fucosylated
biantennary N-glycans. The extensions of the core structure were analysed by digestion with
β-galactosidase, α-fucosidase, α-sialidase and β-N-acetylhexaminidase followed by HPAEC
analysis and co-injection with purchased standards. An additional analysis was carried out by
Figure 3-1. N-glycan analysis by HPAEC, IEF and mass spectrometry. For carbohydrate analysis of EPO, IEF
and HPAEC were used to obtain information on the sialylation during the fermentation and the purification
process. N-glycans from IgG were analysed normally by HPAEC, the structures were confirmed by ES-MS.
Identification by HPAEC was carried out either using exoglycosidases or purchased standards. The chromato-
grams and images shown in the figure do not refer to a concrete analysis of one glycoprotein.
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LC/ES-MS. An overview over the carbohydrate structures of IgG and the respective
shorthand notation is given in table 3-1.
2.1.   Structure identification
Prior to HPAEC analysis it was assured that suitable conditions were chosen for complete
enzymatic cleavage of the N-glycans. Figure 3-2 shows a SDS-Page gel on IgG under
reducing conditions before and after N-deglycosylation. The results confirmed that
enzymatic deglycosylation was essentially complete indicating a non-specific release of all
N-glycan structures. The heavy chain (H
c
) of the deglycosylated antibody in the right band
moves slightly further than its native counterpart shown next to the standard. Because of the
absence of additional tripeptide recognition sequences in the protein sequence of the
antibody other N-glycosylation sites than Asn-297 could be excluded. SDS-Page confirmed
additionally the absence of O-linked oligosaccharides. The presence of O-glycans often leads
to double to multiple bands, depending on the number of O-glycans, on the SDS-Page (Kim
Table 3-1. N-linked oligosaccharide structures of the anti-Rhesus D-antibody and the respective shorthand
notation on the left. Monosaccharide residues in brackets signify residues where the presence or absence was
not investigated. Residues not directly connected to one branch may appear on either of the branches.
shorthand symbolic notation
bi-0gal
bi-1gal
bi-2gal
bi-1sia
bi-digal
GlcNAc-Man Fuc
Man-GlcNAc-GlcNAc
GlcNAc-Man
GlcNAc-Man Fuc
Gal- Man-GlcNAc-GlcNAc
GlcNAc-Man
Gal-GlcNAc-Man Fuc
Man-GlcNAc-GlcNAc
Gal-GlcNAc-Man
Sia-Gal- GlcNAc-Man Fuc
Man-GlcNAc-GlcNAc
(Gal-)      GlcNAc-Man
(Gal-) GlcNAc-Man Fuc
Man-GlcNAc-GlcNAc
Galα1-3Gal- GlcNAc-Man
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et al., 1994). Here both fragments, the heavy and the light chain migrated as a clearly defined
single band. 
HPAEC analysis of enzymatically released N-glycans, shown in figure 3-3, revealed three
major N-glycan structures eluting at around 20 min using gradient 1. After sample digestion
with β-galactosidase the two later eluting peaks disappeared, whereas the first peak remained
at its position and its area increased as shown in the right chromatogram of figure 3-3. The
results indicated the presence of N-glycans being terminated with zero, one or two galactose
residues. A purchased fucosylated bi-2gal standard co-injected with the sample (result not
shown) additionally confirmed that the elution time of the latest structure corresponded to a
fucosylated, digalactosylated, biantennary complex-type N-glycan. 
Most mammalian cells produce N-glycans with at least partially fucosylated core structures.
Defucosylation of these structures results in a shift of the N-glycan structure to a slightly later
elution time (McGuire et al., 1996) but the structures elute partially overlapping with the
Figure 3-2. SDS-Page of native and deglycosylated
N-glycans from IgG
1
. The deglycosylated heavy chain
band on the right moves slightly further down than the
corresponding band of the glycosylated heavy chain.
Stand.: standard, deg.:deglycosylated sample.
Figure 3-3. N-glycans of IgG
1
 before (on the left) and after (on the right) digestion with β-galactosidase. Peaks
of N-glycans carrying galactose residues disappeared almost completely after digestion, the bi-0gal peak in-
creased in size.
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fucosylated structures. As a consequence a completely fucosylated N-glycan profile is difficult
to tell from its unfucosylated counterpart. In the case of potentially complete core
fucosylation, defucosylation is better controlled by spiking the defucosylated sample with the
native structures. The profile of the spiking experiment is then compared to the native
pattern. The theoretical peak areas of the spiking experiment, in the case of complete core
fucosylation, can be readily calculated and compared to the experimental result. On the right
of figure 3-4 the result of this experiment is shown. Assuming complete core fucosylation,
relative peak intensities of 33%, 48%, 17%, 2% were expected. The profile of the spiked
samples corresponded to the expected profile and showed 31%, 50%, 17% and 1% for the
respective peak areas. The differences were within the error of the method. It was therefore
concluded that core fucosylation was essentially complete.
The structures of the N-glycans were additionally confirmed by LC/ES-MS on N-glycans
produced by CHO MDJ1 (see chapter 4 for information on CHO clones) as shown in figure
3-5. Proteolytic digestion by trypsin resulted in a glycopeptide E293-R301 of the 9 amino
acids EEQYNSTYR which has the molecular weight of 1189.2 Da. Peptides were separated
by on-line RP-HPLC. Ionisation of the glycopeptide resulted in the generation of a
[M+2H]
2+
 ions with the incremental m/z ratios 1317.6, 1398.7 and 1479.9. From these
values the carbohydrate masses of 1446.0, 1608.2 and 1770.6 were calculated. The
carbohydrate masses expected for the structures shown in figure 3-3 were 1445.2 (bi-0gal),
1608.2 (bi-1gal) and 1770.6 (bi-2gal). Considering an error of 2 Da, the biosynthetic pathway
and the presence of the trimannosyl core structure these masses correspond exclusively to
biantennary, fucosylated N-glycans without GlcNAc
i
 and zero, one or two galactose residues.
The ratio of the structure determined by mass spectrum corresponded to the results of
HPAEC analysis on the same sample and are compared in table 3-2. Although HPAEC-PAD
results are not quantitative due to the varying sensitivity of the PAD detector similar
Figure 3-4. N-glycans from IgG
1
. On the left the control, on the right defucosylated N-glycans spiked with an
identical amount of native N-glycans. The pattern indicates that the N-glycans from IgG
1
 are almost completely
fucosylated in their native form. -fuc = defucosylated structures. 
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structures as observed here for the IgG can be expected to yield similar responses from the
detector and may be compared to the ES-MS results.
Some samples showed more complex HPAEC N-glycan profiles than those so far
discussed. Further structure variety on IgG
1
 derived N-glycans, as shown in figure 3-6 and
figure 3-7 may arise from terminal sialylation, the presence of GlcNAc
i
 or the presence of the
galα1-3gal epitope. 
In figure 3-6 the digestion of a sample with α-sialidase from V.cholerae is shown. N-glycans
after α-sialidase digestion are depicted on the right, the control sample is shown on the left.
In the digested sample one of the peaks eluting between 48 and 50 min disappeared,
confirming the presence of monosialylated structures. The increase in size of the bi-2gal peak
is due to the co-elution of this structure and free NeuAc as confirmed by spiking experiments
Figure 3-5. LC/ES-MS of
the N-glycans from CHO
cells. The section of the spec-
trum displayed here shows
three peaks with m/z incre-
ments of 81 Da which could
be assigned to the bianten-
nary, fucosylated complex
type N-glycans with 0-2 galac-
tose residues. 
Table 3-2. The ratios of N-glycans as determined by LC/ES-MS and HPAEC. Both methods
gave similar results on the relative quantities of the N-glycans.
method bi-0gal [%] bi-1gal [%] bi-2gal [%]
LC/ES-MS 62 34 4
HPAEC 56 37 6
bi-0gal
bi-1gal
bi-2gal
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(data not shown). Contrary to the other samples shown in this chapter the sample was eluted
using gradient 0. Gradient 0 corresponds to gradient 1 except that the NaOAc gradient is
steeper for gradient 1. The final NaOAc concentration was identical.
The same sample was additionally treated with α-galactosidase. The disappearance of the
N-glycan structure eluting at 26 min after enzymatic digestion as shown in figure 3-7
indicated the presence of the immunogenic galα1-3gal epitope in this sample. 
Some samples additionally contained small peaks eluting at 15 min and another peak
eluting shortly after the bi-2gal N-glycan (see figure 4-2 in chapter 4). Small amounts of
bi-0gal lacking additionally one GlcNAc residue and afucosyl bi-2-gal potentially may have
been present in these samples. The presence or absence of these structures could not be
determined by HAPEC because of the low signal intensity. HPAEC chromatography is
sensitive towards increased salt concentrations. Exoglycosidase digestion always needs some
Figure 3-6. HPAEC profile of desialylated N-glycans on the right versus the control sample on the left. Elu-
tion with gradient 0. One peak 47- 48 min vanished after sialidase digestion indicating the presence of monosi-
alylated N-glycans.
Figure 3-7. α-Galactosidase digestion of N-glycans in this sample suggested the presence of the immunogenic
galα1-3gal epitope. The peak at 26 min disappeared after incubation with α-galactosidase. The profile of the
control, which is shown on the left still contained the peak.
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sample buffer increasing the salt content of the sample and renders the chromatograms
difficult to interpret because of noisier baselines and broader peaks.
2.2.   Error of the HPAEC analysis
Several samples were analysed in duplicate to assess the error of HPAEC quantification.
The deviation normally observed was less than + 1% of the mean value of both samples. An
example for some of the analysis carried out in triplicate is given in table 3-3. The values given
include one deglycosylation in duplicate and one injection in duplicate before and after
freezing of the sample. The error for the duplicate analysis was not significantly bigger than
the error of the duplicate injection.
3.     The glycosylation of recombinant human erythropoietin
Glycosylation of human and rhuEPO has already been well investigated (see chapter 1,
paragraph 4.2. for details). The rhuEPO discussed here was produced either in stirred tank
reactors (STRs) or in cell spins by CHO cells. Prior to HPAEC analysis N-glycans were
enzymatically released either from immobilised EPO or EPO in solution. Sialylation of the
EPO has to be determined in another run than branching and the number of
N-acetyllactosamine repeats, since the sialylation strongly influences the behaviour of the
structures in HPAEC analysis. Thus the native N-glycan structures were analysed in a first run
and after desialylation the branching and N-acetyllactosamine repeats were studied. The
major structures were then identified by spiking experiments with purchased standards. In
addition to the EPO produced in our lab the EPO standard from the European
Pharmacopeia was analysed by the same approach. 
Table 3-3. Repeated analysis of IgG N-glycans. Mean value of three analysis (two independent deglycosylation
procedures, one injection in duplicate. Duplicate analysis were occasionally repeated on other samples to assess
reliability of the method and showed essentially the same deviations as mentioned below. + values indicate the
maximum deviation observed.
sample bi-0gal [%] bi-1gal [%] bi-2gal [%]
IgG sample 1 52.7 +0.6 39.2 +0.2 8.3 +0.7
IgG sample 2 52.6 +0.3 38.9 +0.3 8.6 +0.5
IgG sample 3 51.4 +0.7 39.3 +0.5 9.4 +0.5
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3.1.   N-glycan release from immobilised proteins
The method presented for the N-glycan release from IgG requires the sample to be
purified. As will be shown in chapter 6 the purification might be selective for certain
glycoforms. To avoid any influence of the purification on the results N-glycans were released
from immobilised EPO. Crude, concentrated cell culture supernatant was separated by
SDS-Page and blotted to a PVDF-membrane (Weitzhandler et al., 1993). The proteins were
then Coomassie blue stained and the band of EPO was identified by a standard applied to the
same gel. The band containing EPO was excised and N-glycans were cleaved directly from
the immobilised protein by N-glycanase F digestion. Coomassie blue staining does not affect
enzymatic deglycosylation (Kuster et al., 1997). The results were compared to an analysis of
N-glycans released from EPO in solution. 
Enzymatic N-deglycosylation in solution of purified EPO was controlled by
sodium-dodecyl-sulfate (SDS)-Page before and after the deglycosylation. According to the
SDS-Page gel depicted in figure 3-8 N-deglycosylation was essentially complete. Not clearly
visible on the scan, but on the original gel was the splitting of the band of EPO after
deglycosylation into two bands indicating partial O-glycosylation.
In figure 3-9 a Coomassie blue stained blot of EPO of different purity is displayed. The
area which was excised for digestion is indicated by a square on the second band from the
left. As control, the area just above and below and a part of the membrane without sample
was excised and digested by N-glycanase F. None of the results implied the presence of
oligosaccharides on these parts of the membrane (chromatograms not shown). Thus the
bands could be generously excised to analyse all N-glycans without the risk of contamination
by other glycoproteins.
Differences in blotting time between 65 Vh and 85 Vh did not influence the result of the
analysis in a preliminary experiment. Blotting times of less than 60 Vh resulted in a poor
Figure 3-8. SDS-Page of native
and deglycosylated EPO. The
broad band of native EPO is
caused by the different glycofor-
ms of the protein. N-deglycosyla-
tion is essentially complete as
shown in the right band. Not ob-
served on the scan is the right
band consisted of a smaller band
and a larger band indicating that
the EPO was partially O-glyco-
sylated (difficult to see on scan).
Stand.: standard, deg: deglyco-
sylated.
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45.1
31
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sample transfer. A blotting time of 70 Vh at 200 mA was therefore chosen for the analysis of
the different batches.
A direct comparison on the HPAEC profile of N-glycans from an identical sample of EPO
released from EPO in solution and from EPO immobilised on a membrane is shown in
figure 3-10. The chromatograms showed some minor differences, notabely the appearance of
a peak at 20-21 min for the N-glycans released from blotted EPO and in the peak areas of the
less sialylated samples but the overall pattern is highly similar. Because the additional peak
appeared only on HPAEC profiles of N-glycans released from immobilised EPO and was
resistant to sialidase digestion it was considered an artifact of this method. Several small peaks
eluting between 10 and 20 min were detected by samples of N-glycans released in solution
not present on the N-glycan sample from blotted EPO. The differences in the
chromatograms may at least partly be explained by differences in buffer composition and
concentration, purity of the samples and sample amount. 
Figure 3-9. Coomassie blue stained
blot of EPO after separation by
SDS-Page. The EPO band was iden-
tified with a standard in a previous
run, excised from the membrane and
N-glycans were released from the
immobilised protein with N-Glyca-
nase F. The scan here shows EPO of
different purity. The approximate
area which was excised is indicated
on the band next to the standard.
Figure 3-10.  HPAEC chromatograms of N-glycans derived from the same sample of EPO released enzymat-
ically in solution (on the right) and from immobilised protein (on the left). Minor differences in peak separation,
shape and signal intensity might be due to different salt concentrations and other impurities which were not
identical for both samples. Blotted samples always included an artifact eluting at 20-21 min.
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3.1.1.  Reproducibility of N-glycan analysis from immobilised proteins
Deglycosylation from immobilised proteins may introduce a bigger error into carbohydrate
analysis than deglycosylation of enzymes in solution. Smaller sample amount, reproducibility
of the blotting, interference by the Coomassie blue staining and a more difficult access to the
glycosylation site of blotted proteins might interfere with enzymatic digestion. Samples from
the same blot were tested in duplicate and the same sample immobilised on different blots
were used to study the reproducibility of the method. Identical samples from different blots
showed a bigger error than samples blotted to the same membrane. As a consequence
comparison of results from different blots was avoided if the number of the samples allowed
it. Only the comparison of the different CHO cell clones for EPO production necessitated
the comparison of samples from different blots (see chapter 4).
Figure 3-11 shows three times the same sample, analysed in duplicate on one blot and
analysed after immobilisation on another membrane. The repeated analysis of the sample
resulted in a slightly modified HPAEC profile. Tetrasialylated oligosaccharides were less
present whereas the amount of lower sialylated forms increased. This behaviour might be
explained simply by the error of the method which might be bigger if the sample is blotted to
different membranes. Another explanation might be that some desialylation occurred during
storage of the sample. This interpretation was confirmed by other samples analysed
independently in duplicate because these showed usually a smaller error. The error observed
Figure 3-11. The upper two chromatograms show
N-glycans of EPO released from protein blotted on
the same membrane, the differences are essentially
identical. Blotted on another membrane later (chro-
matogram below) the chromatogram showed a par-
tial loss of higher sialylated structures.
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there for the analysis of the sialylated N-glycans actually varied only by +2% (see table 5-12 in
chapter 5 for data). Semi-quantitative analysis of differently sialylated N-glycans was achieved
by integration of peak surfaces under the respective peaks after manual baseline adjustment.
3.2.   N-glycan structures of EPO
Table 3-4. Native N-glycans from EPO in the different forms of notation In the shorthand notation bi/
tri/tetra are standing for the number of branches. LacNAc-repeats and NeuAc are preceded by the number of
residues present on the structure. R = LacNAc repeat. NeuAc not directly attached to a branch may appear on
any galactose residue.
shorthand oligosaccharide structure
bi-1NeuAc 
-0R
bi-2NeuAc
-0R
tri-3NeuAc
-0R
tetra-
4NeuAc-0R
tetra-
4NeuAc-1R
tetra-
4NeuAc-2R
Galβ1-4GlcNAcβ1-2Manα1 Fucα1
6             6
Manβ1-4GlcNAcβ1-4GlcNAc
3
Galβ1-4GlcNAcβ1-2Manα1
NeuAcα2-3
Galβ1-4GlcNAcβ1-2Manα1 Fucα1
6             6
Manβ1-4GlcNAcβ1-4GlcNAc
3
Galβ1-4GlcNAcβ1-2Manα1
NeuAcα2-3
NeuAcα2-3
Galβ1-4GlcNAcβ1
6
Galβ1-4GlcNAcβ1-2Manα1 Fucα1
6             6
Manβ1-4GlcNAcβ1-4GlcNAc
3
Galβ1-4GlcNAcβ1-2Manα1
NeuAcα2-3
NeuAcα2-3
NeuAcα2-3
Galβ1-4GlcNAcβ1
6
Galβ1-4GlcNAcβ1-2Manα1 Fucα1
6             6
Manβ1-4GlcNAcβ1-4GlcNAc
3
Galβ1-4GlcNAcβ1-2Manα1
6
Galβ1-4GlcNAcβ1
NeuAcα2-3
NeuAcα2-3
NeuAcα2-3
NeuAcα2-3
Galβ1-4GlcNAcβ1
6
Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-2Manα1 Fucα1
6                                  6
Manβ1-4GlcNAcβ1-4GlcNAc
3
Galβ1-4GlcNAcβ1-2Manα1
6
Galβ1-4GlcNAcβ1
NeuAcα2-3
NeuAcα2-3
NeuAca2-3
NeuAca2-3
Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1
6
Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-2Manα1 Fucα1
6                                  6
Manβ1-4GlcNAcβ1-4GlcNAc
3
Galβ1-4GlcNAcβ1-2Manα1
6
Galβ1-4GlcNAcβ1
NeuAcα2-3
NeuAcα2-3
NeuAcα2-3
NeuAcα2-3
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The chromatograms and tables shown in this paragraph give an overview of the structures
detected on recombinant human EPO. In table 3-4 the native N-glycan structures of EPO are
shown including the shorthand notation. For retention times please refer to chapter 2,
paragraph 4.7.
Figure 3-12 shows the HPAEC profile of native N-glycans from rhuEPO using gradient 2.
The structures identified by spiking experiments are directly indicated on the chromatogram.
Since the elution time of sialylated structures is mainly determined by the number of sialic
acid residues, structures carrying identical numbers of sialic acids elute close to each other or
overlap. In the chromatogram appear first the neutral structures, then N-glycans carrying an
increasing number of sialic acid residues. Only for the tetrasialylated structures was an
identification of most structures possible. Due to greater heterogeneity of glycoforms with
fewer sialic acid residues these structures can not be clearly separated in their native form.
Not identified was the peak eluting between the di- and trisialylated oligosaccharides.
Structures eluting prior to tetra-4NeuAc-2R may represent N-glycans carrying three
LacNAc-repeats, often detected on rhuEPO (Watson et al., 1994; Ohta et al., 2001).
Subsequently the sample was digested with α-sialidase from A. ureafaciens and eluted with
the same gradient. Because of the broad specificity of the detector, structures on the
chromatogram may not be caused by carbohydrates but by other molecules. After sialidase
digestion no signal eluting after 21 min was detected confirming carbohydrate origin of the
signals observed (chromatogram not shown). For further analysis the oligosaccharides were
desialylated by sialidase addition and were analysed again by HPAEC and gradient 3. The
neutral structures identified by co-injection with purchased standards are listed in table 3-5
Figure 3-12. Identified N-glycan structures in the HPAEC profile of native N-linked oligosaccharides which
were enzymatically released from EPO. The structures were identified by co-injection with purchased standards.
n.i.= not identified. 
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and consisted of bi-, tri- and tetraantennary N-glycans partially elongated with
N-acetyllactosamine repeats. For retention times please refer to chapter 2, paragraph 4.7.
Elution of the neutral structures is mainly determined by their antennarity and the number
of N-acetyllactosamine repeats. Contrary to their sialylated counterpart neutral structures
elongated by LacNAc repeats elute earlier than structures without these repeats. A
chromatogram of desialylated N-glycans is shown in figure 3-13. A quantification of the
amount of NeuAc (as moles sialic acid per mol protein) was not carried out. Due to the
Table 3-5. Identified neutral N-glycan structures of EPO after sialidase digestion. Shorthand notation on the
left. R = LacNAc repeat. 
shorthand oligosaccharide structure
bi-0R
tri-0R A
tri-0R B
tetra-0R
tetra-1R
tetra-2R
Galβ1-4GlcNAcβ1-2Manα1 Fucα1
6            6
Manβ1-4GlcNAcβ1-4GlcNAc
3
Galβ1-4GlcNAcβ1-2Manα1
Galβ1-4GlcNAcβ1
6
Galβ1-4GlcNAcβ1-2Manα1 Fucα1
6            6
Manβ1-4GlcNAcβ1-4GlcNAc
3
Galβ1-4GlcNAcβ1-2Manα1
Galβ1-4GlcNAcβ1-2Manα1 Fucα1
6            6
Manβ1-4GlcNAcβ1-4GlcNAc
3
Galβ1-4GlcNAcβ1-2Manα1
6
Galβ1-4GlcNAcβ1
Galβ1-4GlcNAcβ1
6
Galβ1-4GlcNAcβ1-2Manα1 Fucα1
6             6
Manβ1-4GlcNAcβ1-4GlcNAc
3
Galβ1-4GlcNAcβ1-2Manα1
6
Galβ1-4GlcNAcβ1
Galβ1-4GlcNAcβ1
6
Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-2Manα1 Fucα1
6                                  6
Manβ1-4GlcNAcβ1-4GlcNAc
3
Galβ1-4GlcNAcβ1-2Manα1
6
Galβ1-4GlcNAcβ1
Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1
6
Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-2Manα1 Fucα1
6                                  6
Manβ1-4GlcNAcβ1-4GlcNAc
3
Galβ1-4GlcNAcβ1-2Manα1
6
Galβ1-4GlcNAcβ1
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method employed for the N-glycan release (see paragraph 3.1.) the precise amount of the
deglycosylated protein was not known. The peaks eluting after the tetra-0R and the tetra-1R
structure were not identified by spiking experiments but all structures eluting later than 39
min disappeared after digestion with endo-β-galactosidase (data not shown), indicating that
these structures carried LacNAc repeats. From this result, the literature (Hermentin et al.,
1992) and the elution order of the tetrasialylated N-glycans it was concluded that these peaks
represent the tri-1R and the tri-2R structures. 
N-glycans from EPO may contain, to a smaller extent, structures with more than 2
N-acetyllactosamine repeats (Sasaki et al., 1987; Watson et al., 1994), which might explain the
structures eluting in the chromatogram of figure 3-13 between 48 and 50 min. Although
some changes in the profile occurred, the digestion with endo-galactosidase from B. fragilis
could, due to the small amount of the structures and the poor separation of the peaks already
in the control sample, not clarify the presence of these structures.
3.3.   HPAEC analysis of N-glycans of the EPO standard
Two times 100 µg of the standard from the European Pharmacopeia were immobilised,
cleaved using N-glycanase F and analysed by HPAEC. Figure 3-14 shows the result of the
analysis of native N-glycans. 
A direct confrontation of the profiles of the Pharmacopeia standard and the samples
analysed in this study revealed major differences. Almost 90% of the native structures were
composed of tri- and tetrasialo oligosaccharides with tetra-4NeuAc-0R being the major
Figure 3-13. Identified peaks of desialylated N-glycans from EPO. The small peak between di-0R and tri-0R
could not be identified, the smaller peaks eluting after tetra-2R represent structures could not be identified by
endo-β-galactosidase digestion.
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signal. The remaining 10% consisted almost exclusively of disialo structures. In contrast the
EPO produced in our laboratory consisted of 70-75% tri- and tetrasialo N-glycans after
purification an contained a higher fraction of trisialo oligosaccharides compared to the
standard. 
3.4.   IEF analysis of sialylation
IEF may be used to monitor the sialylation of N-glycans. The information of an IEF is
different than the information obtained by HPAEC because the glycans remain attached to
the protein for IEF analysis, but a sample with a low number of sialic acid residues in HPAEC
should also show more bands with a higher pI in the IEF and vice versa. IEF was carried out
for EPO in a pH range from pH 3.5 to pH 6.5. Samples were subsequently blotted on a
PVDF membrane and EPO was detected by immunostaining. IEF does not reveal any
carbohydrate structures but it can be used to verify the results on different sialylation levels by
HPAEC and was useful to monitor changes in sialylation. 
In figure 3-15 an IEF of different EPO samples is displayed. The results of the IEF were
compared with the HPAEC analysis and did generally confirm the results. The individual
samples will be discussed in more detail in chapter 4, paragraph 2 where the influence of the
Figure 3-14. N-glycan profile of EPO from the euro-
pean Pharmacopeia standard by HPAEC. Native oli-
gosaccharides.
Figure 3-15. IEF pattern of differently sialylat-
ed EPO samples. The results were - as far as it is
possible due to the differences in the method -
confirmed by HPAEC which also indicated a
higher sialylation for samples C1 compared to
the other samples. C1r was a sample from C1 pu-
rified by anion exchange chromatography.
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clone on EPO glycosylation is addressed. Samples containing carbohydrates with lower
sialylation in HPAEC analysis showed, as expected, more bands in the more basic region of
the IEF.
4.     Discussion
Enzymatic deglycosylation resulted in an essentially complete and thus unspecific release
of all N-glycans from both glycoproteins as shown by SDS-Page. Confrontation of the
HPAEC profile of N-glycans released from immobilized protein or protein in solution only
revealed small differences which may be attributed to the general error of the method and the
different loading buffers for HPAEC analysis.
The error for repeated analysis of N-glycans released from glycoproteins in a solution did
not exceed + 1%. Errors might be caused by differences in the eluent preparation,
equilibration of the column and by differences in the manual adjustment of the baseline prior
to peak integration. Adjusting the baseline manually is however necessary since small
differences occur in every run and the automatic peak recognition by the software sometimes
gives poor results. When the N-glycans were released from immobilised proteins the error
increased to + 5%. Reduced accessibility of the N-glycosylation sites due to immobilisation
may be an explanation although it has been reported that the release of N-glycans from
recombinant t-PA was not sterically hindered by immobilisation (Papac et al., 1998).
Differences in the blotting of different glycoforms - which are difficult to assess - and the
significantly smaller sample quantity might have all contributed to an augmentation of the
error. In addition the profile of EPO was much more complex than the profile of N-glycans
from IgG
1
. Because of the complex pattern peaks were usually not well separated which
increases the error of the integration. The bigger error observed for identical samples derived
from different blots may be explained not by the method as such but with the storage of the
samples. All samples were stored at 4°C, analysis on the same sample was usually not carried
out the same day but sometime later. During storage desialylation, which was the major
difference observed, might have taken place due to the presence of sialidase (Warner et al.,
1993). 
For N-glycans from IgG
1
 the HPAEC results were confirmed qualitatively and
quantitatively by LC/ES-MS. Smaller differences comparing the two methods might arise
from the structure-dependent sensitivity of the electrochemical detection used for HPAEC
analysis (Townsend et al., 1989) and the potential fragmentation of oligosaccharides during
ionisation using LC/ES-MS. For EPO the comparison of IEF and HPAEC results showed
that IEF can be used to assess the sialylation of EPO. Most samples were repeatedly
separated, blotted and analysed for satisfying results. Detection settings of the ImageMaster
software had to be adjusted manually for optimal recognition of the bands present on a blot.
The software did not always distinguish between bands and background, especially in the
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region where the sample was applied and bands were usually distorted. Despite the drawbacks
the ImageMaster analysis is useful for visualising the results, especially for comparing scanned
images where also some information is lost due to the minor quality of a scan compared to
the original blot. The graphs shown for the image analysis should be interpreted carefully.
They should be considered a method which gives a useful indication of general trends in the
sialylation of proteins. 
The N-glycans observed for the IgG
1
 correspond to the structures reported in literature
(Fujii et al., 1990; Jefferis et al., 1990; Bergwerff et al., 1995), who found biantennary
N-glycans terminated by sialic acid, galactose or N-acetyglucosamine to be the most
abundant N-linked oligosaccharides on IgG
1
. The level of terminal sialylation of F
c
-derived
N-glycans on IgG
1
 is normally low, (Bergwerff et al., 1995; Lifely et al., 1995) which was also
confirmed by this study. Minor constituents of the IgG glycoform pool may be afucoslyated
structures and oligosaccharides carrying GlcNAc
i
 or the galα1-3gal epitope (Fujii et al., 1990;
Sheeley et al., 1997). The latter was also identified in some of the samples investigated here.
Due to the complexity of N-linked oligosaccharides on rhuEPO the structure analysis of
oligosaccharides from EPO was less complete than the analysis for IgG
1
 derived N-glycans.
Still, most major peaks were identified and all structural aspects of interest, branching,
number of LacNAc repeats and sialylation could be analysed using HPAEC in combination
with exoglycosidase digestion or by co-injection with standards. The N-glycan structures
identified in this study on EPO are in accordance with the structures reported so far in
literature (Sasaki et al., 1987; Sasaki et al., 1988; Tsuda et al., 1988; Nimtz et al., 1993; Watson
et al., 1994; Kanazawa et al., 1999) and were of the complex bi-, tri- and tetraantennary type
with 0-2 N-acetyllactosamine residues and showed partial terminal sialylation. SDS-Page
revealed the presence of partial O-glycosylation which was reported previously on Ser-126
(Lai et al., 1986). The absence of GlcNAc
i
 was not explicitly studied but CHO cells, used for
the production of EPO and most IgG-samples in this study, usually do not posses
N-acetyl-glucosaminyltransferase III (Jenkins et al., 1996) and are consequently incapable of
producing structures containing GlcNAc
i
. 
The N-glycan pool of EPO obtained by the European Pharmacopeia showed qualitatively
a similar pattern but the degree of sialylation was significantly higher. 90% of the native
structures were trisialo and tetrasialo N-glycans. In contrast native N-glycans of EPO
produced in our lab normally consisted of mostly di- and trisialo structures with a significant
amount of monosialo N-glycans, even after purification (see chapter 6 for more details).
Generally sialylation of N-glycans from EPO, including the profile of the European
Pharmacopeia sample, appeared low on HPAEC chromatograms compared to literature
(Watson et al., 1994). This may be caused by the age of the electrode, detector response
towards sialic acids might decrease with time (Weitzhandler et al., 1997; Dionex, 2000). 
HPAEC studies generally gave reproducible results for both analysis, the profiling of
neutral and the profiling of sialylated structures. If samples were analysed from immobilised
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proteins a semi-quantitative comparison of asialo structures and monosialylated structures
was partly handicapped because of the appearance of an artifact co-eluting with the
monosialylated structures. Although this must be considered a potential drawback of the
method this observation is of little practical importance given the observed peak area
normally accounted for only 1-2% of the overall structures.
5.     Conclusions
In this chapter the aim of the carbohydrate analysis for this work was defined. The
analytical methods were introduced, analysis of N-glycan structures on IgG and EPO were
presented, results of different analytical techniques were compared and the error of the
methods was elucidated. The accuracy and reproducibility of the results obtained by HPAEC,
independent of the employed for the N-glycan cleavage, proved it to be a suitable analytical
tool for the batch-to-batch analysis of both model glycoproteins. The important glycosylation
features of the model glycoproteins could be assessed in a semi-quantitative analysis using
HPAEC. Carbohydrate structures of both proteins were, as far as studied, in accordance with
the literature. Given the differences in glycosylation the combination of both glycoproteins
seemed a good basis to study in a general manner the influence of process parameters on the
glycosylation of recombinant proteins.
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CHAPTER 4       CLONAL AND CELL-TYPE DEPENDENT 
N-GLYCOSYLATION OF IgG AND EPO
summary
Glycosylation might vary significantly for different cell types, even if derived from the same
species. This is mainly due to the different enzymes present in different cells and to their
respective activity and expression. Besides clonal differences in glycosylation may occur. The
aim of this chapter was to confirm the influence of the production cell on the glycosylation of the
model glycoproteins. Cell-lines studied for IgG included chinese hamster ovary (CHO) cells, a
murine myeloma cell line, SP2/0 and human embryonic kidney (HEK-293) cells. All cells
produced biantennary, complex-type N-glycans. Variations were observed mainly in the level of
terminal galactosylation. According to HPAEC analysis CHO cells produced N-glycans with
agalactosyl structures accounting for 40-70% of the total N-glycan pool. HEK-293 cells showed
a higher level of galactosylation, agalactosyl N-glycans accounted for less than 30% of the
overall glycan pool. In SP2/0 cells additionally smaller amounts of sialylated oligosaccharides
and the galα1-3gal epitope were detected. Variation in the glycosylation of the IgG if produced
in different CHO clones was limited to changes in the level of galactosylation. Contrary to the
recombinant proteins the N-glycans from human polyclonal anti-Rhesus D-antibodies contained
additionally either afucosylated core structures and/or intersecting GlcNAc. Nine different
clones of CHO cells were analysed by HPAEC and partially by IEF for the sialylation of
erythropoietin. According to HPAEC sialylation varied from 9-45% asialo, 20-34% monosialo,
21-32% disialo, 11-27% trisialo and 1-14% tetrasialo N-glycans. The results confirm a strong
influence of the choice of the production cell-line on the glycosylation, independent of the
glycoprotein.
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A major decision in the process development of recombinant proteins is the choice of the
host cell. For the production of biopharmaceuticals mammalian cell expression systems are
usually given preference because of their capability to perform posttranslational modifications
in a human-like manner. As already discussed in more detail in chapter 1 posttranslational
modifications and especially glycosylation may influence the properties of pharmaceutical
proteins. 
Proteins produced by bacteria normally lack N-linked glycans, few carry O-linked
carbohydrates but the observed structures differed from those present in mammals (Jenkins
et al., 1996). Consequently bacteria are rarely used for glycoprotein production. Yeast, plant
cells and insect cells normally glycosylate proteins but the glycan structures are different from
those observed in human cells. Yeast usually lacks the capability to process N-glycans and
produces oligomannose type N-glycans, often substituted with a large number of mannose
residues (hypermannose structures), reviewed in (Kornfeld and Kornfeld, 1985; Herscovics
and Orlean, 1993). N-glycans derived from plant cells are usually of the complex type. The
trimannosyl core structures may be extended with α1-3fucose or xylose, the latter not being
found on human glycoproteins (Jenkins et al., 1996). 
Insect cells used so far for glycoprotein production include baculovirus transfected
Spodoptera frugipera (Sf9 and Sf21) cells. The N-glycan pool of human interferon-γ (IFN−γ)
produced by Sf9 cells contained predominantly structures with terminal GlcNAc residues and
structures with an incomplete trimannosyl core-structure (James et al., 1995). Monkey
recombinant EPO was produced in Drosophila melanogaster S2 cells (Lee et al., 2000), human
recombinant EPO in Sf9 cells (Quelle et al., 1989). The molecular weight of 24-26 kDa,
observed in both studies, suggests considerable underglycosylation. Contrary to mammalian
N-glycans, N-linked oligosaccharides from insect cells may carry immunogenic terminal
α1-3mannose structures (Donaldson et al., 1999) or fucose attached to the core structure via
an α1-3 linkage, often in addition to the α1-6 linked fucose (Kubelka et al., 1994). Other
reports were more positive about recombinant glycoproteins from insect cells. Despite the
differences in the glycosylation the production of an in vitro functional human anti-RhD in
Sf9 cells was reported (Edelman et al., 1997) but the potential immunogenicity of the
glycostructures was not investigated in this study. Sialylation has not yet been observed in
insect cells but remains subject to discussion (Marchal et al., 2001).
The main characteristics of the glycosylation of different cell types are summarized in table
4-1. Of course glycosylation mutants of each cell type may be created or discovered which
produce different glycoforms (Stanley et al., 1996) but those will not be discussed here. In
mammalian cells the type of N-glycan is usually a conserved feature of the corresponding
glycosylation site, determined by the protein structure, reviewed by (Cumming, 1991).
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Differences in the N-glycosylation of mammalian cells often can be attributed to the
presence/absence or variable activity of glucosaminyltransferases (GnTs,) sialyltransferases
(STs), α1-3 galactosyltransferase and the activity of the different fucosyltransferases (FTs).
Mammalian cell-types commonly considered suitable for glycoprotein production are hamster
cell-lines like chinese hamster ovary (CHO) cells (Werner et al., 1998) or baby hamster kidney
(BHK) cells (Mueller et al., 1999). Another group of rodent cells frequently used are mouse or
rat hybridoma or myeloma cell lines such as SP2/0, NS0 and Y0 (Lifely et al., 1995; Werner et
al., 1998). At least the murine myeloma cell lines SP2/0 and NS0 potentially produce
immunogenic N-glycans with terminal α-galactose residues (Bergwerff et al., 1995; Sheeley et
al., 1997; Baker et al., 2001). NS0 cells were also reported to produce significant amounts of
terminal NeuGc (Baker et al., 2001). Because of these drawbacks mouse cell lines normally
are not employed for the production of pharmaceuticals. Y0 (rat myeloma) cells were
reported to produce complex biantennary structures containing GlcNAc
i
 (Lifely et al., 1995)
which were not found in mouse cell-lines (Tandai et al., 1991; Lifely et al., 1995) but are
present on human N-glycans. 
Table 4-1. Cell type specific glycosylation of non-mammalian and mammalian cells.The glycosylation charac-
teristics listed in the table should not be understood as general qualities. Of course mutants may occur which
glycosylate differently or some subspecies might display different glycosylation.
cell type important glycosylation characteristics
bacteria no N-linked oligosaccharides
no or little O-linked oligosaccharides for some bacteria
yeast (high-) oligomannose structures
insect cells tri-mannosyl core structure 
no or little processed carbohydrate chains 
presence of terminal α1-3mannose
potentially fucose α1-3 linked to the core structure
plant cells tri-mannosyl core structure α1-3-fucosylated 
addition of xylose to the core structure
murine cells potentially produce terminal α-galactose and NeuGc (NS0)
hamster cells
human cells
no GlcNAc
i
produce NeuGc
high diversification depending on tissue type
almost exclusively NeuAc, 
tissue dependent: GlcNAc
i
, α1-3 linked fucose
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Hamster cells usually lack α2-6ST and GnT-III activity. EPO, for example, contains 60%
α2-3 linked and 40% α2-6 linked NeuAc if purified from human urine but recombinant EPO
contains exclusively α2-3 linked NeuAc (Takeuchi et al., 1988). Recently efforts were
undertaken to construct CHO cells which contain both functioning enzymes for the sialic
acid transfer resulting in a more human-like sialylation with α2-3 and α2-6 linked NeuAc
(Grabenhorst et al., 1995; Minch et al., 1995; Bragonzi et al., 2000). The benefit of producing
both linkage types still has to be evaluated. GnT-III was also successfully expressed in CHO
cells (Sburlati et al., 1998; Umana et al., 1999) for the production of IFN-β and IgG
1
, albeit at
product titers below 1 mg/l. Although 80% of the N-glycan pool of EPO produced in a
lymphoblastoid cell line was substituted with GlcNAc
i
 the protein did not show improved
blood clearance rates (Cointe et al., 2000). Some CHO cells produced smaller quantities of
N-glycan structures terminated with NeuGc (Bergwerff, 1994; Baker et al., 2001). 
Employing human cell-lines like human embryonic kidney (HEK-293) cells for the
production for pharmaceuticals is generally considered a risk with regard to the danger of
viral infections and other diseases which might be easily transmitted through such a product.
For this reason human cell lines are usually not considered adequate for the production of
pharmaceuticals. The glycosylation in mammalians varies depending on the tissue type where
the cells are taken from. To our knowledge N-glycosylation of IgG in HEK-293 cells has not
yet been investigated. (Hofmann et al., 2001) concluded from the resistance of a HEK-293
produced glycoprotein to Endoglycosidase-H digestion the presence of complex-type
N-glycans. The enzyme cleaves specifically oligomannose- and hybrid type but not complex
type N-glycans. Human luteinizing hormone produced by HEK-293 carried almost entirely
fucosylated complex type N-glycans without GlcNAc
i
 (Manna et al., 2001).
In industrial production of recombinant proteins nowadays often CHO cells are used
because their glycosylation is relatively close to that of humans and the cells are well
characterised. CHO cells are used for the industrial production of IgG
1
, for example
CAMPATH-1H which was produced by the Wellcome laboratories as an anti-cancer drug or
EPO (by Amgen and the Kirin Brewery) to improve red blood cell formation in patients
suffering from renal failure. 
However glycosylation might not only vary with the cell-type. Clonal differences in
glycosylation were observed for the production of a monoclonal antibody by murine
hybridoma cells (Rothman, 1989) and by SP2/0 subclones (Bergwerff et al., 1995). These
papers reported differences in the ratios of the expressed structures rather than specific
glycostructures for clones. Another paper reported significant differences for the N-linked
glycosylation of a recombinant antibody if produced in two different clones derived from the
same parental B-lymphocyte cell line (Cant et al., 1994).
In this chapter the influence of the cell-type and cell-clone on the glycosylation is
addressed, starting with the anti-RhD antibody as model glycoprotein. Then clonal
differences in the glycosylation of EPO will be described. The aim was to study for a variety
of different cells the changes in the glycosylation of a single product. To our knowledge the
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influence of different CHO clones on the sialylation of N-glycans from EPO has not yet been
studied. The study was limited to mammalian cells since they are currently the only feasible
expression system for recombinant pharmaceutical glycoproteins. While CHO clones for the
EPO production were all cultivated under identical culture conditions the clones for IgG
production were not always cultivated identically. This is partly due to the differences of the
clones, for example adherent clones had to be cultivated differently to clones growing in
suspension, partly to some improvements, mainly to the amino acid content of the medium,
during the project. 
1.     Cell-dependent glycosylation of the anti-Rhesus D-antibody 
1.1.   Cell type dependent glycosylation of IgG
Cell-types included in this study were CHO cells, SP2/0 cells and HEK-293 cells. All
cultures for the comparison study were conducted in stirred tank reactors. SP2/0 and CHO
cells were stable transfected clones, HEK-293 cells were transiently transfected.
Briefly summarised, the glycosylation pattern of the monoclonal antibody (Mab) produced
in the different cell types varied with regard to the level of galactosylation and the presence or
absence of terminal sialylation. In figure 4-1 the basic structure of the IgG linked N-glycans is
displayed. The core structure is shown in italics, the residues written in regular remained
unchanged for all the cell-types studied here. Variation occurred for the residues indicated in
bold. 
N-glycan profiling in the different cell-types was carried out by HPAEC. In figure 4-2 the
chromatograms of enzymatically released N-glycans from each cell type is shown. The results
are summarised in table 4-2. According to HPAEC analysis CHO cells produced exclusively
neutral oligosaccharides with a variable level of terminal galactosylation. Some
chromatograms contained a minor signal appearing before the bi-0gal which could not be
identified using β-N-acetylhexaminidase which cleaves the GlcNAcβ1-2Man linkage. For
details concerning the identification of the structures please refer to chapter 3, paragraph 2.1. 
Figure 4-1. N-glycan structure from IgG
1
. Residues in italics present the core structure, monosaccharides in
bold the variable part of the structure, substituents in regular were always present. The galα1-3gal epitope found
in SP2/0 products is not shown here. The position of the NeuAc residue was not determined.
Galβ1-4GlcNAcβ1-2Manα1 
Galβ1-4GlcNAcβ1-2Manα1
Manβ1-4GlcNAcβ1-4GlcNAcβ1-Asn
6
3
Fucα1-6
NeuAcα2-3
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The antibody from SP2/0 cells carried additionally small amounts of oligosaccharides with
terminal sialic acid residues or the galα1-3gal epitope (see figure 3-7 in chapter 3). The
principal type of sialic acid in SP2/0 derived N-glycans (see also figure 3-6 in chapter 3) was
shown to be N-acetylneuraminic acid which co-eluted with the bi-2gal structure after
digestion. Free NeuGc elutes at 48 min and was not detected by HPAEC and gradient 0.
The HPAEC profile of N-glycans from HEK-293 cells showed, like the pattern of
N-glycans from CHO cells, three major peaks eluting at 19, 21 and 22 min. N-glycans from
both cells co-injected eluted simultaneously suggesting qualitatively identical N- glycosylation.
However, human cells might not entirely fucosylate the pentasaccharide core and might carry
GlcNAc
i
. The retardation in elution time caused by the absence of fucose might be
compensated by the presence of GlcNAc
i
 and thus not be easily visible on the
chromatogram. Additionally the HEK and SP2/0 profiles shown in figure 4-2 shows that a
small peak appeared eluting later than the fucosylated bi-2gal which might have been
afucosylated bi-gal without GlcNAc
i
 or fucosylated bi-gal carrying GlcNAc
i
. N-glycans from
HEK-293 cells where defucosylated with fucosidase from bovine kidney and the pattern was
compared to the pattern of the native structures but the analysis after digestion gave no clear
Figure 4-2. N-glycans of IgG
1
 produced in different
cell-types. CHO cells shown above on the left and
HEK cells, shown above on the right produced a
similar profile but quantitative results varied. The
peaks at 55-60 min in the chromatogram of the HEK
cells could not be related to any oligosaccharide
structure. SP2/0 cells showed a more complex pro-
file. Elution of the N-glycans from SP2/0 was car-
ried out with gradient 0.
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results. The identity of the peak was not further studied. Table 4-2 summarizes the main
results of the carbohydrate analysis Of N-glycans from IgG produced by different cell-types
1.2.   Cell-clone dependent glycosylation of IgG
The three different antibody producing CHO-clones used in this study were all stably
transfected from the same parent cell line (dhfr
-
/dhfr
-
) CHO DG-44. Plasmids for the heavy
and light chain were co-transfected by a modified calcium-phosphate transfection method
(Batard et al., 2001). Production clones were identified by ELISA and cultivated in spinner
flasks to assess long-term stability of the transfection (de Jesus et al., 1999). CHO MDJ1 was
adherent-growing whereas CHO AMW was cultivated in suspension. From the clone CHO
MDJ8 two subclones were selected, one grew in suspension, CHO MDJ8s, the other, CHO
MDJ8m, grew adherently. 
Changes in the galactosylation were observed by comparing the two clones CHO AMW
and CHO MDJ8s as displayed in figure 4-3. These clones were produced under identical
Table 4-2. Main differences of anti-RhD glycosylation in different cell-types according to HPAEC analysis. SP
2/0 cells contained additionally the galα1-3gal epitope and terminal NeuAc. Values of CHO represent data from
different clones (see below). n.d.= below the detection limit of 1-2% of total carbohydrate structures.
1 
fucosyla-
tion essentially complete according to HPAEC, 
2
 see remarks above.
cell-type α1-6fucose bi-0gal GlcNAc
i
galα1-3gal NeuAc
CHO complete
1
40-70% n.d. n.d. n.d.
SP2/0 complete
1
20% n.d. present present
HEK-293 complete
1,2
25% n.d.
2
n.d. n.d.
Figure 4-3. Comparison by HPAEC of typical N-glycans profiles from CHO MDJ8s (on the left) and CHO
AMW (on the right) showed a higher galactosylation for CHO AMW. The slightly earlier elution of the CHO
AMW N-glycans may have been due to the age of the column. The structures derived from both clones co-elut-
ed in a spiking experiment (not shown).
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standard culture conditions in 1l stirred tank reactors. AMW produced 40-45% of N-glycans
without terminal galactose residues whereas usually 65% +5% of the N-glycans from MDJ8s
did not carry terminal galactose. Accordingly the amount of completely galactosylated
oligosaccharides was also doubled in AMW cells. Also the adherently growing clones showed
differences in the level of galactosylation. The amount of agalactosyl N-glycans was 13%
higher in CHO MDJ8m compared to CHO MDJ1. Between the two subclones MDJ8s and
MDJ8m no significant differences were observed. All MDJ clones produced only 5% of
completely galactosylated and 27-35% of mono-galactosylated N-glycans and thus terminated
predominantly in GlcNAc. The results are summarised in table 4-3. The results show for
several clones that the galactosylation of N-glycans from IgG was dependent on the cell
clone.
1.3.   The glycosylation of polyclonal anti-Rhesus D-antibodies
In addition to the glycosylation of the monoclonal antibodies the glycosylation of
polyclonal human antibodies purified from blood was investigated in this study. The antibody
was purified from the current product Rhophylac R using Rhesus positive red blood cells and
subsequently analysed by HPAEC using gradient 1 as described for the monoclonal antibody.
Neutral N-glycan structures released from polyclonal anti RhD, eluting between 18 and 25
min, showed more heterogeneity than the N-glycans from Mabs. Increased heterogeneity is
probably due to the presence of afucosyl N-glycans and oligosaccharides carrying GlcNAc
i
.
The structures were not further studied because of limited sample amount. The elution
position of the peaks at 35-38 min corresponds to those of monosialylated N-glycans.
Disialylated structures which eluted at 46 min using gradient 1 (as determined with a fully
sialylated fucosylated bi-2gal standard) were not present in detectable amounts.
Table 4-3. Overview over the galactosylation of the antibody in different CHO cell clones. Data
for MDJ1 are an average of three batches, MDJ8m a single batch, MDJ8s five batches and AMW
four batches. Values are given as % of total of relative abundance as determined by HPAEC. + val-
ues indicate the maximum deviations observed.
cell clone bi-0gal [%] bi-1gal [%] bi-2gal [%]
CHO MDJ1 55 +2 39 +1 6 +1
CHO MDJ8m 68 27 5
CHO MDJ8s 67 +4 27 +3 6 +1
CHO AMW 43 +3 45 +3 12 +2
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2.     Clonal differences in the N-linked glycosylation of EPO 
Nine EPO producing CHO clones derived from the same parent cell were studied for their
sialylation characteristics by HPAEC analysis. The cells were cultivated for 24h in 175 ml
T-flasks containing 100 ml fresh MAM-PF2 medium supplemented with 0.6 mM
L-glutamine. The main results of the cell culture are summarised in table 4-4.
Cell growth and EPO production varied significantly for each clone. EPO concentrations
in the culture supernatant after a 24 h incubation were determined by RP-HPLC and varied
between 7 mg/l for clone C8 to 26 mg/l for clone C4. Cells grew up to between 1.3x10
5
cells/ml and 8.3x10
5
 cells/ml. Judged purely by the product titers clone C4 looked the most
promising. Viability was around 90% except for clone C6 which only showed a viability of
75% at 1.3x10
5
 cells/ml. Cell concentrations varied significantly despite an only 24 h
incubation since the inoculation was not carried out with a defined cell number but a defined
volume of pre-culture supernatant.
The N-glycans were released enzymatically from EPO which was previously immobilised
on a PVDF membrane after SDS-Page. SDS-Page was carried out directly on cell culture
supernatants after concentration of the samples in centricon tubes. The overview given in
table 4-5 indicates major differences in the sialylation for the different clones. The highest
Figure 4-4. HPAEC profile of N-glycans from
human polyclonal anti-RhD. The profile shows
higher variability for the neutral structures as well
as the presence of monosialo N-glycans.
Table 4-4. EPO production and cell growth of the CHO clones used for the comparison study during the 24
h production period.
culture parameter C1 C2 C3 C4 C5 C6 C7 C8 C9
EPO [mg/l] 13 19 13 26 16 13 14 7 15
viable cells 
[x10
5
 cells/ml] 8.3 4.5 3.9 5.3 2.2 1.3 7.3 6.4 1.4
viability [%] 94 92 87 92 93 75 95 91 89
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level of sialylation - meaning the highest amount of tri- and tetrasialylated structures - was
observed for the clones C1, C2 and C7. Clone C4, which was interesting because of the high
concentration of EPO in the supernatant produced a low amount of tri- and tetrasialylated
structures of 20% compared to 37% for clone C1. Only 2% of tetrasialylated structures were
present in the N-glycan pool of clone C4. All clones produced at least 28% of asialo or
monosialo structures. In clone C6 asialo and monosialo oligosaccharides accounted for
two-third of the total carbohydrate structures. 
The relative ratios of the differently sialylated N-glycans were obtained by integration and
addition of the peak area under the groups of the respective peaks for the a-, mono-, di-, tri-
and tetrasialo structures. The ratios obtained by HPAEC do not represent absolute values
because of variable sensitivity of the detector towards structurally different oligosaccharides. 
HPAEC chromatograms are shown for clone C2 and C3 in figure 4-5. Clone C3 did not
produce significant amounts of tetrasialylated structures (eluting from 51-59 min) but more
than 50% asialo and monosialo N-glycans. N-glycans from clone C2 contained significantly
Table 4-5. Relative ratios of the different sialylation degrees of N-glycans from EPO produced by 9 different
CHO clones obtained by integration of the respective peak areas of the HPAEC profile. NeuAc 0-4= number
of NeuAc residues.
NeuAc C1 C2 C3 C4 C5 C6 C7 C8 C9
0 9 8 17 19 22 45 7 20 10
1 22 21 32 33 32 20 21 32 28
2 32 31 29 28 28 21 30 27 30
3 27 27 17 17 16 11 28 25 14
4 10 14 5 2 1 3 13 6 8
Figure 4-5. HPAEC analysis revealed significant differences in sialylation for different CHO clones. Clone C2
shown on the left sialylated the EPO better than clone C3 shown on the right. Clone C3 produced mostly mo-
nosialo N-glycans.
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more tri- and tetrasialo structures. All other clones showed a sialylation level in between these
two clones. 
These results were confirmed for a selection of clones by IEF. According to the IEF
profile shown in figure 4-6 clone C1 sialylated the EPO similar to clone C2. Both clones
showed more pronounced bands in the acidic region than clone C3 which sialylated the
N-glycans poorly. Clone C6, which carried a similar amount of tri- and tetrasialylated
N-glycans as clone C3 had a similar IEF profile as clone C3. All clones produced N-glycans
with a significantly higher ratio of more basic glycoforms if compared to the European
Pharmacopeia standard as shown in the IEF in figure 4-6.
3.     Discussion
In this chapter the glycosylation of IgG
1
 and EPO produced by different cell-types and
different CHO clones has been compared. IgG
1
 produced by CHO, HEK-293 and SP2/0
cells showed distinct N-glycosylation profiles for each cell-type. CHO cells produced a set of
only three glycoforms consisting of a biantennary complex type N-glycan with essentially
complete core fucosylation, no detectable amounts of GlcNAc
i
 and variable terminal
galactosylation. The structures identified are in accordance with the literature (Routier et al.,
1997; Sheeley et al., 1997). Sialylation, as occasionally reported for a CHO derived IgG
1
(Lifely et al., 1995), was not observed here. N-glycan heterogeneity was more pronounced in
murine SP2/0 cells compared to CHO or HEK-293 cells. The N-glycan pool of IgG from
SP2/0 contained structures terminating in NeuAc and glycans carrying the galα1-3gal
epitope. Both structures have been previously reported for murine myeloma cells (Bergwerff
et al., 1995). According to HPAEC HEK-293 cells produced Mabs with a relatively simple
glycosylation pattern resembling qualitatively the N-glycosylation of the CHO cells. A small
peak eluting after the bi-2gal N-glycan potentially indicated afucosyl bi-2gal or bi-2gal
carrying GlcNAc
i
. Unfortunately defucosylation experiments gave no clear results. Human
kidney cells are generally capable of producing N-glycans carrying GlcNAc
i
 but to our
knowledge HEK-293 have not been reported neither to produce N-glycans carrying GlcNAc
i
Figure 4-6. IEF of different clones confirmed
clonal heterogeneity in N-glycosylation and the
results obtained by HPAEC. Sample C1r is par-
tially purified EPO from clone C1 and will be dis-
cussed later.
pH 6.5
pH 3.5
482
nor to produce substantial amounts of afucosyl N-glycans (Yan et al., 1993; Manna et al.,
2001). The presence of small amounts of any of these structures can however not be
excluded.
Clonal differences in antibody glycosylation were studied closer with the CHO clones
MDJ1, MDJ8 and AMW. Of CHO MDJ8 two subclones were studied, CHO MDJ8m, which
grew adherent and CHO MDJ8s which grew in suspension. Although differences in the level
of terminal galactosylation were observed, the main glycosylation characteristics remained
constant for all CHO clones. According to HPAEC analysis the two subclones showed no
detectable differences in glycosylation, contrary to the observations by (Bergwerff et al.,
1995). The appearance of new types of N-glycans for different clones derived from the same
parent cell as the appearance of hybrid-type N-glycans on IgG (Cant et al., 1994) was also not
observed in this study. Considerable differences might not occur unless the transfection
procedure seriously damages a DNA region associated with oligosaccharide biosynthesis. The
present study confirmed the results obtained by (Rothman, 1989) on clonal differences of
IgG
1
 produced by murine hybridomas and also confirmed that the type of glycosylation is
usually a conserved feature of a distinct glycosylation site (Cumming, 1991). 
Comparing different cell-types and clones it has to be taken into account that these may
need to be grown differently. Murine cells were grown in a different medium than CHO cells,
adherent growing cells need to be cultivated in a reactor type different from cells growing in
suspension. Since the culture conditions might influence the glycosylation, as will be
discussed in chapter 5, differences can not always be attributed to clonal- or cell-type
differences in glycosylation. However, there was little difference observed between the two
subclones of MDJ8 which were cultivated in roller bottles and in stirred tank reactors,
suggesting that the culture conditions in this case did not affect the glycosylation in a
significant manner. As will be shown in chapter 5 the glycosylation of the antibody was rather
robust under different culture conditions. The clones CHO MDJ1 and MDJ8m were grown
identically in roller bottles and the clones CHO AMW and CHO MDJ8s were grown
identically in STRs. Still, the different clones grown identically showed distinct glycosylation
profiles indicating that the observed differences were of clonal origin. It should be kept in
mind though that purely quantitative differences in glycosylation as observed between
HEK-293 and CHO cells and different CHO clones might be true only for certain culture
conditions and that the ratios might shift if other culture conditions were employed. 
EPO was produced in different CHO clones derived from the same parent cell. The
comparative study on the terminal sialylation was carried out under identical culture
conditions for all clones, albeit at different inoculum concentrations. All clones produced
structures with 0 to 4 terminal sialic acid residues but the relative ratio of the sialylated
structures varied significantly. Because of the more complicated carbohydrate structures of
EPO the clonal differences in glycosylation could not be studied in detail. The appearance of
new structures depending on the clone may have occurred. A comparison of the
chromatograms however suggested the glycosylation remained qualitatively essentially
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unchanged for the different CHO clones. The results obtained by HPAEC were confirmed
for a selection of samples by IEF. The structures observed here correspond qualitatively to
those reported in literature (Watson et al., 1994).
Polyclonal anti-RhD showed a higher structural variety than most of the recombinant
antibodies. The set of neutral structures might comprise structures containing afucosylated
N-glycans extended with GlcNAc
i
. Both glycoforms are common on IgG
1
 derived from
human blood (Jefferis et al., 1990). These structures partly co-elute and the number of neutral
glycoforms might actually even be higher than the chromatogram suggests. Sialylated
glycoforms are common on human IgG
1
 but sialylation of N-glycans attached to the F
c
-part
is usually low (Rademacher et al., 1986). Accordingly it was observed in the present study that
the main HPAEC fraction was a neutral N-glycan structure. The glycostructures of human
anti-RhD are discussed here because it served as a control for the biological activity assays of
the recombinant antibodies which will be discussed in chapter 5.
4.     Conclusions
In this chapter the influence of the choice of cell-type and cell clone on the glycosylation
of two different proteins was investigated. IgG produced by different cell-types carried
different sets of N-glycan structure. For different CHO clones variances in the level of
terminal galactosylation were observed but the qualitative pattern was identical for all clones.
Clonal differences in glycosylation with respect to terminal sialylation were also observed for
EPO produced by CHO. The results showed the importance of the choice of the cell-type
and cell-clone for the production of IgG and EPO. 
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CHAPTER 5      GLYCOSYLATION OF IgG AND EPO UNDER 
DIFFERENT CULTURE CONDITIONS
summary
Culture conditions may have an impact on the activity of glycosyltransferases, expression levels
of glycosyltransferases, availability of oligosaccharide precursor structures and their
intracellular transport across compartments, residence time of proteins inside the cell
compartments, and presence of degrading glycosidases in the cell culture supernatant. Culture
conditions may be modified in order to produce pharmaceutical glycoproteins with an improved
glycosylation. In this chapter the influence of medium supplementation, temperature, pH,
butyrate addition and dissolved oxygen on glycosylation were investigated. According to
HPAEC and, in the case of EPO, IEF, culture conditions influenced the glycosylation only to a
smaller extent than initially assumed. For the IgG a decrease in culture temperature from 37°C
to 32°C/33°C and a decrease in culture pH from 7.2 to pH 6.9 decreased the level of
agalactosyl IgG by 10% +2%. Variations in the dissolved oxygen concentration and the addition
of 6 mM butyrate normally showed no detectable influence on the glycosylation of the antibody.
The sialylation of EPO could be improved by adding butyrate at concentrations of 1.5 mM,
according to IEF. At a culture temperature of 34°C instead of 37°C the sialylation of EPO
decreased. It was tested if the decrease in sialylation may be caused by an increment in
intracellular UDP-HexNAc at lower temperatures. Intracellular nucleotide sugars were
measured by HPAEC-UV. Because of low intracellular levels of nucleotide sugars the results
remained unclear. Feeding of GlcN and uridine or ManN and cytidine, which resulted in an
increase of intracellular nucleotide sugars but almost no detectable change in glycosylation
implied that the changed glycosylation at lower temperature might be due to other reasons than
the availability of precursor structures. In summary these results show that cultivation conditions
provided only a limited possibility to change the glycosylation pattern of a given cell line.
The optimisation of culture conditions in the production of recombinant
proteins comprises improvements in titers, cell growth, economic parameters and
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product quality. Aspects of product quality include consistency and homogeneity of the
product, the absence of immunogenic epitopes, normally low clearance rates from blood and
high in vivo biological activity. In the case of glycoproteins any of these factors may be
influenced either by the protein fraction itself or by the glycosylation.
Cell culture conditions have been reported frequently to influence the glycosylation of
recombinant proteins and therefore product quality. The influence of culture conditions on
glycosylation is complex. Different cells might react differently to a changes in the culture
environment while for a given change in a culture condition the outcome may be variable for
different production cell lines. The protein itself plays an important role. Normally changes in
glycosylation due to culture conditions are limited to the relative expression of glycoforms
out of a pool of structures characteristic for a certain glycosylation site of a given protein.
The influence on the glycosylation of changing process conditions may occur at several
levels. mRNA expression of glycosyltransferases might be subject to environmental changes.
The availability and transport of oligosaccharide precursor structures, intracellular and
intracompartmental physiological conditions like pH are affected by a variety of extracellular
parameters. Also the residence time of glycoproteins in the ER and golgi compartments is
considered to be of importance for the glycosylation (Nabi and Dennis, 1998). Once secreted
by the cell the glycoprotein might be a substrate for glycosidases (Warner et al., 1993).
Discussion on the importance of extracellular glycosidases is continuing. (Gawlitzek et al.,
1995; Gawlitzek et al., 2000) argued for biosynthetic, but not degradative, mechanisms for
altered glycosylation patterns because incubation studies with the CHO culture medium
showed no effect on N-glycan integrity despite a significant galactosidase and sialidase
concentration. 
Site-occupancy. Among glycosylation properties affected by culture conditions are
site-occupancy, branching, terminal sialylation, the number of N-acetyllactosamine repeats
and fucosylation. Glucose limitation resulted in diminished levels of the nucleotide sugar
pools and, at extreme glucose starvation, also in decreased site occupancy of IFN-γ (Turco,
1980; Nyberg et al., 1999). Under glucose starvation, a decreased formation of the lipid-linked
dolichol-precursor structure was observed (Jenkins et al., 1994). (Andersen et al., 2000)
reported a relation between site-occupancy of t-PA and the ratio of CHO cells in the
G(0)/G(1) phase but a decrease of site-occupancy over culture time is contradictory to the
results of (Curling et al., 1990) on CHO produced IFN-γ. Diminished site occupancy might
be at least partly avoided by feeding CHO cells with additional lipids (Jenkins et al., 1994).
Sialylation. Many proteins do not display variable site-occupancy of N-linked glycosylation
sites and glycoform microheterogeneity arises exclusively from the presence or absence of,
and the ratio of, different oligosaccharide structures. Sialylation drew a lot of attention
because for some glycoproteins a high level of terminal sialylation was shown to be essential
for extended blood residence times (Takeuchi et al., 1990) and therefore in vivo biological
activity. Serum-free culture media were reported to improve sialylation in stirred tank reactors
(STRs) (Gawlitzek et al., 1995; Marino et al., 1997) and in a serum free suspension culture
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compared to a serum dependent microcarrier process (Watson et al., 1994). Contrary to these
results (Parekh, 1992) reported decreased sialylation of a murine monoclonal antibody (Mab)
in serum-free medium. Sialylation of IFN-γ decreased at the end of a culture with the
beginning of cell death and cell lysis (Goldman et al., 1998). Na-butyrate (Na-but), often
added to cell cultures to increase production, decreased protein sialylation in CHO cells
(Santell et al.). The effects of butyrate addition are increased mRNA levels and changes to the
intracellular pH (Aaronson et al., 1996). Both effects may affect the glycosylation. Decreased
sialylation of cell surface proteins was also observed at elevated pCO
2 
(Zanghi et al., 1999).
Higher ammonium concentrations decreased sialylation of EPO (Yang and Butler, 2000) and
of IFN-ω (Kopp et al., 1996), both produced by CHO cells. The increase in intracellular pH
was identified as the main reason for decreased sialylation in the presence of ammonium
(Grammatikos et al., 1998). An increase in intracellular pH 7.0 to pH 7.2 caused by
ammonium concentrations of 10-15 mM decreased the activity of CHO α2-3 sialyltransferase
by half (Gawlitzek et al., 2000). Both publications argued against the theory that the
concomitant increase of UDP-N-acetylhexosamine (UDP-HexNAc) was responsible for the
diminished sialylation. On the contrary (Pels Rijcken et al., 1995) reported that higher levels
of UDP-HexNAc obtained by feeding uridine and GlcN hindered the transport of
CMP-N-acetylneuraminic acid (CMP-NANA) into the golgi apparatus in rat hepatocytes. An
increased ManNAc level did neither increase surface protein sialylation in healthy human cells
(Thomas et al., 1985) nor sialylation in CHO and NS0 cells (Baker et al., 2001).
Branching. Ammonium ions also influenced the neutral N-glycan structures by affecting the
availability and formation of nucleotide sugars. At higher intracellular
UDP-N-acetylglucosamine (UDP-GlcNAc) concentrations, induced by addition of
ammonium ions, the antennarity of N-glycans on an interleukin variant produced by baby
hamster kidney (BHK) cells increased significantly (Gawlitzek et al., 1998). This effect was
not observed in CHO cells producing an immunoadhesin glycoprotein (Gawlitzek et al.,
2000) although the UDP-HexNAc concentration was significantly higher in CHO cells
compared to BHK cells. Branching of N-glycans on a pro-urokinase derivative in a
lymphoblastoid cell-line was also improved by decreasing the cultivation temperature (Hosoi
et al., 1995). The effect of influencing the availability of activated precursor structures on the
glycosylation might be cell dependent (Baker et al., 2001) since an increase in UDP-GlcNAc
led to higher branching in CHO, but not in NS0 cells, although both cell types showed
reduced sialylation. Increasing the intracellular CMP-NANA pool did not lead to an increase
in sialylation (Baker et al., 2001). 
Galactosylation. According to (Gawlitzek et al., 2000) ammonium ions decreased the
terminal galactosylation in a tumor-necrosis factor-IgG fusion protein. Apparently the
mechanism by which galactosylation is inhibited is identical to that for the inhibition of
terminal sialylation. β1-4GT has its pH optimum at pH 6.5. Ammonium increases the
intracellular pH of the cells and therefore may change the enzymatic activity. Higher cell
densities, which usually go along with higher ammonium concentrations, were often reported
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to result in decreased galactosylation (Lund et al., 1993; Kumpel et al., 1994; Marino et al.,
1997) but ammonium concentrations were not measured in these studies. Lower
galactosylation of a recombinant antibody produced by a murine hybridoma was also
reported at lower pO
2
 (Kunkel et al., 1998). IgG
1
 from CHO cells was less galactosylated
when produced under serum-free conditions (Lifely et al., 1995).
Unfortunately the influence of culture conditions on glycosylation seems to be dependent
on various factors including the cell-line and product investigated. Some papers reported that
the glycosylation of proteins was completely resistant to different culture conditions or
changed only little. Despite major changes in the nucleotide sugar pool induced by glucose
limitation the changes in the N-glycan structures of IFN-γ produced in CHO were small
(Nyberg et al., 1999). Butyrate addition to a CHO culture did not affect the glycosylation of
the IgG
3
 product (Mimura et al., 2001). The glycosylation of a IgG-fusion protein from CHO
cells did not change under low glucose or low glutamine conditions in a continuous culture
(Cruz et al., 2000). pH shifts affected the glycosylation of a recombinant glycoprotein in
CHO only at extreme pH values below pH 6.9 or above pH 8.2 where cell growth and
production were drastically diminished (Borys et al., 1993). CHO derived t-PA glycosylation
remained constant under elevated pCO
2
 except for a slight increase in NeuGc (Kimura and
Miller, 1997). (Gawlitzek et al., 1995) studied the branching of a interleukin-2 variant in BHK
cells in perfusion culture and did not find any differences under several nutrient limiting
conditions. (Werner et al., 1998) investigated the glycosylation for different proteins in CHO
cells and found that glycosylation only changed if culture conditions were pushed to extreme
conditions regarding pH, process time and ammonium concentrations.
In the present study the influence of the culture conditions on the glycosylation of IgG
and EPO were tested. The results imply that glycosylation of a given glycoprotein produced
by a distinct cell line does not change drastically. Many changes in the production parameters
did not influence the glycosylation significantly, for some parameters small changes in the
glycosylation profile were observed. In this study only conditions were tested which were not
counterproductive to cell growth or production. Since it turned out that culture conditions
affected glycosylation of the model glycoproteins to a lesser extent then initially assumed the
studies were carried out to a smaller extent as planned. The value of culture conditions as a
tool to influence glycosylation will be discussed. 
1.     The glycosylation of IgG under different culture conditions
IgG was the first model glycoprotein produced under different culture conditions. Initially
it was intended to test the influence of culture conditions on the glycosylation using different
cell types and cell clones. In serum-free medium (RPMI-1640) the study using SP2/0 was
prevented by the poor production stability of this cell-line. Antibody production of SP2/0
cells decreased by 90% within the first two transfers after thawing a vial from the cell bank
Glycosylation of IgG and EPO Under Different Culture Conditions
91
and cultivation. In spinner flask cultures the resulting antibody titers were 0.05-0.1 mg/l (data
not shown). HEK 293 cells were only transiently transfected and no stably transfected cell
clone, as necessary for such a study, was made available.
For the studies on the influence of cultures conditions on the glycosylation the CHO
clones AMW and MDJ8 were employed. The anti-RhD antibody produced by CHO cells
generally showed a low level of galactosylation (see also chapter 4). Previous publications on
another anti-RhD antibody suggested that a higher level of galactosylation may be desirable
for an efficient functioning of the anti-rhD antibody (Hadley et al., 1995; Kumpel et al.,
1995). Furthermore low galactosylation is associated with diseases like rheumatoid arthritis.
Galactosylation was consequently followed closely during the different cultures. The relation
of galactosylation and antibody performance in vitro biological activity assays, such as the
antibody dependent cellular cytotoxicity assay (ADCC), was studied. 
1.1.   Reproducibility of glycosylation under standard culture conditions
Batch cultures were performed in an Applikon 1.5 l-stirred tank reactor (STR). Standard
culture conditions were: T=37°C, pH 7.2 and 20% DO in serum-free Biowhittaker
ProCHO5-CDM medium supplemented with 4mM glutamine. Unless stated otherwise
aeration was carried out with a mixture of air and pure oxygen. Culture conditions were varied
with respect to pH, pO
2
, temperature and medium composition. Culture conditions for the
experiments discussed in this section correspond to the above mentioned culture conditions. 
In figure 5-1 a typical growth profile of CHO MDJ8s cells and IgG production in a batch
culture is shown. Cells grew up to 6-8x10
6
 cells/ml at day 6 of the culture. IgG production
continued even as cell viability decreased below 50%. Because of continued production
during the stationary phase the culture was harvested late in the batch culture. Typical specific
Figure 5-1. Growth, viability and IgG
production in a typical CHO MDJ8s batch
culture.
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growth rates were in the range of µmax= 0.035-0.045h-1. CHO MDJ8s usually produced
titers between 5 and 15 mg/l according to ELISA. 
Five control reactors of CHO MDJ8s were compared to determine the reproducibility of
glycosylation using the standard conditions. According to the HPAEC analysis shown in table
5-1 the antibody typically carried 67 +4% of agalactosyl, 27 +3% monogalactosyl and 6 +1%
digalactosyl N-glycans. As shown earlier in chapter 3 the error of the analytical method was
smaller than +1%. Although glycosylation under standard conditions did not show extreme
batch-to-batch variations it introduced a bigger error in the analysis than the error of the
analytical method. Several reactors inoculated in duplicate not considered in the present thesis
however suggested that the batch-to-batch error was smaller for reactors of one set of
bioreactors (see also paragraph 1.3.). For the evaluation of the results the more cautious
option was followed and the larger error for different experiments was taken into account.
During the culture of STR-2 the pH increased temporarily to pH 7.8 which may have caused
the differences in glycosylation compared to the other reactors.
Table 5-1. Reproducibility of the glycosylation in the control reactors of CHO MDJ8s by HPAEC
analysis. Values as percentage of overall relative abundance (set as 100%). The table contains two
control reactors of experiments not further mentioned in this thesis. s = standard deviation
 reactor bi-0gal [%] bi-1gal [%] bi-2gal [%]
STR-pH 69 26 5
STR-T1 69 25 6
STR-T2 66 27 7
STR-1 70 25 5
STR-2 62 32 6
mean value and s 67 +4 27 +3 6 +1
Figure 5-2. Growth, viability and IgG
production in a typical CHO AMW batch
culture.
100000
1000000
10000000
0 50 100 150 200 250 300
time [h]
vi
ab
le
 c
el
ls
 
[x1
0e
xp
5 
ce
lls
/m
0
10
20
30
40
50
60
70
80
90
100
vi
ab
ilit
y 
[%
], I
gG
 
[m
g/
l]
viable cells 
viability [%]
c IgG [mg/l]
Glycosylation of IgG and EPO Under Different Culture Conditions
93
Another set of cultures was carried out with CHO AMW. The cell culture conditions were
identical to those described for CHO MDJ8s. Figure 5-2 shows the growth and production of
CHO AMW. CHO AMW cells normally reached a cell density of 2.5-4x10
6
 cells/ml. Despite
lower viable cell concentration and an earlier decrease in viability compared to CHO MDJ8s,
the IgG
1 
titers were higher for AMW cells. The clone normally produced 15-20 mg/l under
standard conditions and up to 100 mg/l after butyrate addition as measured by ELISA. The
ammonium concentration was only measured for STR1, with a maximum value of 1.1 mg/l at
the end of the culture. An overview over the glycosylation in four control reactors is given in
table 5-2. The IgG from control reactor STR2 was galactosylated slightly differently if
compared to the other two reactors. Usually N-glycans carried 43 +3% agalactosyl-, 45 +3%
monogalactosyl-, and 12 +2% digalactosyl N-glycans. As discussed already in chapter 4
galactosylation of CHO AMW derived IgG was generally higher than the galactosylation of
IgG from CHO MDJ8s.
1.2.   The influence of decreased pH on glycosylation
CHOMDJ8s cells were cultivated at pH 7.2 (control) and at pH 6.9. Neither cell growth
nor production was affected by the lower pH. Cells at pH 7.2 grew up to a maximum cell
density of 7.1x10
6
 cells/ml and produced 11.1 mg/l antibody. At pH 6.9 the cells reached a
slightly lower cell number of 6.7x10
6
 cells/ml and produced 10.5 mg/l. The specific growth
rate µmax was higher with 0.053 h-1 at pH 7.2 compared to µmax=0.033 h-1 at pH 6.9. The
growth rate may contain a large error in this case since the exponential growth curve showed
some irregularities. The maximum cell density was attained after 145 h at pH 7.2 and after 133
h at pH 6.9 suggesting that the cells grew rather similarly.
The level of galactosylation in both cultures was compared using HPAEC-PAD after
enzymatic cleavage of the N-glycans. Results are shown in table 5-3. N-glycans from cells at
pH 6.9 carried 10% less agalactosyl N-glycans and 8% more monogalactosyl structures when
compared to the glycosylation of the control reactor. The number of digalactosyl-structures
Table 5-2. Reproducibility of the glycosylation pattern in the control reactors of CHO AMW, de-
termined by HPAEC analysis. The table contains two control reactors from experiments not further
mentioned in this thesis. s = standard deviation.
 reactor bi-0gal [%] bi-1gal [%] bi-2gal [%]
STR1 45 44 11
STR2 39 48 13
STR-But1 44 42 14
STR-But2 46 44 10
mean value and s 43 +3 45 +3 12 +2
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did not significantly increase at lower pH. No other changes than variable galactosylation
ratios were detected by HPAEC.
1.3.   The influence of the Dissolved Oxygen Concentration
Under standard conditions the dissolved oxygen (DO) was maintained at 20% during a
batch culture. In order to assess the influence of the DO on N-glycosylation of the antibody
in CHO MDJ8s cells the DO was maintained either at 50% or at 15%. The reactor at 15%
DO was carried out in duplicate. Cells grew similarly in all three reactors and reached
maximum cell densities of 6.9x10
6
, 6.7x10
6
 and 6.3x10
6
 cells/ml at growth rates µmax of
0.045 +0.001 h
-1
 for the cultures at 15% DO and 0.036 h
-1
for the culture at 50% DO. IgG
concentrations were 13.4 and 15.6 mg/l for the reactors at 15% DO and 11.3 mg/l at 50%
DO and were within the usual variations. Using HPAEC no significant differences in
galactosylation were observed. As summarised in table 5-4 the N-glycans of IgG of all three
reactors carried 61 +2% agalactosyl, 32 +2% monogalactosyl and 6 +1% digalactosyl
N-glycans, the ratios typically observed for CHO MDJ8S cultures. A 2% difference in the
ratio of the different structures was within the error of the method. The appearance of new
structures was not detected.
1.4.   The influence of butyrate
CHO AMW was cultivated with and without the addition of 6 mM Na-butyrate under
standard conditions. Addition was effected either at day 4 or 5 when the cells entered the
stationary phase. The addition of butyrate to the medium normally led to an increase in
production of the antibody from 10-20 mg/l in control cultures to up to 100 mg/l in cultures
supplemented with butyrate. The specific growth rate µmax varied between 0.036 and
Table 5-3. The galactosylation of IgG produced by CHO MDJ8s cells at different cultivation
pH. Decreasing the pH to pH 6.9 improved the galactosylation according to HPAEC analysis.
pH bi-0gal [%] bi-1gal [%] bi-2gal [%]
7.2 69 26 5
6.9 59 34 7
Table 5-4. The galactosylation of N-glycans from IgG produced by CHO MDJ8s at different
pO
2
 remained essentially constant. Analysis by HPAEC. Culture 15% DO mean value of two
reactors.
DO [%] bi-0gal [%] bi-1gal [%] bi-2gal [%]
15 61 +2 32 +2 6 +1
50 63 30 7
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0.046h
-1
 without any recognizable trend caused by butyrate addition. For the control reactor
of the second experiment the growth rate was not calculated because of an irregular
exponential growth curve. In the second and third experiment IgG titers increased for the
cultures containing butyrate from 4.5 mg/l to 17 mg/l and from 15.2 mg/l to 88.2 mg/l
respectively. An increase in production was not be observed for the first set of reactors where
the titers were 42 +1 mg/l for both reactors.  
As shown in table 5-5 it was observed in a first experiment that the addition of 6 mM
Na-butyrate at day 5 to the culture medium resulted in a decrease in agalactosyl N-glycans
from 44% in the control culture to 35% in the culture containing butyrate. The amount of
bi-1gal and bi-2gal increased correspondingly.
The increase was a unique observation which could not be repeated in two subsequent
experiments. The second set of experiments showed an unusually high amount of agalactosyl
IgG from CHO AMW. The result might be explained by the extremely late harvest at cell
viabilities of less than 5%. At such a late stage of the culture some product degradation might
occur. All cultures contained 52% agalactosyl, 38-39% monogalactosyl and 9-10%
digalactosyl N-glycans. Differences in the glycosylation because of Na-butyrate addition were
not observed during this experiment. 
In a third experiment the harvest time was comparable to experiment 1 and galactosylation
showed a normal level for CHO AMW with 46-48% agalactosyl, 43-44% monogalactosyl and
9-10% digalactosyl N-glycans. The decrease in galactosylation caused by butyrate addition, as
observed in experiment, 1 was not reproduced in this experiment. It was concluded that the
differences in glycosylation observed in the first experiment were due to other reasons than
the butyrate addition. 
Table 5-5. Influence of 6 mM butyrate on the galactosylation of IgG according to HPAEC analysis. 
reactor bi-0gal [%] bi-1gal [%] bi-2gal [%]
control 44 42 14
6 mM Na-but. day 5 35 49 16
control 52 39 9
6 mM Na-but. day 4 52 39 9
6 mM Na-but. day 5 52 38 10
control 46 44 10
6 mM Na-but. day 4 48 43 9
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1.5.   The influence of glucose addition
IgG produced in a CHO MDJ8s culture maintained at a glucose concentration of 1 g/l
showed higher galactosylation as the average of the control reactors, containing 54%
agalactosyl, 41% monogalactosyl and 5% digalactosyl N-glycans. The control reactor was
contaminated, therefore the glycosylation was compared against the average of the control
reactors as shown in table 5-1. Average control reactors contained bi-0gal:bi-1gal:bi-2gal
N-glycans in a ratio of 67:27:6. Because the amount of digalactosyl N-glycans was 13% lower
than in the average control reactor the result indicated that galactosylation improved due to
the feeding of glucose. Table  5-6 summarizes the results of this experiment. As already
observed before changes in glycosylation were exclusively quantitative. 
1.6.   The influence of temperature
The cultivation temperature in many processes is set at 37°C, because at this temperature
cell growth and viability are highest. Lowering the culture temperature is usually considered
because it may decrease the amount of side products and may increase the production or
improve the product quality (Ducommun et al., 2002). 
In this study a culture of CHO MDJ8s was carried out at 37°C and at 33°C/32°C.
Temperature shifts were carried out for the 32°C experiment at day 3 and for the 33°C
experiment at day 5 at the onset of the exponential growth phase. With the exception of
temperature the reactors were maintained at standard conditions. All cultures reached a
Table 5-6. The galactosylation of N-glycans from IgG produced by CHO MDJ8s after glucose
addition. Due to a lack of a control sample the glycosylation was compared to the average control
reactor.
reactor bi-0gal [%] bi-1gal [%] bi-2gal [%]
+ Glc 54 41 5
control 67 27 6
Table 5-7. Influence of lower cultivation temperature on the glycosylation of IgG. Analysis by
HPAEC.
temperature [°C] bi-0gal [%] bi-1gal [%] bi-2gal [%]
37°C 69 25 6
32°C, day 3 53 41 7
37°C 66 27 7
33°C, day 5 59 36 5
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maximal viable cell concentration of 5x10
6
-6x10
6
 cells/ml. IgG titers varied between 17 and
18 mg/l for the first experiment and 11 and 15 mg/l for the second experiment according to
the ELISA assay. 
The results listed in table 5-7 show that at lower temperatures the galactosylation was
improved. The IgG
1
 produced at 32°C carried only 53% of agalactosyl N-glycans whereas the
antibody from the control reactor contained 69% of agalactosyl structures. The fraction of
the bi-1gal structure changed correspondingly, whereas the fraction of the bi-2gal remained
constant. As expected the effect was still visible, though less pronounced, for the temperature
shift to 33°C at day 5. At 33°C the ratio of agalactosyl N-glycans was diminished by 7% from
66% to 59%.
1.7.   β-galactosidase activity 
Low galactosylation may be attributed to galactosidase activity in the cell culture
supernatant, in particular the supernatants of cultures terminated late may contain
galactosidase liberated from dead cells. To determine whether the low galactosylation in
almost all CHO samples of this study may be caused by degradation, 2 mg protein A purified
IgG were incubated in 20 ml IgG-free cell culture supernatant from CHO AMW cells at
37°C, 5%CO
2
 for five days. For this experiment the purified IgG from the second and third
experiment of the butyrate addition (all from CHO AMW) were pooled. A control sample
was incubated in elution buffer at pH 7.0 using the same conditions. Sample and control were
sterile filtered before incubation. After five days the sample was purified by protein A batch
purification. Galactosylation was controlled by HPAEC after enzymatic release of the
N-glycans and is shown in table 5-8.
Both samples showed essentially identical levels of galactosylation with 47%-48% of
agalactosyl, 42-44% monogalactosyl and 9-10% digalactosyl N-linked oligosaccharides. Either
β-galactosidase was not present or not active under the conditions used for incubation and
cultivation. The result showed clearly that the low galactosylation observed must be attributed
to the culture conditions and were not due to degradation of the product.
Table 5-8. The galactosylation of IgG after incubation in culture supernatant for five days. Anal-
ysis by HPAEC. 
sample bi-0gal [%] bi-1gal [%] bi-2gal [%]
control 48 42 10
sample 47 44 9
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1.8.   The inhibition of N-glycosylation by addition of tunicamycin
Tunicamycin is an analogue of UDP-N-acetylglucosamine (UDP-GlcNAc) and inhibits the
addition of UDP-GlcNAc to the dolichol precursor structure (Stryer, 1990). It can therefore
be used to produce partially or completely unglycosylated proteins. Unglycosylated IgG
1
served as a negative control for the ADCC assay because, deprived of the glycan moiety, IgG
is not recognized by macrophages (Nose, 1983). While a minimum concentration of
tunicamycin is required to effectively prevent glycosylation, higher concentrations are toxic.
The precise concentrations are dependent on the clone and have to be experimentally
determined. 
In a preliminary experiment 0.1 mg/l, 0.5 mg/l, 1 mg/l, 1.5 mg/l and 2 mg/l tunicamycin
were added to the medium of cells cultivated in so-called tube spins. Tube spin cultures were
performed in 50 ml falcon tubes containing 5 ml medium. The tubes were placed on a lab
shaker and cells were incubated at 37°C. From these cultures the tunicamycin concentrations
of 0.5, 1 and 2 mg/l were chosen for the production in cell spins. Culture volume was 50 ml,
cell spins were incubated at 37°C and 5% CO
2
. The main culture parameters are summarized
in table  5-9.
Tunicamycin at a concentration of 1 mg/l and more proved toxic for the cells. Addition of
0.5 mg/l did not affect IgG production. Cell viability remained high at 92% at 0.5 mg/l
tunicamycin but cell growth was already inhibited. Cells grew only to a maximum cell density
of 9x10
5
 cells/ ml compared to 5.1x10
6
 cells/ ml in the control culture. The maximum cell
number dropped to 2.5x 10
5
 cells/ ml at 1 mg/l of the antibiotic and to 9x10
4
 cells/ml at 2
mg/l. Cell viability also decreased to 50% and 10% respectively. Product titers were in both
cases around 1 mg/l as determined by ELISA. Figure 5-3 shows the analysis of the samples
by SDS-Page. The control culture produced IgG which showed one defined band for the
heavy chain indicating essentially complete N-glycosylation. The lane with the sample
produced at 0.5 mg/l tunicamycin shows a much broader, less defined band indicating the
presence of a heavy chain of two slightly different molecular weights. At an antibiotic
concentration of 1 mg/l most of the heavy chain moved further compared to the control.
Only a small amount remained glycosylated and moved as the heavy chain of the control
sample (difficult to recognize on the scan). Of the sample produced at 2 mg/l too little IgG
was available for the ADCC assay and the sample was discarded. 
Table 5-9. Cell growth and IgG production in the presence of tunicamycin. IgG concentration measured
by ELISA.
culture parameter control 0.5 mg/l 1 mg/l 2 mg/l
viable cells [x10
5
cells/ ml] 51 9.0 2.5 0.9
viability [%] 80 92 50 10
c
IgG
 [mg/l] 3.7 3.5 1.1 0.8
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1.8.1.  Galactosylation and the biological activity in the ADCC assay
Biological activity of the antibody was tested in vitro with the antibody-dependent cellular
cytotoxicity assay (ADCC) using lymphocytes, according to the method described by
(Urbaniak, 1979) with slight modifications. Rhophylac, a commercially available polyclonal
anti-Rhesus D pharmaceutical served as control sample. The glycosylation of this sample was
discussed earlier in chapter 4, paragraph 1.3. ADCC measures the lysis of antibody coated
targets by immune cells. The aglycosylated antibody was intended to be used as a negative
control for the ADCC. Because tunicamycin was toxic at concentrations which were not
sufficient to completely prevent glycosylation some remaining activity was expected for the
deglycosylated antibody.
Figure 5-4 shows the results of the ADCC assay for a selection of samples, relating
antibody galactosylation to ADCC activity. As expected the - partially- unglycosylated
antibody showed lower activity in the assay as shown on the right. Rhophylac and the control
antibody show similar lysis. Lytic activity decreased for antibodies produced at higher
tunicamycin concentrations. On the left the activity of Rhophylac, IgG
1
 from CHO AMW
Figure 5-3. SDS-Page of IgG produced at different
levels of tunicamycin and an IgG sample from a previ-
ous experiment (IgG old). The lanes show from the
left to the right rising tunicamycin levels. Differences
in the migration caused by - partial - deglycosylation
are small and difficult to see on the scan. 
Figure 5-4. The results of the ADCC assay on differently galactosylated IgG and, as control, the ADCC assay
results of - partially - unglycosylated IgG on the right. The results clearly showed that galactosylation did not
affect the activity of the antibody in the ADCC assay. -gal: degalactosylated sample. 
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before and after β-galactosidase and IgG
1
 from CHO MDJ8s are shown. None of the three
samples showed significant differences indicating that galactosylation did not influence in vitro
biological activity of the antibody, as determined by ADCC.
2.     The influence of culture conditions on the glycosylation of erythropoietin
The glycosylation of IgG was influenced by temperature, monosaccharide addition and pH
consequently these parameters were also studied, or intended to be studied, for EPO.
Butyrate gave no reproducible results for the antibody glycosylation but improved titers and
was consequently also studied for EPO. Because of time limitations and a more intensive
study on the influence of temperature on glycosylation the pH experiments were not carried
out. It was assumed that the changes in glycosylation at lower temperature were due to
modified intracellular activated sugar concentrations. The influence of feeding different
precursors for the oligosaccharide synthesis was investigated and the effect of a lower culture
temperature on intracellular nucleotide-sugar levels was also studied. Serum-free CHO cell
cultures were carried out in STRs and spinner flasks, the process types (batch, repeated batch)
were varied. Culture pH in STRs was maintained at pH 7.2 and DO at 40% air saturation. The
MAM-PF2 medium from Amimed was supplemented with 2 mM glutamine. Cultures were
carried out with CHO clone C1 (see also chapter 4, paragraph 2). 
2.1.   Sialylation during a batch culture 
Glycosylation may vary during a batch culture since the composition of the culture
medium varies significantly during the process. Proteases and glycosidases might be secreted
by - dead - cells into the medium and further change the glycosylation of the product. A
sensitive issue here is the secretion of sialidases which are assumed to decrease sialylation
especially at late stages in CHO cultures (Warner et al., 1993). 
Figure 5-5. Growth and EPO production during a
batch culture are shown in the graph on the left. EPO
production continued during the stationary phase even
after onset of cell death at. Viability dropped to from
90% at 80h to 50% at 150h.
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To assess the change in sialylation samples of different stages of a batch culture were
analysed by IEF. Cells were cultivated at the 2l scale in a Labfors bioreactor. Sampling for the
IEF analysis was effected at the beginning of the culture, during the growth phase, the
stationary phase and after a decline in cell viability to approximately 50%. The growth and
production of EPO for the culture are shown in figure 5-5. Cells grew with a µmax of
0.037h
-1 
up to a maximum of 2x10
6
 cells/ml after 80h. The specific production rate was
2.49x10
-13 
gcell
-1
h
-1
. The IEF in figure 5-6 shows that the sialylation profile of EPO
remained essentially constant during the exponential growth phase. The first sample (S05,
34.5h), taken at the beginning of the growth phase could not be compared to the other
samples. because of its faint signal even after concentration of the sample. The most basic
bands showed an increase in intensity at the end of the culture (sample S14) but the overall
pattern remained essentially identical. Although the results did not unequivocally indicate
product degradation samples for glycosylation studies were always taken before cell viability
decreased as a security measure.
2.2.   Addition of butyrate to cell spin cultures
As shown in chapter 5, paragraph 1.4. for the IgG production, butyrate may significantly
increase the production of recombinant proteins in mammalian cells. To assess the effect of
butyrate on the production of erythropoietin either 1.5 mM or 5 mM Na-butyrate were added
to the MAM-PF2 medium. An overview over the cultures is shown in table  5-10. Cells were
cultivated in 250 ml spinner flasks with 50 ml culture volume at 37°C in an incubator
maintained at 5% CO
2
. Butyrate was added after 74 h of cultivation time at the onset of the
Figure 5-6. Sialylation of EPO during a batch process according to IEF. The first sample was taken at an early
stage of the process where the EPO concentration in the supernatant was very low. The samples were taken at
the following points: S05: beginning of the exponential growth phase, 34.5h, S09: during exp.growth, 66h, S12:
at the end of the exponential growth, 90h; S14: at the end of the stationary phase at a viability below 50%, 141h.
Bands are numbered from the top (no.1) to the bottom (no.14).
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production phase. The cultures were continued until the stationary phase and harvested after
172 h. 
Viable cell concentrations at the harvest time varied between 0.3x10
6
 cells/ml at 5 mM
butyrate and 4x10
6
 cells/ml in the control reactor. The growth rate was elevated at 5 mM
butyrate with 0.043 h
-1
 whereas the control culture and the culture at 1.5 mM showed lower,
similar growth rates. Specific production rates were 3.62x10
-13 
gcell
-1
h
-1
 at 5 mM butyrate,
3.32x10
-13
gcell
-1
h
-1
 at 1.5 mM butyrate and 2.92x10
-13
gcell
-1
h
-1
 in the control reactor
demonstrating the beneficial effect of butyrate on protein production. Because cell viability
was decreased by addition of butyrate at 5 mM, see figure 5-7 on the left, but not at 1.5 mM
butyrate, EPO volumetric titers increased by 44% for the culture at 1.5 mM butyrate and only
by 5% for the culture at 5 mM butyrate The growth rate of the cells grown at 5 mM butyrate
was not affected because butyrate was added at the end of the exponential growth phase. 
Samples for the IEF analysis were taken at 150 h except for the culture supplied with 5
mM butyrate. For this culture sampling was effected after 87h cultivation time to avoid
possible product degradation due to enzymes liberated from dead cells. As shown in figure
5-8 the IEF analysis of the pattern of EPO produced in the presence of 1.5 mM and 5 mM
Table 5-10. Main culture data for the spinner flask experiments at different concentrations of bu-
tyrate in comparison to a control cell spin. 
butyrate 
[mM]
µ 
[h
-1
]
viable cells 
[x10
6
cells/ml]
c
EPO
[mg/l]
0 0.035 4 76
1.5 0.037 1.4 109
5 0.043 0.3 80
Figure 5-7. Cell growth and EPO production at 0, 1.5 mM and 5 mM butyrate. At 5 mM butyrate cells grew
normally in the beginning, after 74 h the cells stopped growing and viability decreased. EPO production was
highest at 1.5 mM butyrate.
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Na-but showed weaker bands for the less acidic structures compared to the control reactor,
although the overall IEF pattern remained similar. The observed differences were small and
thus a second experiment with 1.5 mM butyrate addition was carried out, confirming the
results. The culture with 5 mM butyrate may not have shown a stronger increase in sialylation
because the sample was taken to soon after butyrate addition and a significant part of the
EPO in the sample was produced before butyrate addition.
2.3.   Influence of monosaccharide addition and a temperature shift
Repeated batch cultures were carried out in a 20 l Techfors STR with working volume of
12 l. Cells were allowed to grow up to 1.5-1.8x10
6
 cells/ml in each cycle before the culture
medium was split in a 80:20 ratio (volume fresh medium: volume remaining medium). The
culture was used to test the effect of monosaccharide supplementation and of diminished
cultivation temperature (34°C) on the N-glycosylation of EPO. The mean growth rate of
three control cycles at 37°C without monosaccharide supplementation was µ=0.027 h-1
+0.004 h
-1
 at 34°C the growth rate slowed down to µ=0.010 h-1 +0.001 h-1. The culture was
grown for several cycles at a 50:50 split ratio before the 7 cycles discussed here were carried
out: three control cycles at 37°C, two cycles at 37°C with addition of mannose and galactose
followed by two cycles at 34°C with addition of mannose and galactose.
EPO titers were between 11 and 16 mg/l at 37°C and 21.6 and 43.9 mg/l at 34°C. The
difference in titer for the cultures at 34°C may be explained by adaption of the cells to
decreased culture temperature. Enzymatic determination of the ammonium concentration in
the medium showed that ammonium concentrations remained essentially constant between 2
and 2.4 mM during the entire set of repeated batch cultures and could hence be excluded as a
Figure 5-8. IEF pattern of EPO produced at different NaBut concentrations. The profile looks similar for the
control and the EPO produced in presence of either 1.5 mM or 5 mM Na-butyrate.
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factor affecting glycosylation. The viability of the cells was normally between 85 and 90%.
Table 5-11 summarises the cell culture data of the experiments. 
The resulting changes in sialylation were measured by IEF, displayed in figure 5-9. The
intensities for more basic bands 1-4 was slightly elevated but the observed changes were
small. As control the European Pharmacopeia standard was applied to the same gel. The
observed differences were small but suggested possibly a slight decrease in sialylation for
cultures at 34°C. 
An HPAEC analysis was intended as control of the results of the IEF-analysis, but
electrophoretic separation by SDS-Page could not be achieved, maybe due to the presence of
antifoam or pluronic, which were added to the medium for cultures in STRs, or DNA and
lipids, which might accumulate during the process. Filtering or dialysing the sample did not
Table 5-11. Main culture characteristics for the repeated batch. Viable cell concentration at the time of medi-
um exchange.
cycle conditions µ 
[h
-1
]
viable cells 
[x10
6
 cells/ml]
c
EPO
[mg/l]
ammonium 
[mM/l]
1 control 0.024 1.7 13.5 2.4
2 control 0.030 1.3 11.7 2.4
3 control 0.031 1.2 12.8 2.3
4 +gal, +man 0.030 1.4 15.5 2.4
5 +gal, + man 0.031 1.4 11.0 2.2
6 +gal, +man, 34°C 0.010 1.2 21.6 2.1
7 +gal, +man, 34°C 0.009 1.1 43.9 2.0
Figure 5-9. Repeated batch at 37°C (control), at 37°C with mannose and galactose added and at 34°C with ga-
lactose and mannose added. The IEF contains an additional sample which is not discussed here.
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improve electrophoretic separation. Only after anion exchange chromatography (AEX) could
samples be analysed by this method but the sample quantities taken during the experiment
did not allow for a detailed analysis by HPAEC after purification. As will be shown in chapter
6 AEX inevitably changes the glycosylation pattern of the samples and the glycosylation
profile of EPO purified by AEX is probably not fully representative of the actual
glycosylation pattern of the culture.
The experiment on the effect of temperature on glycosylation was eventually repeated in
another fed-batch experiment but problems concerning the electrophoretic separation
remained. Table 5-12 summarises the results of this culture, which is also graphically depicted
in figure 5-10. The viability of the cells was normally between 90-95% except for the
beginning of the third cycle. Due to a technical problem the initial reactor volume of the third
cycle was smaller than planned. Consequently the viable cell concentration also was very low
after medium was refilled. The drop in cell concentration was comprised by a decrease in
viability. Cells recovered after 2 days. EPO titers were similar for all runs between 31.8 and
38.9 mg/l although the viable cell number almost doubled to 3x10
6
 cells/ml at 37°C.
Ammonium concentrations varied around 3.1 +0.2 mg/l. 
Figure 5-10. Second repeated batch experiment at different temperatures. First cycle was carried out at 34°C,
the second and third at 37°C.
Table 5-12. Principal culture data for second repeated batch experiment at different temperatures. Ammonia
and EPO concentrations are the maximal values reached at the end of each cycle. Values in brackets before
addition of nutrients (see chapter 2, paragraph 2.1.1. for details).
cycle temp. 
[°C]
µ [h-1] viable cells
[x10
6
 cells/ml]
c
EPO
[mg/l]
ammonium 
[mM]
1 34°C 0.014 (0.009) 1.4 31.8 3.0
2 37°C 0.028 (0.016) 3.0 35.5 3.3
3 37°C 0.033 (0.022) 3.0 38.9 2.9
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Glycosylation studies were carried out on cycle 1(34°C) and on cycle 3 (37°C) to allow the
cells to adapt to the new temperature for one cycle. Ammonium concentrations were slightly
elevated compared with the first experiment but were still low (3 mM). This higher
ammonium concentration is probably the result of the higher cell concentrations reached in
the second run. Contrary to the other experiments at different temperatures presented for
EPO the product concentration in this experiment was lower at 34°C if compared to the
concentration at 37°C, probably due to the higher viable cell concentration at 37°C.
Table 5-13 shows the results of the HPAEC analysis on AEX-purified EPO produced at
34°C and at 37°C. N-glycans from EPO produced at 34°C carried 7% less tetrasialo
structures compared to the control at 37°C. The difference is close to the error (regarding
batch-to-batch variability) but was confirmed by several cell spin experiments discussed in
paragraph 2-4 and the IEF-analysis shown in figure 5-9 also suggested a slightly decreased
sialylation. The fraction of trisialo N-glycans remained constant at 30%, the fraction of disialo
constant at 22% for both culture temperatures. Asialo and monosialo N-glycans were slightly
more abundant at 34°C. Comparison of the analysis for 34°C carried out in duplicate on
different membranes confirmed good reproducibility of the method. EPO produced at 37°C
carried more tetrasialylated structures than N-glycans from EPO produced at 34°C. The
results obtained during the second experiment analysed by HPAEC confirmed the results of
the first experiment analysed by IEF. 
2.4.   Addition of oligosaccharide precursor structures
N-glycans are synthesized in the Golgi apparatus by stepwise addition of sugars from
nucleotide activated monosaccharides. These monosaccharides are activated in the lumen of
the cell and then transported via specific antiporters into the GA (see chapter 1). The
addition of nucleotide-sugar precursor structures to the medium might be expected to
influence glycosylation by an increase in availability of activated sugars and provide a tool to
influence glycosylation. In the repeated batch culture a lower sialylation and possibly higher
branching was observed for EPO produced at lower temperatures. This might be explained
by higher levels of UDP-HexNAc as already briefly mentioned by (Gawlitzek et al., 2000). In
order to study if a lower sialylation may be related to the availability of nucleotide-sugars the
following approach was followed:
Table 5-13. Sialylation of EPO produced at different temperatures according to HPAEC analysis on samples
purified by AEX. n.i.: not identified. Analysis at 34°C in duplicate.
cycle asialo [%] monosialo [%] disialo [%] n.i. [%] trisialo [%] tetrasialo [%]
34°C 5 +1 14 +0 22 +1 7 +1 30 +1 21 +1
37°C 3 10 22 7 30 28
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i establishment of the analytical methods and extraction method for nucleotide
sugar measurements
ii feeding of nucleotide precursor structures in order to assess whether these lead to
the expected decrease in sialylation and increase in branching
iii cultivation of cells at different temperatures, measurement of activated sugars and
glycosylation profiling by IEF and HPAEC.
2.4.1.  Analysis of nucleotide sugar standards
The analysis of activated sugars was carried out essentially as described by (Tomiya et al.,
2001). The cells were harvested and, after a short centrifugation, sonicated in ice-cold
ethanol. Cell debris was removed by centrifugation and the frozen solvent was evaporated.
After solvent evaporation the sample was resuspended and either immediately injected into
the HPAEC or shock-frozen and stored at -80°C 
Sample recovery was evaluated by treating purchased standards exactly the same way as the
actual samples, except for washing of the cells. See also chapter 2, paragraph 4.10. for the
identification and separation of the nucleotide sugars. Peak areas obtained for these samples
were compared to the peak areas of the same amount of sample injected without any
preparation. The recoveries varied for the different standards between 90% and 116% as
shown in table 5-14. A recovery higher than 100% can be at least partly explained by the peak
tailing after the extraction procedure. The reason for the tailing could not be clarified. The
experiment was repeated three times and the error of the method was estimated by
comparing the peak areas of the three runs. The method showed an error of 16%, more than
twice as high as the error of 7% mentioned by (Tomiya et al., 2001). During the exponential
growth phase nucleotide concentrations remained almost constant within + 15% as
determined by measuring CDP- and UDP-quantities (peak areas) during a cell spin culture.
The variations were not higher than the error of the method. Because of the low
concentrations of nucleotide-sugars the experiment could not be carried out with
nucleotide-sugars directly.
Table 5-14. Recoveries (mean value of triplicate analysis) for the different nucleotide sugar standards after being
exposed to the extraction procedure. The standard deviation given is the deviation of the activated sugar stand-
ards which were treated independently three times like the samples. CMP eluted 0.5 min earlier than CMP-
NANA.
elution CMP-
NANA
UDP-Glc UDP-Gal UDP-
GalNAc
UDP-
GlcNAc
recovery [%] 116 97 103 115 91
retention time [min] 5.8 +0.2 19.5 +0.2 25.0 +0.2 19.1 +0.2 23.3 +0.2
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2.4.2.  Precursor feeding
As a next step EPO was produced in CHO cells in the presence of 2 mM uridine and 10
mM glucosamine (GlcN) or in the presence of 2 mM cytidine and 10 mM mannosamine
(ManN). Cultures were carried out in MAM-PF2 medium in incubators set at 37°C and 5%
CO
2
 in 1 l spinner flasks containing a culture volume of 200 ml. The cultures were stopped at
1.2 +0.1 x10
6
 cells/ml, reached after 68h for cultures at 37°C. The culture grown at 34°C will
be discussed later. The experiment was to study the influence of increased intracellular
nucleotide-sugar levels on the glycosylation of EPO.
Figure 5-11 shows the growth and production results for one experiment. Viability was
generally above 95% for all spinner flasks and growth rates were similar, the growth rate
µmax= 0.029 +0.004 h-1 did not show slower growth in the presence of hexosamines and
nucleosides . The feeding thus did not show any toxic effect on the cells, judged by the similar
growth rates and titers of 22 + 3 mg/l in all three spinner flasks cultivated at 37°C. Cells were
harvested at 1.2 +0.1 x10
6
 cells/ml.
HPAEC-UV analysis of nucleotide-sugars is shown in figure 5-12. The two upper
chromatograms refer to the cells grown in the presence of uridine and GlcN (on the left, E5)
and cytidine and ManN (on the right, E4). The cells from spinner E4 showed significantly
increased intracellular UDP-HexNAc concentrations if compared to the control culture.
Although GlcNAc is also a precursor structure for the formation of CMP-NANA the level of
CMP-NANA remained below the detection level, which is in the pmol range (Tomiya et al.,
2001). Cells grown in presence of ManN and cytidine showed an increased level
CMP/CMP-NANA in comparison to the control culture. The results show that the
hexosamines, cytidine and uridine were taken up by the cells and were used for the synthesis
of nucleotide sugars. The control culture also showed clearly that the method is limited by the
amount of nucleotide sugar in the sample. Initially only 1 million cells were taken as sample as
described in (Tomiya et al., 2001) but that level was clearly insufficient. Increasing the number
Figure 5-11. Cell growth and EPO production. Cells in medium supplemented with the nucleotide-sugar pre-
cursor structures grew generally at the same growth rate and produced similar amounts of EPO if compared to
the control culture.
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of cells above 3 million cells did not improve the analysis because of poorer resolution and a
noisier baseline. Differences in separation and in retention times compared to the literature
may be explained by the slightly different columns used (CarboPac PA-1 versus CarboPac
PA-100 in this study).
The glycosylation of these cultures was analysed by IEF and HPAEC. For HPAEC analysis
concentrated supernatant was directly separated by SDS-Page and deglycosylated on the
membrane using N-glycanase F. Table 5-15 shows the relative amounts of native N-glycans
Figure 5-12. HPAEC profile of intracellular nucle-
otide sugars The addition of GlcN/uridine addition,
shown on the upper left, led to an increase in the level
of intracellular UDP-GlcNAc which elutes at 20 min.
The ManN/cytidine feeding resulted in an increase in
intracellular CMP-NANA, eluting at 6 min, shown on
the upper right. The sample from the control cell spin
without any feeding of nucleotide sugar precursors is
shown on the lower left. 
Table 5-15. Native N-linked oligosaccharides according to HPAEC analysis. In cell spin E4 cytidine and ManN
and in cell spin E5 uridine and GlcN were added to the culture medium directly at the beginning of the culture.
E3 control culture.Values of HPAEC analysis are always given as percentage of total (100%).n.i: not identified.
All values are mean values of duplicate analysis of duplicate (triplicate) experiments. The + value gives the max-
imum deviation from the mean value observed. E3: control, E4: +cytidine and ManN, E5: +uridine and GlcN.
cell spin asialo 
[%]
monosialo 
[%]
disialo 
[%]
n.i. 
[%]
trisialo 
[%]
tetrasialo 
[%]
E3: control 3 +1 4 +1 16 +2 4 +0 30 +2 43 +3
E4: cyt ManN 3 +0 7 +3 19 +1 6 +2 29 +1 38 +3
E5: uri GlcN 7 +2 12 +4 21 +1 5 +1 27 +3 29 +4
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according to HPAEC analysis. All samples showed the previously observed profile with
56-73% tri- and tetrasialo structures and minor amounts of asialo- and monosialo N-glycans.
EPO produced in the presence of uridine and GlcN contained 14% less tetrasialylated
N-glycans compared to the control culture. The relative amount of asialo, monosialo and
diasialo N-glycans increased correspondingly. Lower sialylation due to uridine/GlcN feeding
was confirmed by independent IEF analysis, shown in figure 5-13. According to the HPAEC
analysis the feeding of cytidine and ManN only caused a minor shift to lower sialylation
compared to the control cell culture. These changes were within the error of the analysis but
independent IEF analysis confirmed a decrease in sialylation. Differences might be due to the
error of the methods, the different principles of IEF and HPAEC (the first measuring
released N-glycans whereas for IEF the oligosaccharides remain attached to the protein for
the analysis) and the O-glycans comprised in IEF analysis but not in HPAEC analysis. 
As mentioned beforehand feeding of GlcN and uridine increases the availability of
UDP-HexNAc and UDP-Hex. Besides the inhibitory effect on sialylation the increased
availability of activated UDP-HexNAc may result in increasing antennarity and/or the
number of LacNAc repeats. 
Figure 5-13. IEF pattern of EPO produced in spinner flasks. Standard from Pharmacopeia was distorted and
is not displayed in the graph on the right. According to IEF sialylation was highest on EPO produced at 37°C
without addition of precursor molecules confirming HPAEC results. Sample E2 will be discussed later.
Table 5-16. HPAEC analysis of desialylated N-glycans. 0-LacNac, 1-LacNAc, 2-LacNAc refers to the number
of N-acetyllactosamine repeats present on the structures. Bi,- tri and tetra refers the number of branches. All
values mean values of duplicate/triplicate experiments with the maximum deviation observed.
cell spin bi [%] tri [% tetra [%] 0-LacNAc 
[%]
1-LacNAc 
[%]
2-LacNAc 
[%]
E3: control 11 +1 28 +2 56 +2 41 +3 34 +3 22 +2
E4: cyt ManN 13 +1 31 +2 57 +3 49 +1 35 +1 16 +1
E5: uri, GlcN 10 +2 31 +2 59 +4 45 +1 37 +1 19 +1
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Desialylated N-glycans were analysed by HPAEC, results summarised in table 5-16 in two
groups. The left of the table shows the antennarity and the right part the relative abundance
of carbohydrates with different numbers of LacNAc-repeats. EPO produced in the presence
of elevated intracellular UDP-HexNAc and UDP-Hex pools did not show increased
antennarity. Generally tetraantennary structures accounted for 56-59% of the structures,
triantennary for 28-31%. Differences are within the error of the experiment. 41-49% of the
N-glycans carried 0, 34-37% 1 and 16-22% 2 LacNAc repeats.
2.4.3.  Influence of temperature on nucleotide-sugar concentrations
Because the feeding experiments indicated that the intracellular availability of
UDP-HexNAc influenced the glycosylation the effect of temperature on the activated sugars
was studied. Cells spins were cultivated at 37°C and 34°C in duplicate. At lower temperatures
the onset of the exponential growth phase was delayed but the growth rate remained almost
constant. Table 5-17 summarises the main culture results. The cells grew slower in the second
experiment (µmax=0.019 +0.001h-1 compared to µmax=0.030 +0.003h-1 in the first set of
cell spins). Cells were harvested later in the second experiment. For graphic depiction of cell
growth and production of E2 and E3 please refer to figure 5-11.
Table 5-17. Main culture data from cell spin cultures at 34°C and 37°C.
cell spin µ 
[h
-1
]
viable cells 
[x10
6 
cells/ml]
c
EPO
[mg/l]
E2, 34°C 0.027 1.1 28
E3, 37°C 0.032 1.3 25
E5, 34°C 0.018 1.8 36
E6, 37°C 0.019 2.0 23
Table 5-18. Native N-glycans from spinner flask cultures at 34°C and 37°C. The percentages given refer to the
signal intensity as measured with HPAEC-PAD analysis and do not signify absolute values. Higher temperature
repeatedly showed a slightly higher sialylation.n.i: not identified.
cell spin asialo 
[%]
monosialo 
[%]
disialo 
[%]
n.i. [%] trisialo 
[%]
tetrasialo 
[%]
 E2, 34°C 3 7 20 4 34 24
 E3, 37°C 3 4 17 4 32 40
E5, 34°C 5 9 17 5 28 36
E6, 37°C 4 5 14 4 28 45
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Culture supernatant from the cell spins was concentrated and N-glycans were
enzymatically cleaved from immobilised EPO. According to the HPAEC analysis shown in
table 5-18 EPO derived from cell grown at 34°C showed 9-16% reduction in the amount of
tetrasialo N-glycans. The amount of trisialo carbohydrates remained essentially constant and
the relative abundance of asialo-disialo glycoforms increased. The second set of cell spins
showed generally higher levels of sialylation compared to the first experiment, maybe because
of harvest at higher viable cell concentration but confirmed qualitatively the results made
during the first experiment. The lower level of sialylation was also confirmed by IEF as
shown in figure 5-13. 
Neutral N-glycan structures were obtained by enzymatic desialylation. In table 5-19 the
relative abundance of the different neutral structures are shown. In both experiments EPO
produced at 34°C contained 10% less tetraantennary structures than in the control culture at
37°C. The amount of triantennary structures increased correspondingly whereas the relative
abundance of biantennary oligosaccharides remained constant. The relative abundance of
carbohydrates carrying two repeats increased by 5% at 34°C, the amount of structures
without LacNAc repeats increased by the same percentage.
Intracellular nucleotide-sugars were measured as mentioned above for both cultures at
different temperatures. In the first experiment the expected increase in UDP-HexNAc was
observed but in a second experiment no differences appeared in the level of UDP-HexNAc.
A major problem was the low intracellular concentration of the activated sugars resulting in
poor signal intensity if cultivated in media not supplied with precursor structures. A further
optimization of the analysis could not be carried out since the cells were not available for a
continuation of the project.
Table 5-19. Relative amounts of desialylated N-glycans of EPO produced in cell spins at 34°C and 37°C ac-
cording to HPAEC analysis.
cell spin bi [%] tri [%] tetra [%] 0-LacNAc 
[%]
1-LacNAc 
[%]
2-LacNAc 
[%]
E2, 34°C 13 39 48 34 39 28
E3, 37°C 11 29 60 41 38 22
E5, 34°C 13 37 50 37 39 25
E6, 37°C 12 30 58 43 37 20
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3.     Discussion
Cell culture conditions were varied with respect to temperature, pH, pO
2 
and the addition
of monosaccharides, nucleotide-sugar precursor structures, tunicamycin and Na-butyrate.
Generally the influence of the culture conditions on glycosylation were smaller compared to
the influence of the choice of the cell type or cell clone (see chapter 4). Limitations in the
semi-quantitative comparison by HPAEC were given by variations in the glycosylation
observed for identical control cultures and not by the analytical method itself. In the case of
the antibody an explanation for these variations might have been the usually late harvest time
at low cell viabilities or the variations observed for the growth in the control cultures. The
differences in growth might also have influenced the glycosylation. The observation shows
that it is essential to estimate the error including the reproducibility of the cultures and not
only by exclusively assessing the error of the analytical method.
To exclude that the observed glycosylation profiles of the antibody were affected by
galactosidase activity, purified IgG was incubated in cell-free culture supernatant and
glycosylation was compared to a control sample. Both samples showed essentially the same
glycosylation. Either galactosidase was absent in the culture supernatant or it was not active at
the standard culture conditions. It was concluded that the changes in the glycosylation and
the generally low galactosylation were due to the culture conditions and the host cell and not
caused by degradative enzymatic activity. EPO may have shown a decrease in sialylation
during the late stationary phase at low cell viabilities. The decrease either may have been due
to sialidase activity or the formation of by-products of the cell metabolism such as lactate,
with the concomitant increase in base addition, and ammonium. These factors change the
metabolism of the cell and might also have contributed to the changes in glycosylation.
Although the results did not clearly show a decrease in sialylation the harvest time was chosen
early to avoid possible degradative changes in the glycosylation profile. Ammonium was not
explicitly mentioned during the presentation of the results but cultures carried out with CHO
AMW resulting in 1.1-3.5 mM final ammonium concentration achieved by glutamine-feeding
suggested that ammonium did not influence the glycosylation of the antibody. It should be
noted though that for these cultures several culture parameters were changed simultaneously
and a direct comparison of the reactor as to the influence of ammonium on the glycosylation
is difficult.
One of the parameters exclusively tested for the antibody production was dissolved
oxygen. Although elevated dissolved oxygen (DO) was reported earlier by (Kunkel et al.,
1998) to increase galactosylation of antibodies from murine cells in continuous culture, the
galactosylation of batch-wise produced anti-RhD in CHO cells appeared to be unaffected by
variations in DO. Contradictory results may be attributed to the different process and cell
types used in both studies. 
At lower pH the amount of agalactosyl antibody decreased by 10%. Galactosyltransferases
of CHO cells show maximum activity at pH 6.5 (Gawlitzek et al., 2000). According to the
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relation given by (Fellenz and Gerweck, 1988) a shift in extracellular pH (pH
e
) from 7.2 to pH
6.9 decreases intracellular pH (pH
i
) of CHO cells by 0.12. Because of the generally lower pH
in the GA it seems thus unlikely that the decrease in pH
i
 affected glycosyltransferase activity
but other enzymes involved in glycosylation might have been affected. The effect was not
further investigated and from the results obtained here the change in glycosylation can not be
attributed to a distinct mechanism. A change in glycosylation due to small changes in pH
contradicts the results obtained by (Borys et al., 1993) who found that glycosylation of
placental lactogen produced by CHO cells remained constant between pH 6.9 and 8.2. 
The precise mechanism of action of butyrate on cells is not yet fully understood. It
probably acts on the release of mRNA from the ribosomes and therefore increases the
transcription rate. Another effect is the increase in pH
i
. For cultures supplemented with
butyrate often an increase in productivity is observed. Both effects may also influence
glycosylation, either by expression levels of glycosyltransferases or by influencing
glycosyltransferase activity via the pH
i
. The influence of Na-but on glycosylation was tested
for both proteins. Concerning the IgG a first experiment confirmed the assumption that
butyrate affects glycosylation but two subsequent cultures showed constant glycosylation
profiles despite butyrate addition. The results confirm the findings of (Mimura et al., 2001)
who reported that butyrate addition had no impact on the glycosylation of an
immunoglobulin produced by CHO cells despite the improved production. Since butyrate
also failed to enhance protein production in the first experiment it seems likely that either a
mistake during the feeding (preparation of the solution) was made or the cells did not take the
butyrate up as normally in this experiment. This may explain why the first experiment showed
different results than the following experiments, but does not explain the variation in the
glycosylation observed for this cultures. Although butyrate did not effect the galactosylation
of the antibody it increased sialylation of EPO at lower concentrations. As observed already
for IgG the production of EPO was also improved by butyrate addition, albeit at lower
butyrate concentrations. Higher concentrations were not beneficial for the product titer and
affected cell growth negatively. Underlying mechanisms were not studied closer. The different
effects of butyrate on both processes may be explained by the type of glycosylation, cell clone
and product implicated.
Tunicamycin concentrations necessary for partial inhibition of antibody glycosylation were
higher than those reported for hybridoma cells (Barnabe and Butler, 1998). Different cell
types may display a different sensitivity towards tunicamycin. As expected incomplete
antibody glycosylation led to a decrease in ADCC activity. Some remaining activity may be
explained by the observation that deglycosylation was not complete. Deglycosylated IgG has
also been reported to retain some activity (Koide et al., 1977). In contrast to partial
deglycosylation the level of galactosylation did not influence in vitro biological activity as
determined by ADCC. Antibodies of different galactosylation levels behaved essentially
identical in the assay. The observation clearly contradicts the studies by (Hadley et al., 1995;
Kumpel et al., 1995) who reported decreased ADCC activity for degalactosylated or lower
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galactosylated anti-RhD antibodies. The reason for the different behaviour could not yet been
clarified.
The availability of monosaccharides was reported by (Tachibana et al., 1994) to influence
glycosylation. Additional monosaccharides may be transformed to activated sugars and
incorporated directly in oligosaccharides. In accordance with literature an increase in
galactosylation was observed for the CHO MDJ8s cells cultivated at increased glucose
concentrations. Although the glucose-experiment for the antibody production lacked a direct
control reactor because of a contamination, a comparison with the average control reactor
implied an increase in galactosylation for IgG from glucose supplied cultures. The addition of
mannose and galactose in EPO production showed no effect on the sialylation according to
IEF. HPAEC analysis of the neutral structures could not be carried out due to the
aforementioned problems with samples from cultures supplemented with pluronic and
antifoam. 
A detailed study on how a single culture parameter affects glycosylation was carried out for
the culture temperature. Lower cultivation temperature increased the galactosylation of IgG
in CHO cells and decreased sialylation of EPO in repeated batch cultures. For the
comparison of the level of sialylation of EPO produced at 34°C and 37°C in repeated batch
cultures it had to be taken into consideration that the EPO was already purified by AEX.
Thus glycosylation studies on samples from spinner flasks cultured at 34°C and 37°C
analysed without prior purification were carried out, confirming the results. Ammonium may
be a potential explanation because lower culture temperatures may decrease ammonium
production (Ducommun et al., 2002) but ammonium concentrations were similar in cultures
at 34°C and 37°C. At lower cultivation temperature the consumption of glucose for biomass
and product formation slows down. The glucose may then be available for the formation of
activated sugars (see also chapter 1, paragraph 2.1.). The observation that a decreased culture
temperature leads to an increased UDP-HexNAc pool has already been made by (Gawlitzek
et al., 2000). Since increased UDP-HexNAc pools may also influence the extent of sialylation
by impairing transport of CMP-sialic acid into the GA (Pels Rijcken et al., 1995) this would
also explain the observed decline in terminal sialylation at lower temperatures. In order to
determine intracellular nucleotide-sugar concentrations cells were grown at different
temperatures, harvested and the cell extract analysed by HPAEC-UV. 
The changes in glycosylation observed in the repeated batch cultures for lower culture
temperature were confirmed in the cell spin experiments. At 34°C sialylation and the amount
of tetaantennary structures decreased by 9-16%. Although the observed increase in structures
carrying more LacNAc repeats at 34°C was close to the error the repeatedly identical result
indicated that the culture temperature might also influence the number of these repeats.
HPAEC-UV analysis of intracellular nucleotide-sugar availability at different temperatures
gave no clear results because the intracellular nucleotide sugar concentrations were close to or
below the detection limit. Although the sensitivity of the method prevented the direct
observation of a relation between temperature and availability of activated sugars it may be
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argued that the changes in glycosylation at lower temperature can not be exclusively explained
by changes in activated sugar availability. EPO produced by cells with higher intracellular
levels of UDP-HexNAc obtained by feeding the cells with uridine and GlcN showed a
decrease in sialylation but antennarity remained constant. In contrast EPO produced at lower
temperature carried less tetrasialylated and less tetraantennary N-glycans. Although this
argumentation does not exclude that the availability of activated sugars influenced
glycosylation at lower temperatures it may be concluded that other mechanisms also must
have played a role. Because the ammonium concentration was almost constant at different
temperatures it can be excluded as a factor influencing the glycosylation in this case.
Constant antennarity at different UDP-HexNAc levels contradicts the results of (Pels
Rijcken et al., 1995; Gawlitzek et al., 2000). Cytidine and ManN-feeding did not affect the
sialylation level, as already observed by (Baker et al., 2001) but in contrast to (Gu and Wang,
1998). The different observations made in literature and the present study may be explained
by the different cells and products employed in the respective studies. As already pointed out
in the introduction of this chapter different cells may react differently to changed intracellular
nucleotide-sugar levels. Different cells reacted differently on elevated levels of intracellular
UDP-HexNAc comparing BHK and CHO cells (Gawlitzek et al., 1998) (Gawlitzek et al.,
2000) and comparing NS0 and CHO cells (Baker et al., 2001). It should be noted that in some
studies ammonium was employed to alter UDP-HexNAc concentrations, which may affect
glycosylation by other mechanisms than the intracellular levels of activated sugars. Given that
cell spins were used in the present study other changes in the culture medium affecting
glycosylation also can not be completely excluded since cultures in cell spins are not as
well-controlled as in STRs. Similar growth and production data suggested however that
growth conditions were essentially identical. Besides the results of the glycosylation analysis
on EPO from cells spins maintained at different temperatures corresponded to the results
from repeated batch cultures carried out in STRs. 
Several reasons might have contributed to the error of the nucleotide-sugar analysis. Firstly,
nucleotide and nucleotide sugar concentrations are known to change quickly if cells are
exposed to a different environment. Taking samples and sample treatment were done
manually and are thus error prone because handling times and the handling itself might be
subject to small changes. Although the method showed sufficient reproducibility using
standards, this verification leaves out the actually most sensitive step, the centrifugation of the
cells. During this time cells are exposed to a drastically different environment for several
minutes which almost certainly will influence the intracellular concentrations. The error of
this step can not easily be determined, except by shortening the exposure time of the cells to
the new conditions. It is advisable to further minimize cell treatment before extraction. Once
the nucleotide sugars are extracted they proved relatively stable if handled carefully.
Unfortunately the experiments had to be terminated because the cells were not available for
further studies and an improvement of the analytical methods. Ideally the sampling and most
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of the sample treatment should be automated and the experiment should be repeated several
times to assess nucleotide sugar levels at different temperatures.
4.     Conclusions
Generally the changes in glycosylation due to different culture conditions for the cell lines
and products investigated in the present study were limited. The effects of a single culture
parameter on glycosylation presented here were in part congruent in part contradictory to
literature and confirm that the effect of culture conditions on glycosylation depend on the
cell-line and product. Using culture conditions as a tool to influence glycosylation in industrial
processes may thus be only of limited practical value. The different glycosylation of EPO at
lower temperature could not be clearly related to changes in the intracellular level of
nucleotide-sugars. Increasing intracellular nucleotide-sugar levels by feeding precursor
structures changed glycosylation differently than a shift in the culture temperature indicating
that the changed glycosylation at lower temperature can not be explained by changes in
nucleotide-sugar concentrations only.
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CHAPTER 6     GLYCOSYLATION AND DOWNSTREAM 
PROCESSING
summary
With respect to glycosylation, the purification of recombinant glycoproteins may aim at a
decrease in product heterogeneity and removal of undesired (biologically not active or
immunogenic) carbohydrate structures. Generally this approach, to obtain an improved final
glycosylation pattern, has the potential drawback that a significant part of the product may be
lost during the purification because it does not carry the correct glycosylation. In this study the
sialylation of EPO was monitored by isoelectric focusing (IEF) and high-pH anion-exchange
chromatography (HPAEC). The results obtained show clearly that anion exchange
chromatography and hydroxyapatite chromatography may be useful chromatographic
techniques for the purification of highly sialylated recombinant proteins. Recoveries however
were low and suggested that glycosylation should be improved at an earlier step in the process.
Because IgG did not show glycosylation dependent activity in the ADCC assay a selective
purification with respect to glycosylation was not intended. 
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Cell culture supernatants are highly dilute solutions of the recombinant product. Titers are
usually between 1-100 milligrams per liter. The aims of the downstream processing are to
concentrate these dilute solutions, to separate the product from other proteins present in the
supernatant, the removal of contaminants such as viruses, endotoxins and DNA and the
transfer of the protein into a suitable storage buffer. If the product is homogeneous, high
product recovery and purity will be the aim of the downstream processing. For heterogeneous
products the selective purification of certain isoforms may be an additional goal. Often a four
step purification process as shown in figure 6-1 is used.
Oligosaccharides of glycoproteins are usually situated on the surface of the protein. This
position makes carbohydrates ideal targets for interactions with ion exchange groups or
affinity groups as often used in the chromatographic purification. The selective purification
of glycoforms may be aimed either at the removal of immunogenic structures or the selection
of therapeutically relevant glycoforms. Unfortunately selective purification always means that
a part of the product has to be discarded. Amgen, a commercial manufacturer of
erythropoietin (EPO) recovers only 20% of the product after purification because of the
selective removal of low active (and thus low-value) EPO glycoforms (Alper, 2001). 
Providing that a molecule with a high, selective affinity for the protein exists, affinity
chromatography may be employed as a capture step. For glycoproteins the affinity of the
capture molecule might be directed against either the protein or the carbohydrate part. In the
case of antibodies bacterial proteins, protein A and protein G, exist which specifically bind to
the F
c
-part of a broad range of IgGs. The binding of protein A is directed against the protein
part and is not influenced by the glycosylation (Nose, 1983). 
Specific lectins may be employed for affinity purification. Lectins are carbohydrate specific
proteins of non-immune origin. Most lectins were isolated from plants (seeds) but they occur
also in animals and bacteria. Common features are the ability to agglutinate cells, e.g.
erythrocytes and the precipitation of glycoconjugates. Precipitation is due to the presence of
Figure 6-1. General purification scheme for recom-
binant proteins from dilute cell culture supernatants.
For the purification of glycoproteins each step may be
additionally employed for the purification of the desired
glycoforms. Adapted from (Amersham-Pharmacia-bio-
tech, 1999)
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multiple sugar binding sites on each lectin molecule. Although the interaction between lectins
and sugars is complex and seldom shows a narrow specificity, lectins are commonly classified
according to the monosaccharide which inhibits the interaction between the erythrocytes and
the lectin. A large number of lectins are available for carbohydrate research, (Montrieul, 1991;
Lis and Sharon, 1998). Differently sialylated erythropoietin has been purified using several
lectins with distinct binding specificities (Storring et al., 1996). Lectins reacting with common
glycan features may be used for the non-selective purification of glycoproteins. Concanavalin
A (ConA) recognizes α-linked mannose as present on the pentasaccharide core structure of
mammalian N-glycans. It has been used for the purification of secretory component (SC)
(Rindisbacher et al., 1995), but only 8-15% of recombinant EPO bound to ConA (Storring et
al., 1996). 
Separation by hydroxyapatite chromatography (HAC) involves at least three different
interactions of the protein with the active groups of the hydroxyapatite. Anionic interactions
occur between the protein and Ca
2+
 sites, cationic exchange between the PO
4
3-
 and the
positively charged sites of the protein. The contribution of each type of interaction depends
on the pH, salt concentration and the charge distribution on the protein (Gagnon, 1998).
Using HAC for the purification of EPO results in the separation of fractions with variable
biological activity of which fractions with a higher biological activity eluted earlier (Miyake et
al., 1977). These results may be explained by the glycosylation of EPO. Because structures
with a high number of sialic acids will bind stronger to the anionic binding sites of the column
these fractions may be retained longer.
Selective glycoform purification by anion exchange chromatography (AEX) normally
makes use of the charge introduced by sialic acid residues. Because sialic acids are negatively
charged at neutral pH, glycoforms with a higher number of sialic acid residues will bind
stronger to an anion exchanger than less sialylated glycoforms. The purification of differently
sialylated recombinant EPO was reported using a MonoQ-column anion exchange column
(Morimoto et al., 1996). (Inoue et al., 1994) separated sialylated from non-sialylated human
urinary EPO using AEX. 
In this study the application of downstream processing with the aim to purify certain
glycoforms of erythropoietin was attempted. Studies on the biological activity, especially of
the blood clearance rate of EPO, were not carried out within this project, even though
literature strongly suggests that the terminal sialylation of EPO plays a major role in its
clearance from blood. Consequently the selective removal of fractions with a low sialic acid
content was a primary goal of the purification process. Other factors, such as branching and
the number of polylactosamine repeats, may influence biological activity as well (Takeuchi et
al., 1990). The purification of IgG will also be shortly addressed. 
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1.     The glycosylation of IgG during the downstream processing
Large scale purification of IgG for reactors from 10-50 l culture volume were carried out
using expanded bed chromatography. Large scale cultures were used to supply sufficient IgG
for the project and to define scale-up criteria but were not used for the glycosylation studies
presented earlier in this thesis. The purity required for these samples was higher than
necessary for glycosylation analysis and the technique was not practical for the simultaneous
purification of small batches. Because IgG showed no variation in in vitro biological activity, a
selective purification with respect to highly galactosylated glycoforms of the antibody was not
intended. The aim of the capture step was to recover as much IgG as possible. Medium and
large-scale productions were purified additionally by cation exchange chromatography on SP
Sepharose FF and by size exclusion chromatography on a HiPrep Sephacryl column. 
1.1.   Glycosylation of IgG during the purification process
After Streamline recombinant protein A purification normally 95% of the antibody was
recovered. Recoveries after IEX were 85% of the initial IgG and 75% of the initial amount of
IgG after SEC. For two batches, one production at the 12 l scale and one production at the 50
l scale the glycosylation was analysed after the capture step and after SEC. The HPAEC
analysis of these samples, as shown in table 6-1, revealed no significant differences in
N-linked glycosylation. In a first experiment the N-glycan pool consisted of 52-55% bi-0gal,
38-40% bi-1gal and 5-7% bi-2gal before and after purification. In the second experiment
galactosylation was generally lower with 60-63% bi-0gal, 31-34% bi-1gal and 6-7% bi-2gal but
remained also constant during the purification process.
2.     Purification of sialylated glycoforms of EPO
Biological activity of erythropoietin is known to be influenced by the glycosylation of the
protein, especially its terminal sialylation. (Zanette et al., 1996) used phenyl boronate
Table 6-1. The glycosylation of IgG during the purification process as determined by HAPEC.
The first mentioned sample was produced at the 50 l scale, the second at the 12 l scale.
step bi-0gal [%] bi-1gal [%] bi-2gal [%]
protein A 52 40 7
size exclusion 55 38 5
protein A 60 34 7
size exclusion 63 31 6
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chromatography to separate biologically highly active EPO from less active glycoforms.
Separation of EPO glycoforms was also achieved by lectin affinity chromatography (Storring
et al., 1996) and by AEX (Inoue et al., 1994). In the present study it was shown that
purification of highly sialylated EPO can be achieved by using AEX and HAC
chromatography. Prior to the purification experiments the cell culture supernatant was
centrifuged to remove cell debris and concentrated by filtration. The glycosylation during the
purification was monitored by isoelectric focusing (IEF). Additionally high-pH
anion-exchange chromatography (HPAEC) was used to analyse a selection of the eluting
fractions. 
2.1.   Purification of highly sialylated EPO by anion exchange chromatography
Two different experiments were carried out using AEX. First the sialylation of crude cell
culture supernatant was purified on AEX and the IEF pattern before and after the
purification was compared. Then different fractions of the eluate were studied by IEF.
2.1.1.  Purification of EPO from cell culture supernatant
In figure 6-2 the scanned IEF pattern and the intensity of the bands according to the
Pharmacia ImageMaster software are shown. Of the EPO in the filtrated culture supernatant
69% were recovered after AEX purification as fraction AXE-E using a Q Sepharose XL
column and a NaCl-gradient. Sialylation of EPO in the supernatant, the flowthrough and the
eluate was analysed using IEF.
The IEF shown in figure 6-2 clearly showed that the supernatant contained a large fraction
of low sialylated EPO which did not bind strongly to the AEX column and eluted mostly in
Figure 6-2. IEF of cell culture supernatant concentrated by filtration (SNF) and purified by AEX. AEX-TF:
anion exchange chromatography flowthrough, AXE-E: anion exchange chromatography eluate. On the right
the Pharmacia Image Analyser diagram. Samples appear from left (top of the scan) to the right (bottom of the
scan). See also samples C1 and C1r in figure 4.6. of chapter 4.
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the flowthrough AXE-FT. The eluate AXE-E was enriched in higher sialylated glycoforms.
The original IEF also showed bands of low intensity for more basic glycoforms of EPO in
the sample AXE-E which are not visible on the scan shown here. The purified fraction still
contained significant amounts of EPO showing a lower sialylation compared to the
Pharmacopeia standard shown on the left of the IEF.
2.1.2.  IEF analysis of fractions from anion exchange chromatography
The results from the previous chapter showed that anion exchange might be a potent tool
for the separation of glycoforms. In a second experiment improved purification of highly
sialylated EPO was attempted. Anion exchange chromatography was carried out on Q
Sepharose HP using a NaCl gradient at either pH 7.5 and pH 4.5 respectively. Washing and
elution at lower pH may remove EPO with a comparatively low sialic acid content (high pI).
The eluting peak of the AEX chromatography was separated in two fractions and the
fractions were analysed for sialylation by IEF. The sample used in this experiment was already
semi-purified and displayed a higher sialylation in the beginning than the sample previously
discussed. Figure 6-3 shows the elution profile of the AEX purification. 
In a first run elution with the NaCl-gradient was carried out at pH 4.5 (F1 and F2), in the
second run the elution was performed at pH 7.5 using the same gradient (F3 and F4). At an
elution buffer pH of 4.5 EPO, with a pI higher than the pH of the elution buffer, is less likely
not to bind to the column. The elution profile was essentially identical in both cases and was
divided into two fractions and analysed by IEF, the first two fractions (F1 and F3) correspond
to fraction 8-10 as indicated on the chromatogram in figure 6-3, F2 and F4 were combined
fractions 11-15. In both cases IEF analysis showed a clear separation of differently sialylated
glycoforms between the - lower sialylated - first fraction and the significantly better sialylated
second fraction. A scan of the blot and analysis using the Image Master software are shown in
Figure 6-3. Ion exchange
purification of EPO. The
experiment was carried out
in double and each time the
peak was divided in an earli-
er (F1 and F3) and a late (F2
and F4) eluting fraction.
The fractions were analysed
by IEF.
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figure 6-4. As expected higher sialylated EPO bound stronger to the column and
consequently eluted later than the lower sialylated glycoforms.
2.2.   Purification of highly sialylated EPO by hydroxyapatite chromatography
In the experiment described here EPO purified by AEX chromatography was further
purified using HAC. Because separation by HAC relies essentially on ionic interactions it may
provide a useful purification method for the purification of highly sialylated EPO.
Purification experiments of EPO on HA were carried out using semi-purified EPO as
starting material. Previous purification included AEX. EPO was eluted from the HA column
using a potassium phosphate gradient at pH 6.9. Two separate fractions eluted from the HA
column. The fraction of an earlier eluting, smaller peak 1 (HAC F1), was collected and
analysed separately. The later eluting peak two showed some tailing and was split in two
separate fractions (HAC F2 and F3). The experiment was carried out in duplicate and showed
Figure 6-4. The IEF shows clearly that differently sia-
lylated fractions of EPO can be separated on an anion
exchange column. Image analysis on the left. 
Figure 6-5. Sialylation of different eluate fractions from a hydroxyapatite chromatography step.standard: Phar-
macopeia standard, startM: starting material (partly purified), HAC F1-3: Hydroxyapatite fraction 1-3. On the
right the Pharmacia Image analysis. Bands top to the bottom of the gel are displayed from the left to the right
on the diagram. 
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two times essentially identical results.As shown in the scan displayed in figure 6-5 the
sialylation of EPO gradually decreased with prolonged retention time on the column. It
should be noted that faint bands of more basic EPO glycoforms remained visible on the
original blot, even for the HAC F 1 fraction. These bands did not appear on the scanned
image because of the low intensity and were consequently also not detected by the Image
software. The scans and the graph of figure 6-5 thus imply a better purification of high
sialylated forms than actually achieved.
Table 6-2 shows the recovery of EPO after HAC purification. The overall recovery was
83%, but only 28% eluted in the first fraction which showed the best sialylation profile
according to IEF. According to IEF and HPAEC analysis, shown figure 6-5 and table 6-2,
sialylation was highest in the first eluting fractions and diminished continuously for the
following fractions. EPO of HAC F1 seemed still to comprise more glycoforms than the
standard but the intensity of the most acidic bands was higher according to IEF. Sample HAC
F3 was not investigated by HPAEC because of the low amount of sample. 
The HPAEC results summarized in table 6-3 revealed some more details about the
glycostructures after the different purification steps. As expected from the IEF results HAC
F1 showed an elevated ratio of tri- and tetrasialo structures (69%) if compared to HAC F2
(57%). HAC F2 contained a similar sialylation pattern as CSE 1. The structure that could not
be identified (see chapter 3 for structure identification) eluted exclusively in fraction HAC F2.
According to HPAEC the final product still contained 10-15% of low sialylated N-glycans.
The fraction of hydroxyapatite purified EPO that showed an improved sialylation pattern,
compared to earlier purification steps, accounted only for 8% of the initial amount of EPO. 
HAC was highly selective for the unidentified structure eluting between the di-, and
trisialylated glycoforms at 37.7 min. The peak appeared exclusively in fraction 2. Since this
fraction HAC F1 HAC F2 HAC F3 HAC F4 total
recovery [%] 28 31 10 14 83
Table 6-2. Recovery of EPO in different hydroxyapatite fractions (HAC F), fraction 1 eluting first. Overall re-
covery was 83% (partly purified starting material = 100%). Sample HAC F4 was not analysed for the glycosyla-
tion.
Table 6-3. HPAEC analysis of HAC F1 and F2. The earlier eluting HAC fraction contained EPO with more
tri- and tetrasialo N-glycans than HAC F2. The profile of HAC F1 did not contain any signal for the unidentified
structure eluting between disialo and trisialo structures. n.i.= not identified.
fraction asialo [%] monosialo 
[%]
disialo 
[%]
n.i. [%] trisialo 
[%]
tetrasialo 
[%]
HAC F1 2 7 22 0 36 33
HAC F2 3 12 23 5 30 27
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structure has not been identified the reason why it exclusively appears in the later fraction
remains unclear. 
3.     Discussion
Both glycoproteins were purified using a combination of different chromatographic
techniques. Recovery was high for the antibody and not selective for the glycosylation. The
recovery for EPO was lower but more active glycoforms were successfully separated from the
most of the glycoforms containing asialo and monosialo oligosaccharides.
As expected the glycosylation profile, as determined by HPAEC, remained constant for the
IgG after protein A affinity chromatography, cation exchange chromatography and size
exclusion chromatography. None of the chromatographic techniques employed displays a
selective interaction for certain glycoforms. Protein A is directed against the F
c
 part of IgG
and was shown earlier to be independent of the glycosylation (Nose, 1983). Cation exchange
chromatography may have an influence on the purification of glycoproteins if charged
carbohydrate structures are present on the surface of the protein. The glycans of IgG
produced by CHO (none of the large scale purifications was carried out on IgG from SP2/0
cells) were neutral and did not influence the retention time on the column. Size exclusion
chromatography is usually not applicable for the separation of glycoforms since the
differences in size due to glycosylation are too small. Little has been so far reported in
literature on the selective purification of IgG glycoforms. The higher content of sialic acid,
Gal and GlcNAc found in AEX purified IgG compared to protein G purified IgG (Bond et
al., 1993) is probably due to the light chain glycosylation and not to the glycosylation at the
conserved glycosylation site as discussed in the same paper. 
A high level of sialylation is important for extended blood residence time and thus
biological activity of EPO (Takeuchi et al., 1990; Higuchi et al., 1992). Selective purification of
sialylated forms may be achieved using AEX chromatography or HA chromatography. Due
to the negative charges introduced on the protein surface by sialic acids, glycoforms of high
sialic acid content will bind stronger to anion exchange columns and may also bind stronger
to the anion exchange groups of hydroxyapatite columns. 
Unfortunately the glycosylation analysis by HPAEC of EPO from crude culture
supernatant was because the electrophoretic separation could not be carried out (see also
chapter 5, paragraph 2.1.). A direct comparison of the AEX purified material to the starting
material was not possible using HPAEC. IEF analysis however showed clearly that
glycoforms with a low sialic acid content did not bind to the column and eluted in the
flowthrough. 
For the glycoforms investigated the binding was not dependent on the pH for
4.5<pH<7.5. Since EPO glycoforms with a pI>pH will bind to a lesser extent to an AEX
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column it can be concluded that the glycoforms used in the starting material already had a
pI<4.5. Improvement of the purification of highly sialylated glycoforms of EPO by AEX
may be achieved be decreasing the pH even further, but this experiment was not carried out
in the present study. 
The precise mechanism of protein binding to HAC has not been completely studied but
includes ionic interactions between Ca
2+
, PO
4
3-
 and orientation of the charges on the protein
surface with respect to the charges on hydroxyapatite. The interaction is probably dependent
on pH, salt concentrations and the protein used (Gagnon, 1998). According to HPAEC and
IEF, EPO showing a higher sialylation eluted earlier from the column than the lower
sialylated forms. If the retention was mostly due to anionic binding, EPO with a lower level of
sialic acid residues should have eluted earlier. The results obtained here confirm and may
explain the studies by (Miyake et al., 1977) who reported that EPO of a higher activity eluted
earlier from a HA column, without relating the effect to glycosylation. The unidentified
structure exclusively elutes in the second fraction. The results show that binding to
hydroxyapatite is complex and can not be easily predicted. HAC was however a useful
technique in the separation of differently sialylated EPO.
4.     Conclusions
The results showed that the glycosylation of the final product might be significantly
improved during downstream processing. Selective purification of glycoforms was considered
only for EPO since the activity of IgG did not depend on the glycosylation according to an in
vitro ADCC assay. Highly sialylated, biologically active forms of EPO (or other sialylated
recombinant proteins) may be effectively purified from supernatants using either AEX, HAC
or a combination of these methods. Optimisation of the glycosylation pattern of recombinant
proteins through purification inevitably leads to a loss of product. Although this is
comparable to recoveries mentioned in the literature for industrial processes (Alper, 2001) it
seems obvious that measures to improve glycosylation should be taken earlier in the process.
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CHAPTER 7     DEVELOPMENT OF A SCREENING 
TECHNIQUE FOR CELLS PRODUCING 
DESIRED GLYCOSTRUCTURES
summary
The overall results of this thesis presented so far showed that the main parameter for the
glycosylation of recombinant proteins is the choice of the cell-line and the cell-clone. Cell culture
conditions did not change the glycosylation to the same extent as the choice of the cell clone
will, a selective purification was resulting in with low recovery. Screening for clones which
exhibit desired glycosylation features can be significantly improved if the number of screened
clones is increased. The development of a method was started which potentially allows the
screening of a large number of cells by their glycosylation pattern. It was proposed to
encapsulate single CHO cells in an alginate matrix carrying an antibody directed against the
product of the cell, in the present study, secretory component (SC). During an incubation period
the cell produces SC which diffuses into the matrix and will be captured by the anti-hSC
antibody. The detection of glycoforms can then be carried out using the specific, fluorescently
labelled lectins. The work carried out within the present thesis aimed at the proof of principle.
Each step of the bead modification was monitored using fluorescently labelled intermediates.
Cell-free beads were incubated with SC which was subsequently detected using the lectins
Concanavalin A and Ricinus Communis Agglutinin I, which is directed against terminal
galactose residues. It was shown that the bead matrix can be modified, bead formation is
feasible using biotinylated alginate and that glycoproteins can be captured by a specific
antibody and detected via fluorescently labelled lectins. The method may be automated using a
FACS for the screening of a large number of cells.
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Process development of recombinant proteins usually starts with the generation of the
production cell-line. Cells are transfected and a large number of clones is tested for the
suitability as a production clone. The decision as to which clone(s) will be used for the
process development is mainly governed by good growth, high production and stability of the
clone(s). Considerations on the glycosylation characteristics of the clone normally play, if at
all, only a marginal role in early process development although a certain glycosylation profile
may be essential for a good performance of the protein as a pharmaceutical agent. 
After the clone(s) has/have been chosen cell banks are established and first cultures are
carried out, with very few clones are being tested for their glycosylation characteristics. For
clones producing glycoproteins this approach has two major drawbacks. First, the number of
clones tested for their glycosylation characteristics is limited. Glycosylation analysis still
requires time-consuming analytical techniques and the analytical expertise needed is not
routinely available in all laboratories. Additionally the first choice of the potential clones is
made based on parameters other than glycosylation, such as the clone producing the highest
product titers, which may actually produce unfavourable glycoforms (see chapter 4). It may
not be possible to adapt the culture conditions in a way that the glycosylation of the product
is significantly improved (see chapter 5). As shown before, the purification process might be
employed for selective removal of undesired glycoforms. However this approach almost
certainly will result in low product recoveries (see chapter 6). A technique enabling the choice
of an adequate clone at an early stage of process development thus seems highly desirable.
Several approaches have so far been proposed to overcome this problem. If different
structures or higher expression of certain glycoforms are needed, cells may be genetically
modified to (over-)express the related glycosyltransferases. Although sometimes successful
(Weikert et al., 1999; Fukuta et al., 2000) this approach may be hampered by the poor
production (Umana et al., 1999) and instability of clones carrying multiple genetic
modifications. Creating a clone with the desired glycosylation and good production
characteristics may be time-consuming. Other groups focus on the in vitro glycosylation of
proteins produced by bacteria (Meynial-Salles and Combes, 1996; Macmillan et al., 2001).
Synthetic oligosaccharides may be added to activated glycosylation sites. In another approach
glycosyltransferases and the corresponding substrate are being added to the culture medium
for post-production modifications of the carbohydrate chains. The first mentioned approach
is not yet fully developed while the second has the general drawback that pure
glycosyltransferases are expensive and the method is not economic at larger scale. A further
possibility is the use of glycosylation mutants (Stanley et al., 1996) however this is only useful
for the removal of undesired glycostructures.
To our knowledge no method has been proposed so far for the screening of transfected
cells of a transfection according to the glycosylation characteristics of the clone. The method
may be a valuable alternative to the above cited methods since it does not rely on multiple
genetic modifications or costly post-process modifications of the carbohydrate chains or may
be used as a screening method of cells with multiple genetic modifications. As shown in
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chapter 4 clones from one transfection differ considerably in their glycosylation capabilities.
These “naturally” occurring differences are significant but the screening of cells according to
the glycosylation of the product necessitates the development of new screening techniques. 
A prerequisite for this approach is a technique enabling a high throughput and a relatively
simple and cheap detection for clones producing the desired glycostructures. High
throughput screening techniques have already been described in literature, however these do
normally not take into account the quality of the product. The microdrop gel technique
described first by (Gray et al., 1995) however possesses the potential for the screening of
clones depending on their glycosylation characteristics providing that a specific detector for
the glycosylation characteristic of interest is available. In most cases lectins may be useful as a
detector molecule because of the availability of lectins with a broad range of specificities. 
In figure 7-1 the principle of this method is schematically displayed. Single cells are
immobilized in alginate beads carrying biotin-linked streptavidin on the surface. Subsequently
the cells are incubated with a biotinylated capture antibody recognizing specifically the
product of interest. After a production period in cell culture media the beads are incubated
with a fluorescently labelled lectin. The lectin will bind to a specific carbohydrate structure.
The more of the corresponding structure produced by the cell the more lectin will bind to the
bead surface and the stronger the fluorescent signal will be. Two lectins were used for
detection in the present study: Concanavalin A (Con A), a lectin isolated from Canavalia
ensiformis, specific for α-mannose structures and RCA I, a lectin from Ricinus Communis
Agglutinin I specific for terminal galactose residues and N-acetylgalactosamine. Beads may be
sorted according their fluorescence using a FACS, similar to the high-throughput screening of
free cells (Meng et al., 2000). The above described method would provide a useful tool for the
selection of adequate production clones of glycoproteins.
After selection cells can be easily released from the alginate beads and used for the creation
of a working bank. The method, usually referred to as microgel drop or secretion capture and
report web (SCRW) has already been successfully used for the selection of high-producer
hybridoma clones (Gray et al., 1995; Kenney et al., 1995; Weaver et al., 1997). As proposed by
(Kenney et al., 1995) the product may be labelled by multiple detectors in order to monitor
more than one parameter, e.g. glycosylation and production.
So far agarose has been used as bead matrix but cell immobilization may also be achieved
by using alginate beads. Immobilisation of cells using alginate has been previously described
and can be automated to obtain uniform beads (Serp et al., 2000). Single cell occupancy of a
bead may be achieved by suitably adjusting the alginate: cell number ratio according to
poisson statistics. Generally alginate permits the diffusion of larger molecules but is not
suitable for cell growth. After selection of the cells e.g. FACS, the alginate beads can be easily
dissolved using alginase or a divalent ion complexing agents such as citrate or EDTA and the
selected cells can be recovered for further cultivation. 
7136
The development of a SCRW for glycosylation may be divided in two major parts. First it
has to be shown that the principle idea works and the incubation concentrations and
conditions for the bead modification determined. This may be achieved by carrying out every
step without cells but with a successive incubation of fluorescently labelled molecules. For
example this means that to control the attachment of the capture molecule to the matrix,
which already carries the spacer and the streptavidin, beads have to be incubated with a
fluorescently labelled and biotinylated capture antibody. In this case the negative control is
beads without streptavidin incubated with the labelled capture antibody. All experiments
discussed here have been carried out at least in duplicate. In a second step the method should
be tested with cells for diffusion of the product and sufficient sensitivity of the method. This
study presented here aimed at the proof of the principle of the method. 
Figure 7-1. The principle of the screening method modified for the detection of carbohydrates. Single cells can
be immobilized in biotinylated alginate beads. Subsequently the beads are incubated with streptavidin and with
the capture antibody, in this case a anti-hSC. After a production period at 37°C the secreted and captured SC
can be detected via its carbohydrates with fluorescently labelled lectins. 
streptavidin         capture  antibody       secretory component         lectin                  fluorescent label
cell
alginate bead
biotinylated 
alginate
cells
1 2
4 5
3
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1.     Production, purification and glycosylation of Secretory Component
1.1.   Production and purification
Secretory component was produced either in cell spin cultures or in stirred tank reactors
using CHO SSF3 cells. Serum-free cultures were carried out at pH 7.2, 37°C using the
CHOMaster medium. After production the supernatant was centrifuged and concentrated. A
two step purification process using Con A affinity chromatography and size exclusion
chromatography for desalting was carried out. Purity was assessed by SDS-Page and
Coomassie blue staining. The SDS-Page gel shown in figure 7-2 indicates that SC was
essentially free of other proteins after purification. The high apparent molecular weight can
be explained by the high level of glycosylation of SC slowing down the migration of the
protein in SDS-Page.
1.2.   The glycosylation of recombinant Secretory Component
Secretory Component (SC) was used for the development of the screening technique
discussed in chapter 7. Since the development of the screening focused on sialylated
glycostructures only the level of sialylation of SC is of interest. 
The HPAEC chromatograms displayed in figure 7-3 show native and desialylated secretory
component. N-glycans were cleaved enzymatically using N-glycanase F, desialylation was
achieved by digestion with sialidase from A.ureafaciens. Native and desialylated structures were
eluted using gradient 1. The chromatogram on the left shows a the native sample. Neutral
structures eluted at 18-23 min, monosialylated oligosaccharides at 37-41 min, disialylated
forms at 49-51 min. After desialylation, shown in the same figure on the right, all peaks
eluting later than 30 min disappeared. The comparison of both chromatograms indicates a
higher level of sialylation. Desialylated structures showed a high level of structural diversity
Figure 7-2. Secretory component after the purification and desalting by
SDS-Page and Coomassie blue staining. According to SDS-Page the sam-
ple was essentially free of other proteins. In some purifications a small
band at approximately 25 kDa was observed accounting for less than 10%
of the total protein as judged by visual comparison. SC appears has a high
apparent molecular weight due to the high glycosylation which significant-
ly influences the migration of the protein in SDS-Page. 
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that might be explained by the occurrence of multiple fucosylation of the N-glycans (Hughes
et al., 1999). 
2.     Modification of the alginate matrix
2.1.   Biotinylation of alginate and the attachment of streptavidin
The matrix was biotinylated before the formation of beads. After manual bead formation
the beads were incubated with streptavidin. Successful biotinylation and attachment of
streptavidin was confirmed using fluorescently labelled streptavidin (fluorescein-
Streptavidin). Beads made from unbiotinylated and from biotinylated alginate were incubated
with fluorescein-streptavidin and fluorescence was controlled using a confocal microscope.
Figure 7-4 shows the beads made from biotinylated alginate on the left and the control
sample on the right. The control sample did not show any fluorescence at identical sensitivity
and is shown here at higher sensitivity to visualize the beads. The biotinylated sample showed
a strong fluorescence on the bead surface indicating that biotinylation of the alginate was
successful and streptavidin was attached to the modified bead surface.
2.2.   Attachment of the anti-human SC capture antibody
In principle the capture and detection of proteins by their glycosylation site may be carried
out by either capturing glycoproteins via the desired carbohydrate structures and detecting it
unspecifically using a fluorescently labelled antibody or by an unspecific capture step with
respect to glycosylation and specific detection with fluorescently labelled lectins. In this study
Figure 7-3. HPAEC profile of native SC on the left and desialylated on the right. It should be noted that due
to steric hindrance not all glycosylation sites of SC are equally accessible for the enzyme and according to
SDS-Page deglycosylation was not complete. The relatively high structure variability observed for the neutral
structures may be explained by the presence of Lewis-type N-glycans (Hughes et al., 1999). 
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the latter method was given preference because it allows multiple labelling of the captured
molecule and the captured protein could be anlaysed for glycosylation and overall product
quantity. 
Biotinylated beads were incubated with streptavidin and subsequently with biotinylated
and 200 pmol fluorescently labelled anti-hSC (fluorescein-anti-hSC). Beads not carrying
streptavidin but incubated with the same amount of fluorescein-anti-hSC served as a control
sample. The antibody was biotinylated via the carbohydrates in order to avoid later
interactions between the carbohydrates of the antibody and the detector lectin. Figure 7-5
shows that the fluorescence of the sample was higher than in the control sample although the
overall fluorescence was low and unevenly distributed over the surface. 
Figure 7-4. The biotinylation was verified by incubating beads made from biotinylated alginate with fluores-
cently labelled streptavidin. Beads made of unmodified alginate served as control. The modified beads show a
significantly higher fluorescence.Control beads on the right at higher sensitivity. At the same sensitivity beads
were not visible.
Figure 7-5. Beads incubated with fluorescein-labelled anti-hSC. On the left the sample (beads carrying strepta-
vidin incubated with fluorescein-anti-hSC), on the right the control lacking streptavidin.
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2.3.   Attachment of fluorescently labelled Secretory Component
An important step is the capture of the product by the capture antibody. Biotinylated
beads carrying streptavidin were incubated with 200 pmol fluorescently labelled SC
molecules, beads without the capture antibody were used as a negative control. The
fluorescence observed in figure 7-6 on the left shows that SC bound to the capture antibody.
Also some fluorescence was observed in this step on the control sample, shown on the right
indicating that some SC bound to the unmodified bead matrix.
3.     Detection of carbohydrates with lectins
Detection of SC via the carbohydrate residues was carried out using the lectins from
Concanavalin A and from Ricinus Communis Agglutinin I. 
Figure 7-6. Beads incubated with fluorescein-la-
belled capture anti-hSC capture antibodies. The sam-
ple on the upper left, the control on the upper right
shows no fluorescence. The photo on the left shows
a control sample at enhanced sensitivity.
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3.1.   Concanavalin A
So far all intermediate steps were controlled with fluorescently labelled molecules. Figure
7-7 shows the detection of SC by fluorescein-Con A. The fluorescence of the sample versus
the control (without SC) at the same sensitivity. The sample on the left shows a significantly
higher fluorescence than the control on the right confirming that detection of proteins
immobilised on alginate beads can be carried out by lectins, even though some fluorescence
was also observed for the control. Although the carbohydrates of IgG are not easily accessible
and were additionally used for the biotinylation, it can not be excluded that Con A recognized
some carbohydrate binding sites of the antibody.
In an additional experiment the optimum concentration of fluorescein-Con A was
determined. using concentrations of 1-1000 pmol for 10 +1 beads. Concentrations lower than
100 pmol fluorescein-SC resulted in a low signal intensity, concentrations higher than 250
pmol led to a significant background (fluorescence in the control sample without SC). The
result was used to determine the concentrations for the experiments and allow an estimation
if the method would be sensitive enough for the detection of the amounts of SC produced by
a single cell. 
Figure 7-7. Beads carrying SC on the left and the control without SC on the right after incubation with fluo-
rescein-Con A. The sample on the left shows a significantly higher fluorescence than the control on the
right.The faint diagonal line on the photo corresponds to the X-axes of the diagram. 
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3.2.   Ricinus Communis Agglutinin I
For the application as a screening method the fluorescence on the bead surface needs to be
quantified. It had to be shown that the fluorescence on the bead surface is related to the
glycan structures of SC. Initially it was planned to detect carbohydrates via the sialic acid
residues and to compare the fluorescence to desialylated and partially desialylated SC.
Because the fluorescent labelling of the lectin did not show satisfying results a fluorescently
labelled lectin was purchased. Since no fluorescently labelled lectin, directed against sialic
acids which did not display broad specificity also towards other monosaccharide residues was
available, the inverse experiment was carried out. Desialylated SC was detected via a
fluorescently labelled RCA I lectin directed against terminal galactose. Native SC, which
contained SC terminating in galactose to a lesser extent, see also figure 7-7, was used as
control. In a second experiment beads without SC were also incubated with the RCA I lectin.
It was expected that the surface of beads incubated with desialylated SC followed by
incubation with fluorescein-RCA I would show an increased fluorescence compared to the
beads carrying the native form of SC and that beads without SC would show only some
unspecific fluorescence. The results of both experiments are summarized in table 7-1.
For quantification, images of the beads were taken using a fluorescent microscope and the
digital images analysed with a LabView based software programmed by Dr. P. Girard.
Because beads always show higher fluorescence on the outer boundaries only the inner bead
surface was measured. A representative square corresponding to 40000 pixels was excised
from the image and analyzed for signal intensity. In the first experiment beads carrying
desialylated SC showed and average fluorescence of 24.2 on an arbitrary, linear scale from
0-255. Beads incubated with the native form of SC showed decreased fluorescence of 18.4.
The background observed showed an average value of 4.8 on the same scale. Analysed were
12-20 beads for each, control and sample. In a second experiment the observed fluorescence
was lower but showed also small differences between beads carrying SC with a different level
of terminal galactosylation. Beads carrying asialo SC showed average intensity of 12.2, the
control beads of 8.3. As a negative control beads without SC were used in this experiment.
These beads showed a significantly lower fluorescence of 2.4.
Table 7-1. Intensity of fluorescence on a defined bead surface area of 40000 pixels. + give the standard
deviation s. n.d.= not determined.
experiment asialo SC native SC without SC blank
1 24.2 +2.7 18.4 +1.6 n.d. 4.8
2 12.2 +4.2 8.3 +1.7 2.4 +1.6 n.d.
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4.     Discussion
The study presented here showed that the SCRW-, or microdrop gel-technique can be
modified for the detection of carbohydrate structures and may, after optimisation, be used for
the screening of cells for glycoprotein production. Each single step of the bead modification
has been controlled by incubation with the respective fluorescently labelled molecule and
measured against a control sample. Some unspecific. fluorescence, as observed in some
control samples, may be due to unspecific interactions of the fluorescent molecule with the
bead surface. These interactions are not a practical drawback except for the last incubation
step since no fluorescent intermediates will be used. The fluorescence observed in the control
sample of the last step using Con A may be due to the interactions of the lectin with the
carbohydrates of the capture antibody. Although the IgG is biotinylated and thus attached to
the streptavidin via the carbohydrates the modification may not have prevented
lectin-carbohydrate interactions completely. The observed fluorescence of the control was
however low if compared to the fluorescence of the sample. Still, the glycosylation of the
antibody may be of importance if lectins are used which are directed against carbohydrate
epitopes occurring on the antibody. 
Beads incubated with the RCA I lectin directed against terminal galactose residues were
analysed with a normal fluorescent microscope in order to determine the fluorescence of the
bead surface. The lectin from RCA I did apparently not bind to the terminal galactose
residues of the antibody since the fluorescence of the control beads was very low. Beads
carrying desialylated SC showed higher fluorescence in this duplicate experiment indicating
that quantitative detection may be possible. The observed differences were however small and
it has to be questioned if they were sufficiently big to allow the method to be employed for a
screening technique without further optimisation of the method. A possible explanation for
the small difference between the sample and the control might be that the desialylation of SC
was not complete. SDS-Page confronting deglycosylated and native SC indicated that not all
oligosaccharides were cleaved from the protein (data not shown). The HPAEC analysis in
figure 7-3 may not have been representative for all glycosylation sites of SC and the sample
possibly still carried N-glycans terminating in sialic acid.
Although the principle of the method has been shown to work many practical problems
have to be addressed before the method may be used for screening: 
Product quantity and sensitivity of the method. Single cells will produce little product, therefore
incubation times will have to optimized to allow sufficient production and diffusion of the
product to the bead surface without diffusion of the product to other beads. The maximum
amount of glycoprotein which can be captured by the respective bead of a single cell should
not be exceeded. Incubation times reported so far in the literature are 30 min for the
production of antibodies by hybridoma cells immobilised in agarose beads (Gray et al., 1995).
Similar conditions should be applicable also for the detection only of glycoforms via lectins.
The incubation conditions, mainly concentrations and incubation time, will have to be
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optimized experimentally. Because bead size has to be diminished significantly for these
experiments the concentrations used in the preliminary experiments of this feasibility study
can not be transferred to experiments using cells and smaller beads. A potential drawback
might be the broad range of fluorescence observed for the detection with lectins. It is clear
that for a successful screening a quantitatively reliable method is needed. The differences
observed so far might be explained by insufficient mixing of fluorescent detector in the
beginning of the incubation resulting in an inhomogeneous distribution of fluorescence and
may not be of importance when the protein is produced by immobilized cells. 
Size of the alginate beads and FACS. The alginate beads manufactured using the Encapsulator
Inotech (Inotech, Dottikon, Switzerland) usually have a relatively large diameter of 500 µm.
This observation has two considerable drawbacks. Large beads will need long incubation
times since the product has to diffuse over a larger distance. The bead surface is larger and
more SC is needed to show the same fluorescent intensity as a smaller bead. Additionally
large beads are more difficult to analyse with a FACS. The use of the FACS is crucial for a
high sample throughput. A smaller bead diameter may be obtained by optimisation of the
settings for the encapsulator. Another alternative may be the use of a different polymer.
Agarose beads, already used for the SCRW technique, may be produced with diameters of
25-50 µm (Gift et al., 1996) and may be an alternative to alginate beads.
One challenge in the further development will be given by the detection of differently
sialylated product on the bead surface using fluorescein-lectins and a FACS. The differences
in the fluorescence might be small and not easily to detect using a FACS. A double labelling of
the glycoprotein may be useful in order to separate high producer clones from clones
producing the optimal glycosylation. 
5.     Conclusions
Each step of the alginate modification has been monitored using fluorescently labelled
molecules. It has been shown that the alginate matrix generally can be modified in a way
enabling the capture of a protein and detection via the oligosaccharides using fluorescently
labelled lectins. Using Con A a clear difference in the fluorescence between the sample and
the control sample was observed. Differently glycosylated proteins immobilised on the bead
surface could be distinguished using the lectin RCA I albeit differences in intensity of the
fluorescence were small.
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CHAPTER 8       FINAL CONCLUSIONS
The present work studied the influence of cell-line and process conditions on the
N-glycosylation of two pharmaceutically relevant proteins, IgG
1 
and erythropoietin. In the
first part the analytical methods were presented. It has been shown that N-linked
glycosylation can be monitored precisely using high pH anion exchange chromatography
(HPAEC). The limitations in the precision of the analysis were given not by the analytical
method itself but by the batch-to-batch variability of production runs (see chapter 5).
Structure identification was carried out using commercial standards for co-injection and
exoglycosidase treatment. Both model glycoproteins are already well-studied for the
glycosylation and most structures reported in literature could be identified in the present
study. Once the methods were set up the glycosylation of the proteins was monitored as a
factor of process conditions and cell-line. 
Initially the present thesis was intended to study the influence of cell culture conditions on
the glycosylation of recombinant proteins. The aim was to find relevant parameters which
subsequently may be used for the optimisation of the culture conditions to obtain a product
with improved glycosylation characteristics. Ideally the parameters were valuable for more
than one cell-line or product. It turned out, first for the IgG and later for the EPO, that most
changes in the culture conditions had no or a limited effect on the glycosylation of the
protein. The cell culture conditions comprised in this study were temperature, dissolved
oxygen, pH and the addition of monosaccharides, sodium butyrate, and hexosamines (see
chapter 5) and were tested either for EPO or IgG or for both glycoproteins. Other factors
including osmolality, inoculum concentration and ammonia concentration, not explicitly
mentioned here, were carried out but did not show significant effects on the glycosylation of
the antibody using CHO cells. Lower cultivation temperature decreased the galactosylation of
IgG and the sialylation and N-glycan antennarity of EPO, an effect not desired for the
production of EPO as a pharmaceutical. It was tested if the changes in glycosylation may be
related to changes in the availability of intracellular nucleotide-sugars, but due to low
intracellular levels of the nucleotide sugars these could not be directly measured for the CHO
cells grown at different temperatures. It was concluded from the different changes in
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glycosylation, due to either diminished culture temperature or increased intracellular levels of
nucleotide-sugars obtained be feeding precursor structures, that the observed differences in
glycosylation at 34°C and 37°C were not or, at least not entirely, related to nucleotide-sugar
availability. It may be concluded that for the glycoproteins discussed here the culture
conditions were only of limited importance on the glycosylation of the final product.
Especially for the EPO no culture parameter was identified which may be useful in improving
the sialylation of the protein relevant for industrial production.
Because the cell culture conditions did not appear to be as important for the glycosylation
of the model glycoproteins as initially assumed other parameters of process development
relevant for glycosylation were included in the study. In chapter 4 the glycosylation of EPO
and IgG as a parameter of cell-type and cell-line were presented. Both glycoproteins showed
significant differences in terminal galactosylation (IgG) and terminal sialylation (EPO) if
produced by different CHO clones derived from the same parent cell-line. The results
showed that the choice of the cell-type and the clone had an important impact on the
glycosylation of the protein. Differences in the glycosylation of IgG were bigger for different
cell-types than the clonal differences.
Another parameter influencing the final glycosylation of recombinant proteins is the
purification. In chapter 6 hydroxyapatite and anion exchange chromatography were tested as
a tool to improve sialylation of EPO during purification. IgG did not show any improved
activity at higher galactosylation in the ADCC assay and the process was consequently
designed for maximum recovery of all product. Anion exchange chromatography was tested
on crude culture supernatant and on semi-purified EPO. In both cases the sialylation of the
purified protein was improved in comparison to the starting material. Hydroxyapatite
chromatography, which also relies partly on ion exchange was also useful for the selection of
EPO showing a higher level of sialylation. In a three step purification process including both
techniques highly sialylated EPO was purified (data not shown). The fraction of interest
however accounted only for 8% of the amount of initial protein. The result clearly
demonstrated that a major drawback in employing the purification process for the
improvement of glycosylation is the low recovery of the initial protein.
From the results presented so far the following conclusions were drawn: N-glycosylation
may vary significantly for different CHO clones, even if derived from the same parent
cell-line. Changing culture conditions might also improve glycosylation to some extent,
however the parameters may be difficult to identify. Too little is known about the underlying
mechanisms influencing glycosylation and parameters have to be tested empirically for each
protein and each cell-line employed. The resulting change in glycosylation may be difficult to
predict and contains also time-consuming and work intensive steps. Purification may be used
to significantly increase the product in the desired glycoforms but will be accompanied by the
loss of product.
It was concluded that glycosylation of recombinant proteins is best considered during the
screening of the production clone. At the moment however the screening is limited because
Final Conclusions
149
no adequate technique is available allowing the screening for glycoforms secreted by a single
cell at a high throughput. The number of clones which can be tested by the available methods
is limited because it involves cell culture of every clone and separate analysis, e.g. by HPAEC
or IEF. It was proposed to immobilise single cells in alginate beads, capture the secreted
product on the bead surface using antibodies and detect the glycosylation of the product
using fluorescently labeled lectins. Cell sorting could be automated using a FACS. 
Because of time limitations the technique could not be fully developed within this thesis.
In chapter 7 it was shown that the principle method is working: Beads were formed from
biotinylated alginate, the protein was captured by the capture antibody on the bead surface
and detected by fluorescently labeled lectins. 
There are still a few challenges to meet: Alginate beads have to be made smaller to be
sorted in a FACS and allow faster diffusion of the product outside and capture and detection
may have to be optimised meeting the requirements necessary for selectively detecting the
glycoform of interest at the levels of protein secreted by a single cell. Furthermore
preliminary experiments with the RCA I lectin showed an inhomogeneous distribution of
fluorescence on the bead surface.
As already mentioned in chapter 7 several approaches are currently tested for the
improvement of glycosylation of recombinant proteins on a cellular level, including genetic
modification of the host cell or post-production modification of the glycosylation by
incubating the protein with the respective glycosyltransferases and precursors. None of the
methods has so far found industrial application and every method displays unique drawbacks.
The technique presented here may be difficult to realize because of the unsatisfactory
sensitivity towards different glycostructures so far observed and has probably to be adopted
for each given process. If these initial problems are overcome it may be a useful tool for the
screening of cells for glycoprotein production and may even be used in combination with
genetically modified cells (cells with genetic modifications with respect to glycosylation).
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